<?xml version="1.0" encoding="UTF-8"?><search-results xmlns="http://www.w3.org/2005/Atom" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:opensearch="http://a9.com/-/spec/opensearch/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/"><opensearch:totalResults>2992343</opensearch:totalResults><opensearch:startIndex>2400</opensearch:startIndex><opensearch:itemsPerPage>100</opensearch:itemsPerPage><opensearch:Query role="request" searchTerms="heart" startPage="2400"/><link ref="self" href="http://api.elsevier.com:80/content/search/index:scopus?start=2400&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="first" href="http://api.elsevier.com:80/content/search/index:scopus?start=0&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="prev" href="http://api.elsevier.com:80/content/search/index:scopus?start=2300&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="next" href="http://api.elsevier.com:80/content/search/index:scopus?start=2500&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="last" href="http://api.elsevier.com:80/content/search/index:scopus?start=4900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929430356"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929430356?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929430356&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929430356&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929430356</prism:url><dc:identifier>SCOPUS_ID:84929430356</dc:identifier><eid>2-s2.0-84929430356</eid><dc:title>Myocardial Fibrosis and Left Ventricular Dysfunction in Duchenne Muscular Dystrophy Carriers Using Cardiac Magnetic Resonance Imaging</dc:title><dc:creator>Lang S.</dc:creator><prism:publicationName>Pediatric Cardiology</prism:publicationName><prism:issn>01720643</prism:issn><prism:eIssn>14321971</prism:eIssn><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00246-015-1192-7</prism:doi><dc:description>© 2015 Springer Science+Business Media New York The goal of our study was to characterize the degree of myocardial fibrosis and left ventricular dysfunction in our cohort of Duchenne muscular dystrophy (DMD) carriers using cardiac magnetic resonance imaging (CMR). Seventy percent of males with DMD have mothers who are carriers of the Xp21 mutation. Carrier phenotypic characteristics range from asymptomatic to left ventricular (LV) dysfunction and cardiomyopathy. The true prevalence of cardiac involvement in DMD carriers is unknown. We performed a retrospective observational study. All female DMD carriers who underwent clinical CMR studies at Cincinnati Children’s Hospital Medical Center from December 6, 2006, to August 28, 2013, were evaluated. Patients underwent standard CMR assessment with LV function assessment and late gadolinium enhancement (LGE). In addition, offline feature tracking strain analysis was performed on the basal, mid, and apical short axis. Twenty-two patients were studied, of which 20 underwent adequate testing for myocardial LGE. Four of 22 patients (18 %) were found to have LV dysfunction (ejection fraction &lt;55 %). Seven of 20 DMD carriers (35 %) were found to have LGE. The patients with evidence of LGE had an overall trend to lower absolute deformation parameters; however, this did not meet statistical significance when correcting for multiple comparisons. Our study demonstrates a high rate of LGE as well as LV dysfunction in DMD carriers. Cardiovascular and musculoskeletal symptoms were not statistically different between those with and without cardiac involvement. This study demonstrates the importance of surveillance CMR evaluation of DMD carriers.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024885</affiliation-url><afid>60024885</afid><affilname>University of Arkansas for Medical Sciences</affilname><name-variant>Univ. of Arkansas for Med. Sciences</name-variant><affiliation-city>Little Rock</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030440</affiliation-url><afid>60030440</afid><affilname>Cincinnati Children's Hospital Medical Center</affilname><name-variant>Children's Hospital Medical Center</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010511</affiliation-url><afid>60010511</afid><affilname>Ohio Heart and Vascular Center</affilname><name-variant>Ohio Heart and Vascular Center</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030440</affiliation-url><afid>60030440</afid><affilname>Cincinnati Children's Hospital Medical Center</affilname><name-variant>Children's Hospital Medical Center</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645692200</author-url><authid>56645692200</authid><authname>Lang S.</authname><surname>Lang</surname><given-name>Sean M.</given-name><initials>S.M.</initials><afid>60024885</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56646612500</author-url><authid>56646612500</authid><authname>Shugh S.</authname><surname>Shugh</surname><given-name>Svetlana</given-name><initials>S.</initials><afid>60030440</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004643088</author-url><authid>7004643088</authid><authname>Mazur W.</authname><surname>Mazur</surname><given-name>Wojciech</given-name><initials>W.</initials><afid>60010511</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56523222400</author-url><authid>56523222400</authid><authname>Sticka J.</authname><surname>Sticka</surname><given-name>J. J.</given-name><initials>J.J.</initials><afid>60030440</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55995718500</author-url><authid>55995718500</authid><authname>Rattan M.</authname><surname>Rattan</surname><given-name>Mantosh S.</given-name><initials>M.S.</initials><afid>60030440</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56432476900</author-url><authid>56432476900</authid><authname>Jefferies J.</authname><surname>Jefferies</surname><given-name>John L.</given-name><initials>J.L.</initials><afid>60030440</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35396633800</author-url><authid>35396633800</authid><authname>Taylor M.</authname><surname>Taylor</surname><given-name>Michael D.</given-name><initials>M.D.</initials><afid>60030440</afid></author><authkeywords>Cardiomyopathy | Feature tracking | Late gadolinium enhancement | Myocardial strain</authkeywords><intid>35954616</intid><source-id>20526</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929427619"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929427619?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929427619&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929427619&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929427619</prism:url><dc:identifier>SCOPUS_ID:84929427619</dc:identifier><eid>2-s2.0-84929427619</eid><dc:title>International study of perceived neighbourhood environmental attributes and Body Mass Index: IPEN Adult study in 12 countries</dc:title><dc:creator>De Bourdeaudhuij I.</dc:creator><prism:publicationName>International Journal of Behavioral Nutrition and Physical Activity</prism:publicationName><prism:eIssn>14795868</prism:eIssn><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>May 16, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12966-015-0228-y</prism:doi><dc:description>© 2015 De Bourdeaudhuij et al.; licensee BioMed Central. Background: Ecological models of health behaviour are an important conceptual framework to address the multiple correlates of obesity. Several single-country studies previously examined the relationship between the built environment and obesity in adults, but results are very diverse. An important reason for these mixed results is the limited variability in built environments in these single-country studies. Therefore, the aim of this study was to examine associations between perceived neighbourhood built environmental attributes and BMI/weight status in a multi-country study including 12 environmentally and culturally diverse countries. Methods: A multi-site cross-sectional study was conducted in 17 cities (study sites) across 12 countries (Australia, Belgium, Brazil, China, Colombia, Czech Republic, Denmark, Mexico, New Zealand, Spain, the UK and USA). Participants (n = 14222, 18-66 years) self-reported perceived neighbourhood environmental attributes. Height and weight were self-reported in eight countries, and measured in person in four countries. Results: Three environmental attributes were associated with BMI or weight status in pooled data from 12 countries. Safety from traffic was the most robust correlate, suggesting that creating safe routes for walking/cycling by reducing the speed and volume of traffic might have a positive impact upon weight status/BMI across various geographical locations. Close proximity to several local destinations was associated with BMI across all countries, suggesting compact neighbourhoods with more places to walk related to lower BMI. Safety from crime showed a curvilinear relationship with BMI, with especially poor crime safety being related to higher BMI. Conclusions: Environmental interventions involving these three attributes appear to have international relevance and focusing on these might have implications for tackling overweight/obesity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033316</affiliation-url><afid>60033316</afid><affilname>Universiteit Gent</affilname><name-variant>Ghent University</name-variant><affiliation-city>Ghent</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029644</affiliation-url><afid>60029644</afid><affilname>Belgian National Fund for Scientific Research</affilname><name-variant>National Fund for Scientific Research</name-variant><affiliation-city>Brussels</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022420</affiliation-url><afid>60022420</afid><affilname>Instituto Nacional de Salud Publica</affilname><name-variant>National Institute of Public Health</name-variant><affiliation-city>Cuernavaca</affiliation-city><affiliation-country>Mexico</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022193</affiliation-url><afid>60022193</afid><affilname>University of Canberra</affilname><name-variant>University of Canberra</name-variant><affiliation-city>Canberra</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020004</affiliation-url><afid>60020004</afid><affilname>Pontificia Universidade Catolica do Parana</affilname><name-variant>Pontifical Catholic University of Paraná</name-variant><affiliation-city>Curitiba</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015043</affiliation-url><afid>60015043</afid><affilname>Universidade Federal do Parana</affilname><name-variant>Universidade Federal do Paraná</name-variant><affiliation-city>Curitiba</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023760</affiliation-url><afid>60023760</afid><affilname>Auckland University of Technology</affilname><name-variant>Auckland University of Technology</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60052106</affiliation-url><afid>60052106</afid><affilname>Universidad de Los Andes</affilname><name-variant>Universidad de Los Andes</name-variant><affiliation-city>Bogota</affiliation-city><affiliation-country>Colombia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109654806</affiliation-url><afid>109654806</afid><affilname>Faculty of Physical Culture</affilname><name-variant>Faculty of Physical Culture</name-variant><affiliation-city>Olomouc</affiliation-city><affiliation-country>Czech Republic</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019160</affiliation-url><afid>60019160</afid><affilname>Syddansk Universitet</affilname><name-variant>University of Southern Denmark</name-variant><affiliation-city>Odense</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006541</affiliation-url><afid>60006541</afid><affilname>The University of Hong Kong</affilname><name-variant>University of Hong Kong</name-variant><affiliation-city>Pokfulam</affiliation-city><affiliation-country>Hong Kong</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031846</affiliation-url><afid>60031846</afid><affilname>University of South Australia</affilname><name-variant>University of South Australia</name-variant><affiliation-city>Adelaide</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033019</affiliation-url><afid>60033019</afid><affilname>Universidad Publica de Navarra</affilname><name-variant>Univ. Pública de Navarra</name-variant><affiliation-city>Pamplona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033409</affiliation-url><afid>60033409</afid><affilname>Baker IDI Heart and Diabetes Institute</affilname><name-variant>Baker Heart Research Institute</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030612</affiliation-url><afid>60030612</afid><affilname>University of California, San Diego</affilname><name-variant>University of California San Diego</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018805</affiliation-url><afid>60018805</afid><affilname>Deakin University</affilname><name-variant>Deakin University</name-variant><affiliation-city>Geelong</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">19</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35510873600</author-url><authid>35510873600</authid><authname>De Bourdeaudhuij I.</authname><surname>De Bourdeaudhuij</surname><given-name>Ilse</given-name><initials>I.</initials><afid>60033316</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35621009100</author-url><authid>35621009100</authid><authname>Van Dyck D.</authname><surname>Van Dyck</surname><given-name>Delfien</given-name><initials>D.</initials><afid>60033316</afid><afid>60029644</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35621009100</author-url><authid>35621009100</authid><authname>Van Dyck D.</authname><surname>Van Dyck</surname><given-name>Delfien</given-name><initials>D.</initials><afid>60033316</afid><afid>60029644</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55344440800</author-url><authid>55344440800</authid><authname>Salvo D.</authname><surname>Salvo</surname><given-name>Deborah</given-name><initials>D.</initials><afid>60022420</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202083526</author-url><authid>7202083526</authid><authname>Davey R.</authname><surname>Davey</surname><given-name>Rachel</given-name><initials>R.</initials><afid>60022193</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56014946700</author-url><authid>56014946700</authid><authname>Reis R.</authname><surname>Reis</surname><given-name>Rodrigo S.</given-name><initials>R.S.</initials><afid>60020004</afid><afid>60015043</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56014946700</author-url><authid>56014946700</authid><authname>Reis R.</authname><surname>Reis</surname><given-name>Rodrigo S.</given-name><initials>R.S.</initials><afid>60020004</afid><afid>60015043</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8713212900</author-url><authid>8713212900</authid><authname>Schofield G.</authname><surname>Schofield</surname><given-name>Grant</given-name><initials>G.</initials><afid>60023760</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:15842722100</author-url><authid>15842722100</authid><authname>Sarmiento O.</authname><surname>Sarmiento</surname><given-name>Olga L.</given-name><initials>O.L.</initials><afid>60052106</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603960113</author-url><authid>6603960113</authid><authname>Mitas J.</authname><surname>Mitas</surname><given-name>Josef</given-name><initials>J.</initials><afid>109654806</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55398344800</author-url><authid>55398344800</authid><authname>Christiansen L.</authname><surname>Christiansen</surname><given-name>Lars Breum</given-name><initials>L.B.</initials><afid>60019160</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7202978517</author-url><authid>7202978517</authid><authname>MacFarlane D.</authname><surname>MacFarlane</surname><given-name>Duncan</given-name><initials>D.</initials><afid>60006541</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:18438631200</author-url><authid>18438631200</authid><authname>Sugiyama T.</authname><surname>Sugiyama</surname><given-name>Takemi</given-name><initials>T.</initials><afid>60031846</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:55937628000</author-url><authid>55937628000</authid><authname>Aguinaga-Ontoso I.</authname><surname>Aguinaga-Ontoso</surname><given-name>Ines</given-name><initials>I.</initials><afid>60033019</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7102307209</author-url><authid>7102307209</authid><authname>Owen N.</authname><surname>Owen</surname><given-name>Neville</given-name><initials>N.</initials><afid>60033409</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7101933750</author-url><authid>7101933750</authid><authname>Conway T.</authname><surname>Conway</surname><given-name>Terry L.</given-name><initials>T.L.</initials><afid>60030612</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7102766542</author-url><authid>7102766542</authid><authname>Sallis J.</authname><surname>Sallis</surname><given-name>James F.</given-name><initials>J.F.</initials><afid>60030612</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:14522064200</author-url><authid>14522064200</authid><authname>Cerin E.</authname><surname>Cerin</surname><given-name>Ester</given-name><initials>E.</initials><afid>60006541</afid><afid>60018805</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:14522064200</author-url><authid>14522064200</authid><authname>Cerin E.</authname><surname>Cerin</surname><given-name>Ester</given-name><initials>E.</initials><afid>60006541</afid><afid>60018805</afid></author><authkeywords>Built environment | International | Pooled data | Weight status</authkeywords><intid>2035950242</intid><source-id>14875</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930199119"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930199119?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930199119&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930199119&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930199119</prism:url><dc:identifier>SCOPUS_ID:84930199119</dc:identifier><eid>2-s2.0-84930199119</eid><dc:title>International study of perceived neighbourhood environmental attributes and Body Mass Index: IPEN Adult study in 12 countries</dc:title><dc:creator>De Bourdeaudhuij I.</dc:creator><prism:publicationName>International Journal of Behavioral Nutrition and Physical Activity</prism:publicationName><prism:eIssn>14795868</prism:eIssn><prism:volume>12</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>May 16, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12966-015-0228-y</prism:doi><dc:description>© 2015 De Bourdeaudhuij et al.; licensee BioMed Central. Background: Ecological models of health behaviour are an important conceptual framework to address the multiple correlates of obesity. Several single-country studies previously examined the relationship between the built environment and obesity in adults, but results are very diverse. An important reason for these mixed results is the limited variability in built environments in these single-country studies. Therefore, the aim of this study was to examine associations between perceived neighbourhood built environmental attributes and BMI/weight status in a multi-country study including 12 environmentally and culturally diverse countries. Methods: A multi-site cross-sectional study was conducted in 17 cities (study sites) across 12 countries (Australia, Belgium, Brazil, China, Colombia, Czech Republic, Denmark, Mexico, New Zealand, Spain, the UK and USA). Participants (n = 14222, 18-66 years) self-reported perceived neighbourhood environmental attributes. Height and weight were self-reported in eight countries, and measured in person in four countries. Results: Three environmental attributes were associated with BMI or weight status in pooled data from 12 countries. Safety from traffic was the most robust correlate, suggesting that creating safe routes for walking/cycling by reducing the speed and volume of traffic might have a positive impact upon weight status/BMI across various geographical locations. Close proximity to several local destinations was associated with BMI across all countries, suggesting compact neighbourhoods with more places to walk related to lower BMI. Safety from crime showed a curvilinear relationship with BMI, with especially poor crime safety being related to higher BMI. Conclusions: Environmental interventions involving these three attributes appear to have international relevance and focusing on these might have implications for tackling overweight/obesity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033316</affiliation-url><afid>60033316</afid><affilname>Universiteit Gent</affilname><name-variant>Ghent University</name-variant><affiliation-city>Ghent</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029644</affiliation-url><afid>60029644</afid><affilname>Belgian National Fund for Scientific Research</affilname><name-variant>National Fund for Scientific Research</name-variant><affiliation-city>Brussels</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022420</affiliation-url><afid>60022420</afid><affilname>Instituto Nacional de Salud Publica</affilname><name-variant>National Institute of Public Health</name-variant><affiliation-city>Cuernavaca</affiliation-city><affiliation-country>Mexico</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022193</affiliation-url><afid>60022193</afid><affilname>University of Canberra</affilname><name-variant>University of Canberra</name-variant><affiliation-city>Canberra</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020004</affiliation-url><afid>60020004</afid><affilname>Pontificia Universidade Catolica do Parana</affilname><name-variant>Pontifical Catholic University of Paraná</name-variant><affiliation-city>Curitiba</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015043</affiliation-url><afid>60015043</afid><affilname>Universidade Federal do Parana</affilname><name-variant>Universidade Federal do Paraná</name-variant><affiliation-city>Curitiba</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023760</affiliation-url><afid>60023760</afid><affilname>Auckland University of Technology</affilname><name-variant>Auckland University of Technology</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60052106</affiliation-url><afid>60052106</afid><affilname>Universidad de Los Andes</affilname><name-variant>Universidad de Los Andes</name-variant><affiliation-city>Bogota</affiliation-city><affiliation-country>Colombia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109654806</affiliation-url><afid>109654806</afid><affilname>Faculty of Physical Culture</affilname><name-variant>Faculty of Physical Culture</name-variant><affiliation-city>Olomouc</affiliation-city><affiliation-country>Czech Republic</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019160</affiliation-url><afid>60019160</afid><affilname>Syddansk Universitet</affilname><name-variant>University of Southern Denmark</name-variant><affiliation-city>Odense</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006541</affiliation-url><afid>60006541</afid><affilname>The University of Hong Kong</affilname><name-variant>University of Hong Kong</name-variant><affiliation-city>Pokfulam</affiliation-city><affiliation-country>Hong Kong</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031846</affiliation-url><afid>60031846</afid><affilname>University of South Australia</affilname><name-variant>University of South Australia</name-variant><affiliation-city>Adelaide</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033019</affiliation-url><afid>60033019</afid><affilname>Universidad Publica de Navarra</affilname><name-variant>Univ. Pública de Navarra</name-variant><affiliation-city>Pamplona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033409</affiliation-url><afid>60033409</afid><affilname>Baker IDI Heart and Diabetes Institute</affilname><name-variant>Baker Heart Research Institute</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030612</affiliation-url><afid>60030612</afid><affilname>University of California, San Diego</affilname><name-variant>University of California San Diego</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018805</affiliation-url><afid>60018805</afid><affilname>Deakin University</affilname><name-variant>Deakin University</name-variant><affiliation-city>Geelong</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">19</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35510873600</author-url><authid>35510873600</authid><authname>De Bourdeaudhuij I.</authname><surname>De Bourdeaudhuij</surname><given-name>Ilse</given-name><initials>I.</initials><afid>60033316</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35621009100</author-url><authid>35621009100</authid><authname>Van Dyck D.</authname><surname>Van Dyck</surname><given-name>Delfien</given-name><initials>D.</initials><afid>60033316</afid><afid>60029644</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35621009100</author-url><authid>35621009100</authid><authname>Van Dyck D.</authname><surname>Van Dyck</surname><given-name>Delfien</given-name><initials>D.</initials><afid>60033316</afid><afid>60029644</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55344440800</author-url><authid>55344440800</authid><authname>Salvo D.</authname><surname>Salvo</surname><given-name>Deborah</given-name><initials>D.</initials><afid>60022420</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202083526</author-url><authid>7202083526</authid><authname>Davey R.</authname><surname>Davey</surname><given-name>Rachel</given-name><initials>R.</initials><afid>60022193</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56014946700</author-url><authid>56014946700</authid><authname>Reis R.</authname><surname>Reis</surname><given-name>Rodrigo S.</given-name><initials>R.S.</initials><afid>60020004</afid><afid>60015043</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56014946700</author-url><authid>56014946700</authid><authname>Reis R.</authname><surname>Reis</surname><given-name>Rodrigo S.</given-name><initials>R.S.</initials><afid>60020004</afid><afid>60015043</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8713212900</author-url><authid>8713212900</authid><authname>Schofield G.</authname><surname>Schofield</surname><given-name>Grant</given-name><initials>G.</initials><afid>60023760</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:15842722100</author-url><authid>15842722100</authid><authname>Sarmiento O.</authname><surname>Sarmiento</surname><given-name>Olga L.</given-name><initials>O.L.</initials><afid>60052106</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603960113</author-url><authid>6603960113</authid><authname>Mitas J.</authname><surname>Mitas</surname><given-name>Josef</given-name><initials>J.</initials><afid>109654806</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56662833600</author-url><authid>56662833600</authid><authname>Christiansen B.</authname><surname>Christiansen</surname><given-name>Breum L.</given-name><initials>B.L.</initials><afid>60019160</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7202978517</author-url><authid>7202978517</authid><authname>MacFarlane D.</authname><surname>MacFarlane</surname><given-name>Duncan</given-name><initials>D.</initials><afid>60006541</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:18438631200</author-url><authid>18438631200</authid><authname>Sugiyama T.</authname><surname>Sugiyama</surname><given-name>Takemi</given-name><initials>T.</initials><afid>60031846</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:55937628000</author-url><authid>55937628000</authid><authname>Aguinaga-Ontoso I.</authname><surname>Aguinaga-Ontoso</surname><given-name>Ines</given-name><initials>I.</initials><afid>60033019</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7102307209</author-url><authid>7102307209</authid><authname>Owen N.</authname><surname>Owen</surname><given-name>Neville</given-name><initials>N.</initials><afid>60033409</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7101933750</author-url><authid>7101933750</authid><authname>Conway T.</authname><surname>Conway</surname><given-name>Terry L.</given-name><initials>T.L.</initials><afid>60030612</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7102766542</author-url><authid>7102766542</authid><authname>Sallis J.</authname><surname>Sallis</surname><given-name>James F.</given-name><initials>J.F.</initials><afid>60030612</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:14522064200</author-url><authid>14522064200</authid><authname>Cerin E.</authname><surname>Cerin</surname><given-name>Ester</given-name><initials>E.</initials><afid>60006541</afid><afid>60018805</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:14522064200</author-url><authid>14522064200</authid><authname>Cerin E.</authname><surname>Cerin</surname><given-name>Ester</given-name><initials>E.</initials><afid>60006541</afid><afid>60018805</afid></author><authkeywords>Built environment | International | Pooled data | Weight status</authkeywords><intid>536087453</intid><article-number>62</article-number><source-id>14875</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929317645"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929317645?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929317645&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929317645&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0928098715002080"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929317645</prism:url><dc:identifier>SCOPUS_ID:84929317645</dc:identifier><eid>2-s2.0-84929317645</eid><dc:title>Tanshinone IIA - Loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation</dc:title><dc:creator>Yan H.</dc:creator><prism:publicationName>European Journal of Pharmaceutical Sciences</prism:publicationName><prism:issn>09280987</prism:issn><prism:eIssn>18790720</prism:eIssn><prism:volume>76</prism:volume><prism:pageRange>156-164</prism:pageRange><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejps.2015.05.012</prism:doi><pii>S0928098715002080</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. This paper put forward a deconvolution-based method for designing and optimizing tanshinone IIA sustained-release pellets (TA-SRPs) with improved efficacy in the treatment of variant angina. TA-SRPs were prepared by coating TA ternary solid dispersion immediate-release pellets (TA-tSD-IRPs) with the blends of polyvinyl acetate (PVAc) and polyvinyl alcohol-polyethylene glycol (PVA-PEG) using fluidized bed technology. The plasma concentration-time curve of TA-tSD-IRPs following oral administration as a weight function was investigated in New Zealand white rabbits. The predicted/expected plasma concentration-time curve of TA-SRPs as a response function was simulated according to the circadian rhythm of variant angina during 24 h based on chronotherapy theory. The desired drug release profile of TA-SRPs was obtained via the point-area deconvolution procedure using the weight function and response function, and used for formulation optimization of TA-SRPs. The coating formulation of TA-SRPs was optimized as 70:30 (w/w) PVAc/PVA-PEG with 5% (w/w) coating weight due to in vitro drug release profile of these TA-SRPs was similar to the desired release profile (similarity factor f&lt;inf&gt;2&lt;/inf&gt; = 64.90). Pharmacokinetic studies of these optimized TA-SRPs validated that their actual plasma concentration-time curve possessed a basically consistent trend with the predicted plasma concentration-time curve and the absolute percent errors (%PE) of concentrations in 8-12 h were less than 10%. Pharmacodynamic studies further demonstrated that these TA-SRPs had stable and improved efficacy with almost simultaneous drug concentration-efficacy. In conclusion, deconvolution could be employed in the development of TA-SRPs for angina chronotherapy with simultaneous drug efficacy and reduced design blindness and complexity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005500</affiliation-url><afid>60005500</afid><affilname>China Pharmaceutical University</affilname><name-variant>China Pharmaceutical University</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022050</affiliation-url><afid>60022050</afid><affilname>Xuzhou Medical College</affilname><name-variant>Affiliated Hospital of Xuzhou Medical College</name-variant><affiliation-city>Xuzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643579200</author-url><authid>56643579200</authid><authname>Yan H.</authname><surname>Yan</surname><given-name>Hong Xiang</given-name><initials>H.X.</initials><afid>60005500</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55989014800</author-url><authid>55989014800</authid><authname>Li J.</authname><surname>Li</surname><given-name>Jin</given-name><initials>J.</initials><afid>60022050</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55885614500</author-url><authid>55885614500</authid><authname>Li Z.</authname><surname>Li</surname><given-name>Zheng Hua</given-name><initials>Z.H.</initials><afid>60005500</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35752755400</author-url><authid>35752755400</authid><authname>Zhang W.</authname><surname>Zhang</surname><given-name>Wen Li</given-name><initials>W.L.</initials><afid>60005500</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8226521100</author-url><authid>8226521100</authid><authname>Liu J.</authname><surname>Liu</surname><given-name>Jian Ping</given-name><initials>J.P.</initials><afid>60005500</afid></author><authkeywords>Angina chronotherapy | Deconvolution-based design | Pellets | Pharmacodynamics | Pharmacokinetics | Tanshinone IIA</authkeywords><intid>1535944216</intid><source-id>21331</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929413658"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929413658?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929413658&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929413658&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929413658</prism:url><dc:identifier>SCOPUS_ID:84929413658</dc:identifier><eid>2-s2.0-84929413658</eid><dc:title>Differences in physical activity domains, guideline adherence, and weight history between metabolically healthy and metabolically abnormal obese adults: A cross-sectional study</dc:title><dc:creator>Kanagasabai T.</dc:creator><prism:publicationName>International Journal of Behavioral Nutrition and Physical Activity</prism:publicationName><prism:eIssn>14795868</prism:eIssn><prism:volume>12</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>May 16, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12966-015-0227-z</prism:doi><dc:description>© 2015 Kanagasabai et al.; licensee BioMed Central. Background: Despite the accepted health consequences of obesity, emerging research suggests that a significant segment of adults with obesity are metabolically healthy (MHO). To date, MHO individuals have been shown to have higher levels of physical activity (PA), but little is known about the importance of PA domains or the influence of weight history compared to their metabolically abnormal (MAO) counterpart. Objective: To evaluate the relationship between PA domains, PA guideline adherence, and weight history on MHO. Methods: Pooled cycles of the National Health and Nutritional Examination Survey (NHANES) 1999-2006 (≥20 y; BMI ≥ 30 kg/m&lt;sup&gt;2&lt;/sup&gt;; N = 2,753) and harmonized criteria for metabolic syndrome (MetS) were used. Participants were categorized as "inactive" (no reported PA), "somewhat active" (&gt;0 to &lt; 500 metabolic equivalent (MET) min/week), and "active" (PA guideline adherence, ≥ 500 MET min/week) according to each domain of PA (total, recreational, transportation and household). Logistic and multinomial regressions were modelled for MHO and analyses were adjusted for age, sex, education, ethnicity, income, smoking and alcohol intake. Results: Compared to MAO, MHO participants were younger, had lower BMI, and were more likely to be classified as active according to their total and recreational PA level. Based on total PA levels, individuals who were active had a 70 % greater likelihood of having the MHO phenotype (OR = 1.70, 95 % CI: 1.19-2.43); however, once stratified by age (20-44 y; 45-59 y; and; ≥60 y), the association remained significant only amongst those aged 45-59 y. Although moderate and vigorous PA were inconsistently related to MHO following adjustment for covariates, losing ≥30 kg in the last 10 y and not gaining ≥10 kg since age 25 y were significant predictors of MHO phenotype for all PA domains, even if adherence to the PA guidelines were not met. Conclusion: Although PA is associated with MHO, the beneficial effects of PA may be moderated by longer-term changes in weight. Longitudinal analysis of physical activity and weight change trajectories are necessary to isolate the contribution of duration of obesity, PA behaviours, and longer-term outcomes amongst MHO individuals.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60083158</affiliation-url><afid>60083158</afid><affilname>Norman Bethune College</affilname><name-variant>York University</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000135</affiliation-url><afid>60000135</afid><affilname>University of North Florida</affilname><name-variant>University of North Florida</name-variant><affiliation-city>Jacksonville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:20734341100</author-url><authid>20734341100</authid><authname>Kanagasabai T.</authname><surname>Kanagasabai</surname><given-name>Thirumagal</given-name><initials>T.</initials><afid>60083158</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56646186200</author-url><authid>56646186200</authid><authname>Thakkar N.</authname><surname>Thakkar</surname><given-name>Niels A.</given-name><initials>N.A.</initials><afid>60083158</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6601997274</author-url><authid>6601997274</authid><authname>Kuk J.</authname><surname>Kuk</surname><given-name>Jennifer L.</given-name><initials>J.L.</initials><afid>60083158</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15065139000</author-url><authid>15065139000</authid><authname>Churilla J.</authname><surname>Churilla</surname><given-name>James R.</given-name><initials>J.R.</initials><afid>60000135</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602658858</author-url><authid>6602658858</authid><authname>Ardern C.</authname><surname>Ardern</surname><given-name>Chris I.</given-name><initials>C.I.</initials><afid>60083158</afid></author><authkeywords>Metabolically abnormal obesity | Metabolically health obesity | Physical activity domain | Physical activity guideline adherence | Weight history</authkeywords><intid>2035949636</intid><article-number>64</article-number><source-id>14875</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929318500"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929318500?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929318500&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929318500&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1089860315002098"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929318500</prism:url><dc:identifier>SCOPUS_ID:84929318500</dc:identifier><eid>2-s2.0-84929318500</eid><dc:title>Ageing modifies the effects of beetroot juice supplementation on 24-hour blood pressure variability: An individual participant meta-analysis</dc:title><dc:creator>Siervo M.</dc:creator><prism:publicationName>Nitric Oxide - Biology and Chemistry</prism:publicationName><prism:issn>10898603</prism:issn><prism:eIssn>10898611</prism:eIssn><prism:volume>47</prism:volume><prism:pageRange>97-105</prism:pageRange><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.niox.2015.04.007</prism:doi><pii>S1089860315002098</pii><dc:description>© 2015 Elsevier Inc. All rights reserved. Objectives: Abnormal circadian oscillations of blood pressure (BP) and nocturnal-diurnal BP differences (i.e., dipping) increase cardiovascular risk. Whether inorganic nitrate supplementation influences 24-hr BP variability is currently unknown. We studied the effects of high-nitrate beetroot juice supplementation on BP variability measured by 24-hr ambulatory BP monitoring (24-hr ABPM) in older subjects. Methods: Data from four independent randomised clinical trials were collated. Eighty-five older participants (age range: 55-76 years) were included in the final database. Two trials had an open-label, parallel design and two trials had a cross-over, double-blind design. Participants were randomised to either beetroot juice or placebo. Changes in 24-hr ABPM (daily, diurnal, nocturnal), variability (weighted-SDs), night-dipping, morning surge for systolic and diastolic BP were measured. Meta-analysis was conducted to obtain pooled estimates of the effect size for each BP outcome. Sub-group analyses were conducted to evaluate the influence of age, BMI, gender, BP status and changes in nitrite concentrations on the effect size. Results: The pooled effect of beetroot juice on all BP outcomes was not significant. Beetroot juice ingestion determined a significant decrease in nocturnal systolic BP variability in subjects aged less than 65y (2.8mmHg, -4.5 -1.0, p=0.002) compared to the older group (≥65y; 1.0mmHg, -2.2 4.2, p=0.54). A greater change in NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; concentrations after beetroot supplementation was associated with significant differences for nocturnal mean (-3.4mmHg, -0.6 -2.4, p=0.02) and variability (-0.8mmHg, -1.5 -0.06, p=0.03) of systolic BP. Conclusions: The vascular responsiveness to inorganic nitrate may be modified by mechanisms of vascular ageing influencing the reducing capacity to convert inorganic nitrate into nitrite and tissue-specific responses to dietary nitrate supplementation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006222</affiliation-url><afid>60006222</afid><affilname>Newcastle University, United Kingdom</affilname><name-variant>University of Newcastle upon Tyne</name-variant><affiliation-city>Newcastle</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006222</affiliation-url><afid>60006222</afid><affilname>Newcastle University, United Kingdom</affilname><name-variant>University of Newcastle upon Tyne</name-variant><affiliation-city>Newcastle</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60087634</affiliation-url><afid>60087634</afid><affilname>University of Sulaimaniya</affilname><name-variant>University of Sulaimani</name-variant><affiliation-city>Sulaimaniya</affiliation-city><affiliation-country>Iraq</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026479</affiliation-url><afid>60026479</afid><affilname>University of Exeter</affilname><name-variant>University of Exeter</name-variant><affiliation-city>Exeter</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14623120800</author-url><authid>14623120800</authid><authname>Siervo M.</authname><surname>Siervo</surname><given-name>M.</given-name><initials>M.</initials><afid>60006222</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56441057600</author-url><authid>56441057600</authid><authname>Lara J.</authname><surname>Lara</surname><given-name>J.</given-name><initials>J.</initials><afid>60006222</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56403391400</author-url><authid>56403391400</authid><authname>Jajja A.</authname><surname>Jajja</surname><given-name>A.</given-name><initials>A.</initials><afid>60006222</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56403376500</author-url><authid>56403376500</authid><authname>Sutyarjoko A.</authname><surname>Sutyarjoko</surname><given-name>A.</given-name><initials>A.</initials><afid>60006222</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:50561125500</author-url><authid>50561125500</authid><authname>Ashor A.</authname><surname>Ashor</surname><given-name>A. W.</given-name><initials>A.W.</initials><afid>60006222</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7201686275</author-url><authid>7201686275</authid><authname>Brandt K.</authname><surname>Brandt</surname><given-name>K.</given-name><initials>K.</initials><afid>60006222</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56403175000</author-url><authid>56403175000</authid><authname>Qadir O.</authname><surname>Qadir</surname><given-name>O.</given-name><initials>O.</initials><afid>60006222</afid><afid>60087634</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56403175000</author-url><authid>56403175000</authid><authname>Qadir O.</authname><surname>Qadir</surname><given-name>O.</given-name><initials>O.</initials><afid>60006222</afid><afid>60087634</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7005077062</author-url><authid>7005077062</authid><authname>Mathers J.</authname><surname>Mathers</surname><given-name>J. C.</given-name><initials>J.C.</initials><afid>60006222</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7007064137</author-url><authid>7007064137</authid><authname>Benjamin N.</authname><surname>Benjamin</surname><given-name>N.</given-name><initials>N.</initials><afid>60026479</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005108335</author-url><authid>7005108335</authid><authname>Winyard P.</authname><surname>Winyard</surname><given-name>P. G.</given-name><initials>P.G.</initials><afid>60026479</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:55621672100</author-url><authid>55621672100</authid><authname>Anning C.</authname><surname>Anning</surname><given-name>C.</given-name><initials>C.</initials><afid>60026479</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004860322</author-url><authid>7004860322</authid><authname>Shore A.</authname><surname>Shore</surname><given-name>A.</given-name><initials>A.</initials><afid>60026479</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:35174658200</author-url><authid>35174658200</authid><authname>Gilchrist M.</authname><surname>Gilchrist</surname><given-name>M.</given-name><initials>M.</initials><afid>60026479</afid></author><authkeywords>Ageing | Ambulatory blood pressure | Beetroot juice | Hypertension | Inorganic nitrate</authkeywords><intid>1535943707</intid><source-id>14200</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929313509"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929313509?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929313509&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929313509&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1089860315002050"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929313509</prism:url><dc:identifier>SCOPUS_ID:84929313509</dc:identifier><eid>2-s2.0-84929313509</eid><dc:title>The relationship between plasma and salivary NO&lt;inf&gt;x&lt;/inf&gt;</dc:title><dc:creator>Clodfelter W.</dc:creator><prism:publicationName>Nitric Oxide - Biology and Chemistry</prism:publicationName><prism:issn>10898603</prism:issn><prism:eIssn>10898611</prism:eIssn><prism:volume>47</prism:volume><prism:pageRange>85-90</prism:pageRange><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.niox.2015.04.003</prism:doi><pii>S1089860315002050</pii><dc:description>© 2015 Elsevier Inc. All rights reserved. Several studies have shown that fasting plasma nitrite (NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;) is an indicator of endothelial nitric oxide synthase (NOS) activity while plasma nitrate (NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;) or the sum of NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; and NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; (NO&lt;inf&gt;x&lt;/inf&gt;) does not reflect NOS function. Plasma NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; can also be elevated through dietary NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; where the NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; is partially reduced to NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; by oral bacteria and enters the plasma through the digestive system. NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; is taken up from plasma by salivary glands and the cycle repeats itself. Thus, one may propose that salivary NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; is an indicator of plasma NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; and consequently of NO production. Many brands of nitric oxide (NO) saliva test strips have been developed that suggest that their product is indicative of circulatory NO availability. However, data supporting a relationship between salivary and plasma NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; or NO bioavailability are lacking. Here we have measured basal salivary and plasma NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; and NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; to determine if any correlation exists between these in 13 adult volunteers. We found no significant correlation between basal salivary and plasma NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;. Also no correlation exists between salivary NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; and plasma NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;. However, we did see a correlation between salivary NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; and plasma NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;, and between salivary NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; and plasma NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;. In a separate study, we compared the efficiency of salivary NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; reduction with the efficacy of increasing plasma NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; and NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; after drinking beet juice, a high NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;-containing beverage, in 10 adult volunteers. No significant correlation was observed between the ex vivo salivary reduction of NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; to NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; and plasma increases in NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; or NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;. These results suggest that measures of salivary NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;, NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; or NO&lt;inf&gt;x&lt;/inf&gt; are not good indicators of endothelial function. In addition, the efficiency of saliva to reduce NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; to NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; ex-vivo does not demonstrate one's ability to increase plasma NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt; following consumption of dietary NO&lt;inf&gt;3&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033114</affiliation-url><afid>60033114</afid><affilname>Wake Forest University</affilname><name-variant>Wake Forest University</name-variant><affiliation-city>Winston Salem</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033114</affiliation-url><afid>60033114</afid><affilname>Wake Forest University</affilname><name-variant>Wake Forest University</name-variant><affiliation-city>Winston Salem</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033114</affiliation-url><afid>60033114</afid><affilname>Wake Forest University</affilname><name-variant>Wake Forest University</name-variant><affiliation-city>Winston Salem</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031437</affiliation-url><afid>60031437</afid><affilname>Wake Forest University School of Medicine</affilname><name-variant>Wake Forest Univ. School of Medicine</name-variant><affiliation-city>Winston Salem</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56644682900</author-url><authid>56644682900</authid><authname>Clodfelter W.</authname><surname>Clodfelter</surname><given-name>William H.</given-name><initials>W.H.</initials><afid>60033114</afid><afid>60033114</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56644682900</author-url><authid>56644682900</authid><authname>Clodfelter W.</authname><surname>Clodfelter</surname><given-name>William H.</given-name><initials>W.H.</initials><afid>60033114</afid><afid>60033114</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:9636175900</author-url><authid>9636175900</authid><authname>Basu S.</authname><surname>Basu</surname><given-name>Swati</given-name><initials>S.</initials><afid>60033114</afid><afid>60033114</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:9636175900</author-url><authid>9636175900</authid><authname>Basu S.</authname><surname>Basu</surname><given-name>Swati</given-name><initials>S.</initials><afid>60033114</afid><afid>60033114</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56644584100</author-url><authid>56644584100</authid><authname>Bolden C.</authname><surname>Bolden</surname><given-name>Crystal</given-name><initials>C.</initials><afid>60031437</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56644184900</author-url><authid>56644184900</authid><authname>Dos Santos P.</authname><surname>Dos Santos</surname><given-name>Patricia C.</given-name><initials>P.C.</initials><afid>60033114</afid><afid>60033114</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56644184900</author-url><authid>56644184900</authid><authname>Dos Santos P.</authname><surname>Dos Santos</surname><given-name>Patricia C.</given-name><initials>P.C.</initials><afid>60033114</afid><afid>60033114</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35355474700</author-url><authid>35355474700</authid><authname>King S.</authname><surname>King</surname><given-name>S. Bruce</given-name><initials>S.B.</initials><afid>60033114</afid><afid>60033114</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35355474700</author-url><authid>35355474700</authid><authname>King S.</authname><surname>King</surname><given-name>S. Bruce</given-name><initials>S.B.</initials><afid>60033114</afid><afid>60033114</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7003660509</author-url><authid>7003660509</authid><authname>Kim-Shapiro D.</authname><surname>Kim-Shapiro</surname><given-name>Daniel B.</given-name><initials>D.B.</initials><afid>60033114</afid><afid>60033114</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7003660509</author-url><authid>7003660509</authid><authname>Kim-Shapiro D.</authname><surname>Kim-Shapiro</surname><given-name>Daniel B.</given-name><initials>D.B.</initials><afid>60033114</afid><afid>60033114</afid></author><authkeywords>Nitrate | Nitric oxide bioavailability | Nitrite</authkeywords><intid>2035939651</intid><source-id>14200</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929335255"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929335255?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929335255&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929335255&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0165032715001834"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929335255</prism:url><dc:identifier>SCOPUS_ID:84929335255</dc:identifier><eid>2-s2.0-84929335255</eid><dc:title>Aspirin and statin use and the subsequent development of depression in men and women: Results from a longitudinal population-based study</dc:title><dc:creator>Glaus J.</dc:creator><prism:publicationName>Journal of Affective Disorders</prism:publicationName><prism:issn>01650327</prism:issn><prism:eIssn>15732517</prism:eIssn><prism:volume>182</prism:volume><prism:pageRange>126-131</prism:pageRange><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jad.2015.03.044</prism:doi><pii>S0165032715001834</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Objective: Low-grade chronic inflammation is one potential mechanism underlying the well-established association between major depressive disorder (MDD) and increased cardiovascular morbidity. Both aspirin and statins have anti-inflammatory properties, which may contribute to their preventive effect on cardiovascular diseases. Previous studies on the potentially preventive effect of these drugs on depression have provided inconsistent results. The aim of the present paper was to assess the prospective association between regular aspirin or statin use and the incidence of MDD. Method: This prospective cohort study included 1631 subjects (43.6% women, mean age 51.7 years), randomly selected from the general population of an urban area. Subjects underwent a thorough physical evaluation as well as semi-structured interviews investigating DSM-IV mental disorders at baseline and follow-up (mean duration 5.2 years). Analyses were adjusted for a wide array of potential confounders. Results: Our main finding was that regular aspirin or statin use at baseline did not reduce the incidence of MDD during follow-up, regardless of sex or age (hazard ratios, aspirin: 1.19; 95%CI, 0.68-2.08; and statins: 1.25; 95%CI, 0.73-2.14; respectively). Limitations: Our study is not a randomized clinical trial and could not adjust for all potential confounding factors, information on aspirin or statin use was collected only for the 6 months prior to the evaluations, and the sample was restricted to subjects between 35 and 66 years of age. Conclusion: Our data do not support a large scale preventive treatment of depression using aspirin or statins in subjects aged from 35 to 66 years from the community.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023561</affiliation-url><afid>60023561</afid><affilname>Centre Hospitalier Universitaire Vaudois</affilname><name-variant>CHUV</name-variant><affiliation-city>Lausanne</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009963</affiliation-url><afid>60009963</afid><affilname>Hopitaux universitaires de Geneve</affilname><name-variant>Geneva University Hospital</name-variant><affiliation-city>Geneve</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023561</affiliation-url><afid>60023561</afid><affilname>Centre Hospitalier Universitaire Vaudois</affilname><name-variant>CHUV</name-variant><affiliation-city>Lausanne</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55511554500</author-url><authid>55511554500</authid><authname>Glaus J.</authname><surname>Glaus</surname><given-name>Jennifer</given-name><initials>J.</initials><afid>60023561</afid><afid>60009963</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55511554500</author-url><authid>55511554500</authid><authname>Glaus J.</authname><surname>Glaus</surname><given-name>Jennifer</given-name><initials>J.</initials><afid>60023561</afid><afid>60009963</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506838109</author-url><authid>6506838109</authid><authname>Vandeleur C.</authname><surname>Vandeleur</surname><given-name>Caroline L.</given-name><initials>C.L.</initials><afid>60023561</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16063923700</author-url><authid>16063923700</authid><authname>Lasserre A.</authname><surname>Lasserre</surname><given-name>Aurélie M.</given-name><initials>A.M.</initials><afid>60023561</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:14029321600</author-url><authid>14029321600</authid><authname>Strippoli M.</authname><surname>Strippoli</surname><given-name>Marie Pierre F</given-name><initials>M.P.F.</initials><afid>60023561</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8628275700</author-url><authid>8628275700</authid><authname>Castelao E.</authname><surname>Castelao</surname><given-name>Enrique</given-name><initials>E.</initials><afid>60023561</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:49863248000</author-url><authid>49863248000</authid><authname>Gholam-Rezaee M.</authname><surname>Gholam-Rezaee</surname><given-name>Mehdi</given-name><initials>M.</initials><afid>60023561</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006946995</author-url><authid>7006946995</authid><authname>Waeber G.</authname><surname>Waeber</surname><given-name>Gérard</given-name><initials>G.</initials><afid>60023561</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:16070437200</author-url><authid>16070437200</authid><authname>Aubry J.</authname><surname>Aubry</surname><given-name>Jean Michel</given-name><initials>J.M.</initials><afid>60009963</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55163659400</author-url><authid>55163659400</authid><authname>Vollenweider P.</authname><surname>Vollenweider</surname><given-name>Peter</given-name><initials>P.</initials><afid>60023561</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6701501063</author-url><authid>6701501063</authid><authname>Preisig M.</authname><surname>Preisig</surname><given-name>Martin</given-name><initials>M.</initials><afid>60023561</afid></author><authkeywords>Aspirin | Inflammation | Longitudinal study | Major depressive disorder | Population-based study | Statins</authkeywords><intid>2035939437</intid><source-id>16245</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929166575"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929166575?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929166575&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929166575&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929166575</prism:url><dc:identifier>SCOPUS_ID:84929166575</dc:identifier><eid>2-s2.0-84929166575</eid><dc:title>Activation of mTOR for the loss of skeletal muscle in a hindlimb-suspended rat model</dc:title><dc:creator>Yoo Y.</dc:creator><prism:publicationName>International Journal of Precision Engineering and Manufacturing</prism:publicationName><prism:issn>22347593</prism:issn><prism:eIssn>20054602</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>1003-1010</prism:pageRange><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12541-015-0130-1</prism:doi><dc:description>© 2015, Korean Society for Precision Engineering and Springer-Verlag Berlin Heidelberg. The hindlimb-suspended or unloading rodent model was developed to mimic the microgravity of a spaceflight environment and has been used extensively to study the physiological responses to various aspects of musculoskeletal loading and unloading. This study investigated a compensating response to skeletal muscle loss in a hindlimb-suspended model that involves up-regulation of mTOR phosphorylation at four weeks. Body weight and muscle volume significantly decreased over four weeks in the hindlimb-suspended group compared with the sham control. Expressions of p-mTOR, raptor protein, p-p70S6K, p-Akt, and p-ERK, anti- or pro-apoptotic p53, Bcl-2, Bcl-XL, Bax, and Bak proteins were significantly increased in the hindlimb-suspended group compared to the sham control at four weeks. These results indicate that p-mTOR and p-Akt/p-ERK proteins might be up-regulated to compensate for the loss of skeletal muscle in the hindlimb-suspended model. Expressions of p-AMPK, IRS1, and IRS2 proteins were significantly increased, but that of p-eIF2α was significantly reduced in the hindlimb-suspended group compared to the sham control at four weeks. Our results suggest that the loss of skeletal muscle in a hindlimb-suspended model induces activation of p-mTOR and p-Akt/p-ERK proteins, and that these signaling pathways may preserve protein synthesis and cell growth in skeletal muscles of hindlimb-suspended animals.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016912</affiliation-url><afid>60016912</afid><affilname>Yonsei University</affilname><name-variant>Yonsei University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016912</affiliation-url><afid>60016912</afid><affilname>Yonsei University</affilname><name-variant>Yonsei University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031298</affiliation-url><afid>60031298</afid><affilname>Fraunhofer-Institut fur Keramische Technologien und Systeme - IKTS</affilname><name-variant>Fraunhofer Institute for Ceramic Technologies and Systems</name-variant><affiliation-city>Dresden</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56640580900</author-url><authid>56640580900</authid><authname>Yoo Y.</authname><surname>Yoo</surname><given-name>Yeong Min</given-name><initials>Y.M.</initials><afid>60016912</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55131470400</author-url><authid>55131470400</authid><authname>Park J.</authname><surname>Park</surname><given-name>Ji Hyung</given-name><initials>J.H.</initials><afid>60016912</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37031965600</author-url><authid>37031965600</authid><authname>Seo D.</authname><surname>Seo</surname><given-name>Dong Hyun</given-name><initials>D.H.</initials><afid>60016912</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56600013900</author-url><authid>56600013900</authid><authname>Eom S.</authname><surname>Eom</surname><given-name>Sinae</given-name><initials>S.</initials><afid>60016912</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55734348454</author-url><authid>55734348454</authid><authname>Jung Y.</authname><surname>Jung</surname><given-name>Young Jin</given-name><initials>Y.J.</initials><afid>60016912</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56640109700</author-url><authid>56640109700</authid><authname>Kim T.</authname><surname>Kim</surname><given-name>Tack Joong</given-name><initials>T.J.</initials><afid>60016912</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55195283000</author-url><authid>55195283000</authid><authname>Han T.</authname><surname>Han</surname><given-name>Tae Young</given-name><initials>T.Y.</initials><afid>60031298</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35214918300</author-url><authid>35214918300</authid><authname>Kim H.</authname><surname>Kim</surname><given-name>Han Sung</given-name><initials>H.S.</initials><afid>60016912</afid></author><authkeywords>Akt | Hindlimb-suspended rat | Micro-computed tomography | mTOR | Skeletal muscle</authkeywords><intid>1535916273</intid><source-id>10600153345</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929163691"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929163691?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929163691&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929163691&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929163691</prism:url><dc:identifier>SCOPUS_ID:84929163691</dc:identifier><eid>2-s2.0-84929163691</eid><dc:title>Dietary management in glycogen storage disease type III: what is the evidence?</dc:title><dc:creator>Derks T.</dc:creator><prism:publicationName>Journal of Inherited Metabolic Disease</prism:publicationName><prism:issn>01418955</prism:issn><prism:eIssn>15732665</prism:eIssn><prism:volume>38</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>545-550</prism:pageRange><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10545-014-9756-x</prism:doi><dc:description>© 2014, SSIEM. In childhood, GSD type III causes relatively severe fasting intolerance, classically associated with ketotic hypoglycaemia. During follow up, history of (documented) hypoglycaemia, clinical parameters (growth, liver size, motor development, neuromuscular parameters), laboratory parameters (glucose, lactate, ALAT, cholesterol, triglycerides, creatine kinase and ketones) and cardiac parameters all need to be integrated in order to titrate dietary management, for which age-dependent requirements need to be taken into account. Evidence from case studies and small cohort studies in both children and adults with GSD III demonstrate that prevention of hypoglycaemia and maintenance of euglycemia is not sufficient to prevent complications. Moreover, over-treatment with carbohydrates may even be harmful. The ageing cohort of GSD III patients, including the non-traditional clinical presentations in adulthood, raises ‬‬‬new questions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070240</affiliation-url><afid>60070240</afid><affilname>University of Groningen Medical Center Beatrix Children's Hospital</affilname><name-variant>University Medical Center Groningen</name-variant><affiliation-city>Groningen</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8542743500</author-url><authid>8542743500</authid><authname>Derks T.</authname><surname>Derks</surname><given-name>Terry G J</given-name><initials>T.G.J.</initials><afid>60070240</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640840800</author-url><authid>56640840800</authid><authname>Smit G.</authname><surname>Smit</surname><given-name>G. Peter A</given-name><initials>G.P.A.</initials><afid>60070240</afid></author><intid>1535916787</intid><source-id>15106</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929958434"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929958434?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929958434&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929958434&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929958434</prism:url><dc:identifier>SCOPUS_ID:84929958434</dc:identifier><eid>2-s2.0-84929958434</eid><dc:title>Educating for Vocational Excellence: The Auto/Biographical Exploration of Enacted Craft Pedagogy</dc:title><dc:creator>Tyson R.</dc:creator><prism:publicationName>Vocations and Learning</prism:publicationName><prism:issn>1874785X</prism:issn><prism:eIssn>18747868</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>229-245</prism:pageRange><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12186-015-9132-5</prism:doi><dc:description>© 2015, Springer Science+Business Media Dordrecht. The focus of this article is on education for vocational excellence (the combination of virtue and good judgment or phronesis/practical wisdom) through an examination of episodes from the auto/biographical study of master craftsman Wolfgang B. Vocational excellence is an issue sometimes discussed with regard to teacher training for schools and universities, often from an Aristotelian perspective, but less often when it comes to teaching and teacher training in the various models of craft apprenticeship education that exist. Even though there is no lack of arguments made for the excellence one is able to develop in learning a craft there are fewer takes on how such educational aims have been enacted. This is problematic because teaching vocational knowledge, including excellence, thereby becomes a practice that is less articulated than it could to be and more systematic reflection is inhibited. I will be considering these problems through the educational biography of a master bookbinder, gilder and engraver, Mr. Wolfgang B., and two stories he tells, one of his education in Paris and one of his own deliberations in teaching bookbinding. In doing this I am arguing for a systematic narrative approach to research on how to teach vocational excellence and by extension more generally with regard to teaching. This not only does justice to the particularity of practical wisdom but also calls attention to the imaginative character of being able to deliberate wisely.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028378</affiliation-url><afid>60028378</afid><affilname>Stockholms universitet</affilname><name-variant>Stockholm University</name-variant><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56254435400</author-url><authid>56254435400</authid><authname>Tyson R.</authname><surname>Tyson</surname><given-name>Ruhi</given-name><initials>R.</initials><afid>60028378</afid></author><authkeywords>Aristotle | Biography | Craft | Narrative | Phronesis | Schön | Vocational ethics</authkeywords><intid>536042829</intid><source-id>15700154701</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929312132"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929312132?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929312132&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929312132&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0928098715002055"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929312132</prism:url><dc:identifier>SCOPUS_ID:84929312132</dc:identifier><eid>2-s2.0-84929312132</eid><dc:title>The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides</dc:title><dc:creator>Zhi D.</dc:creator><prism:publicationName>European Journal of Pharmaceutical Sciences</prism:publicationName><prism:issn>09280987</prism:issn><prism:eIssn>18790720</prism:eIssn><prism:volume>76</prism:volume><prism:pageRange>149-155</prism:pageRange><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejps.2015.05.009</prism:doi><pii>S0928098715002055</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. As is well-known, hERG plays an essential role in phase III repolarization of cardiac action potentials. Blocking of hERG channels can lead to LQTS. Inhibition of the metabolism of CYPs activities may elevate plasma levels, to further increase accumulation of drug on cardiac. The elevated serum levels may however elicit unexpected toxicities. Therefore, the inhibition tests of hERG and CYP are central to the preclinical studies because they may lead to severe cardiac toxicity. Berberine is widely used as an antibacterial agent and often combined with macrolides to treat gastropathy. Our objective was to assess cardiac toxicity during the combined use of Berberine with macrolides. (1) Azithromycin reduced hERG currents by accelerated channel inactivation. (2) The combination of Berberine with Azithromycin reduced hERG currents, producing an inhibitive effect stronger than use of a single drug alone, due to the high binding affinity for the onset of inactivation. (3) When cells were perfused concomitantly with Berberine and Clarithromycin, they showed a stronger inhibitive effect on hERG currents by decreasing the time constant for the onset of inactivation. (4) The combined administration of Berberine with Clarithromycin had a powerful inhibitive effect on CYP3A activities than use of a single drug alone. Collectively, these results demonstrated that concomitant use of Berberine with macrolides may require close monitoring because of potential drug toxicities, especially cardiac toxicity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021615</affiliation-url><afid>60021615</afid><affilname>Harbin Medical University</affilname><name-variant>Harbin Medical University</name-variant><affiliation-city>Harbin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100865734</affiliation-url><afid>100865734</afid><affilname>State-Province Key Laboratory of Biopharmaceutical Engineering</affilname><name-variant>State-Province Key Laboratory of Biopharmaceutical Engineering</name-variant><affiliation-city>Harbin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56338971300</author-url><authid>56338971300</authid><authname>Zhi D.</authname><surname>Zhi</surname><given-name>Duo</given-name><initials>D.</initials><afid>60021615</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56457487900</author-url><authid>56457487900</authid><authname>Feng P.</authname><surname>Feng</surname><given-name>Pan Feng</given-name><initials>P.F.</initials><afid>60021615</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56008007900</author-url><authid>56008007900</authid><authname>Sun J.</authname><surname>Sun</surname><given-name>Jia Liang</given-name><initials>J.L.</initials><afid>60021615</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56306218600</author-url><authid>56306218600</authid><authname>Guo F.</authname><surname>Guo</surname><given-name>Fengfeng</given-name><initials>F.</initials><afid>60021615</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56456878400</author-url><authid>56456878400</authid><authname>Zhang R.</authname><surname>Zhang</surname><given-name>Rui</given-name><initials>R.</initials><afid>60021615</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36955804600</author-url><authid>36955804600</authid><authname>Zhao X.</authname><surname>Zhao</surname><given-name>Xin</given-name><initials>X.</initials><afid>60021615</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35203495700</author-url><authid>35203495700</authid><authname>Li B.</authname><surname>Li</surname><given-name>Bao Xin</given-name><initials>B.X.</initials><afid>60021615</afid><afid>100865734</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35203495700</author-url><authid>35203495700</authid><authname>Li B.</authname><surname>Li</surname><given-name>Bao Xin</given-name><initials>B.X.</initials><afid>60021615</afid><afid>100865734</afid></author><authkeywords>Azithromycin (AZM) | Berberine (BBR) | Cardiac toxicity | Clarithromycin (CLR) | Cytochrome P450 (CYP) | hERG</authkeywords><intid>1535943476</intid><source-id>21331</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930205751"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930205751?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930205751&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930205751&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930205751</prism:url><dc:identifier>SCOPUS_ID:84930205751</dc:identifier><eid>2-s2.0-84930205751</eid><dc:title>The endogenous molecular clock orchestrates the temporal separation of substrate metabolism in skeletal muscle</dc:title><dc:creator>Hodge B.</dc:creator><prism:publicationName>Skeletal Muscle</prism:publicationName><prism:eIssn>20445040</prism:eIssn><prism:volume>5</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>May 16, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13395-015-0039-5</prism:doi><dc:description>© 2015 Hodge et al. Skeletal muscle is a major contributor to whole-body metabolism as it serves as a depot for both glucose and amino acids, and is a highly metabolically active tissue. Within skeletal muscle exists an intrinsic molecular clock mechanism that regulates the timing of physiological processes. A key function of the clock is to regulate the timing of metabolic processes to anticipate time of day changes in environmental conditions. The purpose of this study was to identify metabolic genes that are expressed in a circadian manner and determine if these genes are regulated downstream of the intrinsic molecular clock by assaying gene expression in an inducible skeletal muscle-specific Bmal1 knockout mouse model (iMS-Bmal1&lt;sup&gt;-/-&lt;/sup&gt;). Methods: We used circadian statistics to analyze a publicly available, high-resolution time-course skeletal muscle expression dataset. Gene ontology analysis was utilized to identify enriched biological processes in the skeletal muscle circadian transcriptome. We generated a tamoxifen-inducible skeletal muscle-specific Bmal1 knockout mouse model and performed a time-course microarray experiment to identify gene expression changes downstream of the molecular clock. Wheel activity monitoring was used to assess circadian behavioral rhythms in iMS-Bmal1 &lt;sup&gt;-/-&lt;/sup&gt; and control iMS-Bmal1&lt;sup&gt;+/+&lt;/sup&gt; mice. Results: The skeletal muscle circadian transcriptome was highly enriched for metabolic processes. Acrophase analysis of circadian metabolic genes revealed a temporal separation of genes involved in substrate utilization and storage over a 24-h period. A number of circadian metabolic genes were differentially expressed in the skeletal muscle of the iMS-Bmal1 &lt;sup&gt;-/-&lt;/sup&gt; mice. The iMS-Bmal1&lt;sup&gt;-/-&lt;/sup&gt; mice displayed circadian behavioral rhythms indistinguishable from iMS-Bmal1&lt;sup&gt;+/+&lt;/sup&gt; mice. We also observed a gene signature indicative of a fast to slow fiber-type shift and amore oxidative skeletal muscle in the iMS-Bmal1 &lt;sup&gt;-/-&lt;/sup&gt; model. Conclusions: These data provide evidence that the intrinsic molecular clock in skeletal muscle temporally regulates genes involved in the utilization and storage of substrates independent of circadian activity. Disruption of this mechanism caused by phase shifts (that is, social jetlag) or night eating may ultimately diminish skeletal muscle's ability to efficiently maintain metabolic homeostasis over a 24-h period.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015941</affiliation-url><afid>60015941</afid><affilname>University of Kentucky</affilname><name-variant>University of Kentucky</name-variant><affiliation-city>Lexington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015941</affiliation-url><afid>60015941</afid><affilname>University of Kentucky</affilname><name-variant>University of Kentucky</name-variant><affiliation-city>Lexington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56646101900</author-url><authid>56646101900</authid><authname>Hodge B.</authname><surname>Hodge</surname><given-name>Brian A.</given-name><initials>B.A.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56646101900</author-url><authid>56646101900</authid><authname>Hodge B.</authname><surname>Hodge</surname><given-name>Brian A.</given-name><initials>B.A.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56645481600</author-url><authid>56645481600</authid><authname>Wen Y.</authname><surname>Wen</surname><given-name>Yuan</given-name><initials>Y.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56645481600</author-url><authid>56645481600</authid><authname>Wen Y.</authname><surname>Wen</surname><given-name>Yuan</given-name><initials>Y.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56645899900</author-url><authid>56645899900</authid><authname>Riley L.</authname><surname>Riley</surname><given-name>Lance A.</given-name><initials>L.A.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56645899900</author-url><authid>56645899900</authid><authname>Riley L.</authname><surname>Riley</surname><given-name>Lance A.</given-name><initials>L.A.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35367473800</author-url><authid>35367473800</authid><authname>Zhang X.</authname><surname>Zhang</surname><given-name>Xiping</given-name><initials>X.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35367473800</author-url><authid>35367473800</authid><authname>Zhang X.</authname><surname>Zhang</surname><given-name>Xiping</given-name><initials>X.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55908118400</author-url><authid>55908118400</authid><authname>England J.</authname><surname>England</surname><given-name>Jonathan H.</given-name><initials>J.H.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55908118400</author-url><authid>55908118400</authid><authname>England J.</authname><surname>England</surname><given-name>Jonathan H.</given-name><initials>J.H.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56582213000</author-url><authid>56582213000</authid><authname>Harfmann B.</authname><surname>Harfmann</surname><given-name>Brianna D.</given-name><initials>B.D.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56582213000</author-url><authid>56582213000</authid><authname>Harfmann B.</authname><surname>Harfmann</surname><given-name>Brianna D.</given-name><initials>B.D.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102115926</author-url><authid>7102115926</authid><authname>Schroder E.</authname><surname>Schroder</surname><given-name>Elizabeth A.</given-name><initials>E.A.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102115926</author-url><authid>7102115926</authid><authname>Schroder E.</authname><surname>Schroder</surname><given-name>Elizabeth A.</given-name><initials>E.A.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7005114608</author-url><authid>7005114608</authid><authname>Esser K.</authname><surname>Esser</surname><given-name>Karyn A.</given-name><initials>K.A.</initials><afid>60015941</afid><afid>60015941</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7005114608</author-url><authid>7005114608</authid><authname>Esser K.</authname><surname>Esser</surname><given-name>Karyn A.</given-name><initials>K.A.</initials><afid>60015941</afid><afid>60015941</afid></author><authkeywords>Anabolic | Bmal1 | Catabolic | Circadian | Metabolism | Molecular clock | Rev-erbα | Skeletal muscle | Temporal separation</authkeywords><intid>2036082141</intid><article-number>17</article-number><source-id>21100203714</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929413849"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929413849?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929413849&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929413849&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929413849</prism:url><dc:identifier>SCOPUS_ID:84929413849</dc:identifier><eid>2-s2.0-84929413849</eid><dc:title>Evaluation of &lt;sup&gt;11&lt;/sup&gt;C-Acetate and &lt;sup&gt;18&lt;/sup&gt; F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma</dc:title><dc:creator>Territo P.</dc:creator><prism:publicationName>BMC Medical Imaging</prism:publicationName><prism:eIssn>14712342</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>May 16, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12880-015-0058-z</prism:doi><dc:description>© Teritto et al.; licensee BioMed Central. Background: Hepatocellular carcinoma (HCC) remains a global health problem with unique diagnostic and therapeutic challenges, including difficulties in identifying the highest risk patients. Previous work from our lab has established the murine multidrug resistance-2 mouse (MDR2) model of HCC as a reasonable preclinical model that parallels the changes seen in human inflammatory associated HCC. The purpose of this study is to evaluate modalities of PET/CT in MDR2&lt;sup&gt;-/-&lt;/sup&gt; mice in order to facilitate therapeutic translational studies from bench to bedside. Methods: &lt;sup&gt;18&lt;/sup&gt;F-FDG and &lt;sup&gt;11&lt;/sup&gt;C-acetate PET/CT was performed on 12 m MDR2&lt;sup&gt;-/-&lt;/sup&gt; mice (n = 3/tracer) with HCC and 12 m MDR2&lt;sup&gt;-/+&lt;/sup&gt; control mice (n = 3/tracer) without HCC. To compare PET/CT to biological markers of HCC and cellular function, serum alpha-fetoprotein (AFP), lysophosphatidic acid (LPA), cAMP and hepatic tumor necrosis factor α (TNFα) were quantified in 3-12 m MDR2&lt;sup&gt;-/-&lt;/sup&gt; (n = 10) mice using commercially available ELISA analysis. To translate results in mice to patients &lt;sup&gt;11&lt;/sup&gt;C-acetate PET/CT was also performed in 8 patents suspected of HCC recurrence following treatment and currently on the liver transplant wait list. Results: Hepatic&lt;sup&gt;18&lt;/sup&gt;F-FDG metabolism was not significantly increased in MDR2&lt;sup&gt;-/-&lt;/sup&gt; mice. In contrast, hepatic &lt;sup&gt;11&lt;/sup&gt;C-acetate metabolism was significantly elevated in MDR2&lt;sup&gt;-/-&lt;/sup&gt; mice when compared to MDR2&lt;sup&gt;-/+&lt;/sup&gt; controls. Serum AFP and LPA levels increased in MDR2&lt;sup&gt;-/-&lt;/sup&gt; mice contemporaneous with the emergence of HCC. This was accompanied by a significant decrease in serum cAMP levels and an increase in hepatic TNFα. In patients suspected of HCC recurrence there were 5 true positives, 2 true negatives and 1 suspected false &lt;sup&gt;11&lt;/sup&gt;C-acetate negative. Conclusions: Hepatic &lt;sup&gt;11&lt;/sup&gt;C-acetate PET/CT tracks well with HCC in MDR2&lt;sup&gt;-/-&lt;/sup&gt; mice and patients with underlying liver disease. Consequently &lt;sup&gt;11&lt;/sup&gt;C-acetate PET/CT is well suited to study 1) HCC emergence/progression in patients and 2) reduce animal numbers required to study new chemotherapeutics in murine models of HCC.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021947</affiliation-url><afid>60021947</afid><affilname>Indiana University School of Medicine Indianapolis</affilname><name-variant>Indiana University School of Medicine</name-variant><affiliation-city>Indianapolis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Department of Surgery</affilname><name-variant>Radiology and Imaging Sciences</name-variant><affiliation-city>Indianapolis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6601984616</author-url><authid>6601984616</authid><authname>Territo P.</authname><surname>Territo</surname><given-name>Paul R.</given-name><initials>P.R.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602391475</author-url><authid>6602391475</authid><authname>Maluccio M.</authname><surname>Maluccio</surname><given-name>Mary</given-name><initials>M.</initials><afid>60021947</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37012914500</author-url><authid>37012914500</authid><authname>Riley A.</authname><surname>Riley</surname><given-name>Amanda A.</given-name><initials>A.A.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56427606500</author-url><authid>56427606500</authid><authname>McCarthy B.</authname><surname>McCarthy</surname><given-name>Brian P.</given-name><initials>B.P.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56645580500</author-url><authid>56645580500</authid><authname>Fletcher J.</authname><surname>Fletcher</surname><given-name>James</given-name><initials>J.</initials><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602931211</author-url><authid>6602931211</authid><authname>Tann M.</authname><surname>Tann</surname><given-name>Mark</given-name><initials>M.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7202190528</author-url><authid>7202190528</authid><authname>Saxena R.</authname><surname>Saxena</surname><given-name>Romil</given-name><initials>R.</initials><afid/></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603647516</author-url><authid>6603647516</authid><authname>Skill N.</authname><surname>Skill</surname><given-name>Nicholas J.</given-name><initials>N.J.</initials><afid>60021947</afid></author><intid>2035949530</intid><article-number>15</article-number><source-id>16561</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929625307"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929625307?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929625307&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929625307&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929625307</prism:url><dc:identifier>SCOPUS_ID:84929625307</dc:identifier><eid>2-s2.0-84929625307</eid><dc:title>Urban health indicators and indices - Current status</dc:title><dc:creator>Rothenberg R.</dc:creator><prism:publicationName>BMC Public Health</prism:publicationName><prism:eIssn>14712458</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12889-015-1827-x</prism:doi><dc:description>© 2015 Rothenberg et al.; licensee BioMed Central. Though numbers alone may be insufficient to capture the nuances of population health, they provide a common language of appraisal and furnish clear evidence of disparities and inequalities. Over the past 30 years, facilitated by high speed computing and electronics, considerable investment has been made in the collection and analysis of urban health indicators, environmental indicators, and methods for their amalgamation. Much of this work has been characterized by a perceived need for a standard set of indicators. We used publication databases (e.g. Medline) and web searches to identify compilations of health indicators and health metrics. We found 14 long-term large-area compilations of health indicators and determinants and seven compilations of environmental health indicators, comprising hundreds of metrics. Despite the plethora of indicators, these compilations have striking similarities in the domains from which the indicators are drawn - an unappreciated concordance among the major collections. Research with these databases and other sources has produced a small number of composite indices, and a number of methods for the amalgamation of indicators and the demonstration of disparities. These indices have been primarily used for large-area (nation, region, state) comparisons, with both developing and developed countries, often for purposes of ranking. Small area indices have been less explored, in part perhaps because of the vagaries of data availability, and because idiosyncratic local conditions require flexible approaches as opposed to a fixed format. One result has been advances in the ability to compare large areas, but with a concomitant deficiency in tools for public health workers to assess the status of local health and health disparities. Large area assessments are important, but the need for small area action requires a greater focus on local information and analysis, emphasizing method over prespecified content.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012387</affiliation-url><afid>60012387</afid><affilname>Georgia State University</affilname><name-variant>Georgia State University</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012387</affiliation-url><afid>60012387</afid><affilname>Georgia State University</affilname><name-variant>Georgia State University</name-variant><affiliation-city>Atlanta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027142</affiliation-url><afid>60027142</afid><affilname>Organisation Mondiale de la Sante</affilname><name-variant>WHO</name-variant><affiliation-city>Geneve</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005459918</author-url><authid>7005459918</authid><authname>Rothenberg R.</authname><surname>Rothenberg</surname><given-name>Richard</given-name><initials>R.</initials><afid>60012387</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:14720217100</author-url><authid>14720217100</authid><authname>Stauber C.</authname><surname>Stauber</surname><given-name>Christine</given-name><initials>C.</initials><afid>60012387</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56559477700</author-url><authid>56559477700</authid><authname>Weaver S.</authname><surname>Weaver</surname><given-name>Scott</given-name><initials>S.</initials><afid>60012387</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15822088900</author-url><authid>15822088900</authid><authname>Dai D.</authname><surname>Dai</surname><given-name>Dajun</given-name><initials>D.</initials><afid>60012387</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36195748700</author-url><authid>36195748700</authid><authname>Prasad A.</authname><surname>Prasad</surname><given-name>Amit</given-name><initials>A.</initials><afid>60027142</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55826259900</author-url><authid>55826259900</authid><authname>Kano M.</authname><surname>Kano</surname><given-name>Megumi</given-name><initials>M.</initials><afid>60027142</afid></author><authkeywords>Health disparities | Indicators | Indices | Urban metrics</authkeywords><intid>535990293</intid><article-number>494</article-number><source-id>19621</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929301616"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929301616?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929301616&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929301616&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929301616</prism:url><dc:identifier>SCOPUS_ID:84929301616</dc:identifier><eid>2-s2.0-84929301616</eid><dc:title>Beneficial effects of inorganic nitrate/nitrite in type 2 diabetes and its complications</dc:title><dc:creator>Bahadoran Z.</dc:creator><prism:publicationName>Nutrition and Metabolism</prism:publicationName><prism:eIssn>17437075</prism:eIssn><prism:volume>12</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12986-015-0013-6</prism:doi><dc:description>© 2015 Bahadoran et al.; licensee BioMed Central. Background and aim: The ability of inorganic nitrate and nitrite to convert to nitric oxide (NO), and some of its properties e.g. regulation of glucose metabolism, vascular homeostasis, and insulin signaling pathway, have recently raised the hypothesis that inorganic nitrate and nitrite could be potential therapeutic agents in type 2 diabetes. In this review, we reviewed experimental and clinical studies investigating the effect of nitrate/nitrite administration on various aspects of type 2 diabetes. Findings: Studies showed that an altered metabolism of nitrate/nitrite and impaired NO pathway occurs in diabetes which could contribute to its complications. Some important beneficial properties, including regulation of glucose homeostasis and insulin signaling pathway, improvement of insulin resistance and vascular function, hypotensive, hypolipidemic as well as anti-inflammatory and anti-oxidative effects have been observed following administration of inorganic nitrate/nitrite. Conclusion: It seems that dietary nitrate/nitrite could be a compensatory fuel for a disrupted nitrate/nitrite/NO pathway and related disorders in diabetes. Although some beneficial properties of nitrate/nitrite have been reported by experimental investigations, long-term clinical studies with various doses of inorganic nitrate/nitrite supplementation, are recommended to confirm these effects.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018934</affiliation-url><afid>60018934</afid><affilname>Shahid Beheshti University of Medical Sciences</affilname><name-variant>Shahid Beheshti University of Medical Sciences</name-variant><affiliation-city>Tehran</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018934</affiliation-url><afid>60018934</afid><affilname>Shahid Beheshti University of Medical Sciences</affilname><name-variant>Shahid Beheshti University of Medical Sciences</name-variant><affiliation-city>Tehran</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018934</affiliation-url><afid>60018934</afid><affilname>Shahid Beheshti University of Medical Sciences</affilname><name-variant>Shahid Beheshti University of Medical Sciences</name-variant><affiliation-city>Tehran</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018934</affiliation-url><afid>60018934</afid><affilname>Shahid Beheshti University of Medical Sciences</affilname><name-variant>Shahid Beheshti University of Medical Sciences</name-variant><affiliation-city>Tehran</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018934</affiliation-url><afid>60018934</afid><affilname>Shahid Beheshti University of Medical Sciences</affilname><name-variant>Shahid Beheshti University of Medical Sciences</name-variant><affiliation-city>Tehran</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37076706800</author-url><authid>37076706800</authid><authname>Bahadoran Z.</authname><surname>Bahadoran</surname><given-name>Zahra</given-name><initials>Z.</initials><afid>60018934</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24343618800</author-url><authid>24343618800</authid><authname>Ghasemi A.</authname><surname>Ghasemi</surname><given-name>Asghar</given-name><initials>A.</initials><afid>60018934</afid><afid>60018934</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24343618800</author-url><authid>24343618800</authid><authname>Ghasemi A.</authname><surname>Ghasemi</surname><given-name>Asghar</given-name><initials>A.</initials><afid>60018934</afid><afid>60018934</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602877078</author-url><authid>6602877078</authid><authname>Mirmiran P.</authname><surname>Mirmiran</surname><given-name>Parvin</given-name><initials>P.</initials><afid>60018934</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35519137100</author-url><authid>35519137100</authid><authname>Azizi F.</authname><surname>Azizi</surname><given-name>Fereidoun</given-name><initials>F.</initials><afid>60018934</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:9272215900</author-url><authid>9272215900</authid><authname>Hadaegh F.</authname><surname>Hadaegh</surname><given-name>Farzad</given-name><initials>F.</initials><afid>60018934</afid></author><authkeywords>Inorganic nitrate and nitrite | Insulin resistance | Nitric oxide | Type 2 diabetes</authkeywords><intid>1785945957</intid><article-number>16</article-number><source-id>15300154824</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929327707"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929327707?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929327707&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929327707&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1752928X15000724"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929327707</prism:url><dc:identifier>SCOPUS_ID:84929327707</dc:identifier><eid>2-s2.0-84929327707</eid><dc:title>Review of the medical and legal literature on restraint chairs</dc:title><dc:creator>Castillo E.</dc:creator><prism:publicationName>Journal of Forensic and Legal Medicine</prism:publicationName><prism:issn>1752928X</prism:issn><prism:eIssn>18787487</prism:eIssn><prism:volume>33</prism:volume><prism:pageRange>91-97</prism:pageRange><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jflm.2015.04.009</prism:doi><pii>S1752928X15000724</pii><dc:description>© 2015 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All rights reserved. Use of restraint chairs by law enforcement for violent individuals has generated controversy and a source of litigation because of reported injuries and deaths of restrained subjects. The purpose of this study is to review the available medical and legal literature and to allow the development of evidence-based, best practice recommendations to inform the further development of restraint chair policies. This is a structured literature review of four databases, two medical and two legal. The medical review focus was on the restraint chair with additional review of materials regarding other restraint methods and options. The legal review focused on litigation cases involving the restraint chair. The review of the medical literature revealed 21 peer-reviewed studies investigating the physiological or psychological effects of using a restraint chair on humans or primates. Of these studies, 20 were performed on primates. The single human study revealed no clinically significant effects from the restraint chair on test subjects. The legal literature review revealed very few cases where the restraint chair was either a major or minor focus. The overall issues relating to the restraint chair cases involved deviations from set protocols and rarely involved issues with the chair itself. The available medical literature reveals that the restraint chair poses little to no medical risk. Additionally, when used appropriately, the restraint chair alone carries little legal liability. With proper monitoring and adherence to set protocols, the restraint chair is a safe and appropriate device for use in restraining violent individuals.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018246</affiliation-url><afid>60018246</afid><affilname>University of California, San Diego, Medical Center</affilname><name-variant>UCSD Medical Center</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010365</affiliation-url><afid>60010365</afid><affilname>The University of British Columbia</affilname><name-variant>University of British Columbia</name-variant><affiliation-city>Vancouver</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027009</affiliation-url><afid>60027009</afid><affilname>Vancouver General Hospital</affilname><name-variant>Vancouver Hospital</name-variant><affiliation-city>Vancouver</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7102964564</author-url><authid>7102964564</authid><authname>Castillo E.</authname><surname>Castillo</surname><given-name>Edward M.</given-name><initials>E.M.</initials><afid>60018246</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55939726200</author-url><authid>55939726200</authid><authname>Coyne C.</authname><surname>Coyne</surname><given-name>Christopher J.</given-name><initials>C.J.</initials><afid>60018246</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7402680872</author-url><authid>7402680872</authid><authname>Chan T.</authname><surname>Chan</surname><given-name>Theodore C.</given-name><initials>T.C.</initials><afid>60018246</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35589866400</author-url><authid>35589866400</authid><authname>Hall C.</authname><surname>Hall</surname><given-name>Christine A.</given-name><initials>C.A.</initials><afid>60010365</afid><afid>60027009</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35589866400</author-url><authid>35589866400</authid><authname>Hall C.</authname><surname>Hall</surname><given-name>Christine A.</given-name><initials>C.A.</initials><afid>60010365</afid><afid>60027009</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006804102</author-url><authid>7006804102</authid><authname>Vilke G.</authname><surname>Vilke</surname><given-name>Gary M.</given-name><initials>G.M.</initials><afid>60018246</afid></author><authkeywords>Chair restraint | Emergency restraint | Physical restraint | Restraint chair | Restraint safety | Restraint techniques</authkeywords><intid>2035940741</intid><source-id>5100154502</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929340796"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929340796?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929340796&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929340796&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0165032715002682"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929340796</prism:url><dc:identifier>SCOPUS_ID:84929340796</dc:identifier><eid>2-s2.0-84929340796</eid><dc:title>IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation</dc:title><dc:creator>Al-Hakeim H.</dc:creator><prism:publicationName>Journal of Affective Disorders</prism:publicationName><prism:issn>01650327</prism:issn><prism:eIssn>15732517</prism:eIssn><prism:volume>182</prism:volume><prism:pageRange>106-114</prism:pageRange><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jad.2015.04.044</prism:doi><pii>S0165032715002682</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Major depressive disorder (MDD) and schizophrenia are associated with inflammatory processes. Studies have shown that these disorders exhibit increase in the level of one or more proinflammatory markers. However, these studies did not exclude patients with obvious inflammation (i.e., CRP&gt;6 mg/L). Therefore, a comprehensive study should include those inflammatory disorders. In the present study, the inflammatory natures of MDD and schizophrenia were investigated. To achieve this goal, serum levels of interleukin-6 (IL-6), interleukin-18 (IL-18), tumor necrosis factor alpha (TNFα), and soluble interleukin 2 receptor (sIL-2R) in depressed and schizophrenic patients were obtained and compared with those of the control group. Results showed a significant increase (p&lt;0.05) in serum levels of IL-6, IL-18, TNFα, and sIL-2R in MDD and schizophrenic patients compared with the control group. Also patients with schizophrenia group showed higher levels of the inflammatory markers than MDD and control groups. The current study concluded that the immunological response in the MDD and schizophrenic patients groups was significantly stimulated. These disorders may be considered an inflammatory disorder because of elevated levels of proinflammatory cytokines in spite of lacking an overt inflammation. Furthermore results of this study suggested the possibility of the use of anti-inflammatory drugs as adjuvant therapy in schizophrenic and depressive disorders.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60071160</affiliation-url><afid>60071160</afid><affilname>Kufa University</affilname><name-variant>Kufa University</name-variant><affiliation-city>Kufa</affiliation-city><affiliation-country>Iraq</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60071160</affiliation-url><afid>60071160</afid><affilname>Kufa University</affilname><name-variant>Kufa University</name-variant><affiliation-city>Kufa</affiliation-city><affiliation-country>Iraq</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24398507900</author-url><authid>24398507900</authid><authname>Al-Hakeim H.</authname><surname>Al-Hakeim</surname><given-name>Hussein Kadhem</given-name><initials>H.K.</initials><afid>60071160</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56644962500</author-url><authid>56644962500</authid><authname>Al-Rammahi D.</authname><surname>Al-Rammahi</surname><given-name>Duaa Abdulzahraa</given-name><initials>D.A.</initials><afid>60071160</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56644519000</author-url><authid>56644519000</authid><authname>Al-Dujaili A.</authname><surname>Al-Dujaili</surname><given-name>Arafat Hussein</given-name><initials>A.H.</initials><afid>60071160</afid></author><authkeywords>Depression | Inflammation | Interleukin | Schizophrenia | TNFα</authkeywords><intid>535946551</intid><source-id>16245</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929146466"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929146466?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929146466&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929146466&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929146466</prism:url><dc:identifier>SCOPUS_ID:84929146466</dc:identifier><eid>2-s2.0-84929146466</eid><dc:title>Mitochondrial disease associated with complex I (NADH-CoQ oxidoreductase) deficiency</dc:title><dc:creator>Scheffler I.</dc:creator><prism:publicationName>Journal of Inherited Metabolic Disease</prism:publicationName><prism:issn>01418955</prism:issn><prism:eIssn>15732665</prism:eIssn><prism:volume>38</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>405-415</prism:pageRange><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10545-014-9768-6</prism:doi><dc:description>© 2014, SSIEM. Mitochondrial diseases due to a reduced capacity for oxidative phosphorylation were first identified more than 20 years ago, and their incidence is now recognized to be quite significant. In a large proportion of cases the problem can be traced to a complex I (NADH-CoQ oxidoreductase) deficiency (Phenotype MIM #252010). Because the complex consists of 44 subunits, there are many potential targets for pathogenic mutations, both on the nuclear and mitochondrial genomes. Surprisingly, however, almost half of the complex I deficiencies are due to defects in as yet unidentified genes that encode proteins other than the structural proteins of the complex. This review attempts to summarize what we know about the molecular basis of complex I deficiencies: mutations in the known structural genes, and mutations in an increasing number of genes encoding “assembly factors”, that is, proteins required for the biogenesis of a functional complex I that are not found in the final complex I. More such genes must be identified before definitive genetic counselling can be applied in all cases of affected families.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030612</affiliation-url><afid>60030612</afid><affilname>University of California, San Diego</affilname><name-variant>University of California San Diego</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006036910</author-url><authid>7006036910</authid><authname>Scheffler I.</authname><surname>Scheffler</surname><given-name>Immo E.</given-name><initials>I.E.</initials><afid>60030612</afid></author><intid>35915878</intid><source-id>15106</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929324415"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929324415?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929324415&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929324415&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S156757691500226X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929324415</prism:url><dc:identifier>SCOPUS_ID:84929324415</dc:identifier><eid>2-s2.0-84929324415</eid><dc:title>Platycodin D attenuates acute lung injury by suppressing apoptosis and inflammation in vivo and in vitro</dc:title><dc:creator>Tao W.</dc:creator><prism:publicationName>International Immunopharmacology</prism:publicationName><prism:issn>15675769</prism:issn><prism:eIssn>18781705</prism:eIssn><prism:volume>27</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>138-147</prism:pageRange><prism:coverDate>2015-05-16</prism:coverDate><prism:coverDisplayDate>16 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.intimp.2015.05.005</prism:doi><pii>S156757691500226X</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Platycodin D (PLD) is the major triterpene saponin in the root of Platycodon grandiflorum (Jacq.) with various pharmacological activities. The purpose of the present study was to evaluate the protective effects and possible mechanisms of PLD on acute lung injury (ALI) both in vivo and in vitro. In vivo, we used two ALI models, lipopolysaccharide (LPS)-induced ALI and bleomycin (BLE)-induced ALI to evaluate the protective effects and possible mechanisms of PLD. Female BALB/c mice were randomly divided into the following groups: control group, LPS group, LPS plus pre-treatment with dexamethasone (2 mg/kg) group, LPS plus pre-treatment with PLD groups (50 mg/kg, 100 mg/kg), LPS plus post-treatment with dexamethasone (2 mg/kg) group, LPS plus post-treatment with PLD groups (50 mg/kg, 100 mg/kg), BLE group, BLE plus pre-treatment with dexamethasone (2 mg/kg) group, BLE plus pre-treatment with PLD groups (50 mg/kg, 100 mg/kg), BLE plus post-treatment with dexamethasone (2 mg/kg) group, and BLE plus post-treatment with PLD groups (50 mg/kg, 100 mg/kg). PLD was orally administered before or after LPS or BLE challenge with mice. Mice were sacrificed, and lung tissues and bronchoalveolar fluid (BALF) were prepared for further analysis. Our results showed that PLD significantly decreased lung wet-to-dry weight ratio (lung W/D weight ratio), total leukocyte number and neutrophil percentage in the BALF, and myeloperoxidase (MPO) activity of lung in a dose-dependent manner. Besides, cytokine levels, including interleukin (IL)-6, tumor neurosis factor (TNF)-α were also found significantly inhibited in BALF. Furthermore, PLD effectively inhibited the expressions of nuclear factor κB (NF-κB), Caspase-3 and Bax in the lung tissues, as well as restored the expression of Bcl-2 in the lungs and improved the superoxide dismutase (SOD) activity in BALF. In vitro, we used LPS-challenged cell model to evaluate the protective effects and possible mechanisms of PLD. MLE-12 cells were stimulated with LPS in the presence and absence of PLD. The levels of TNF-α, IL-6 and the expressions of NF-κB, Caspase-3, and Bax were remarkably down-regulated, while the expression of bcl-2 was significantly up-regulated in PLD treatment groups in MLE-12 cells. These results showed that the administration of PLD improved ALI both in vivo and in vitro, possibly through suppressing apoptosis and inflammation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005189</affiliation-url><afid>60005189</afid><affilname>Nanjing University of Traditional Chinese Medicine</affilname><name-variant>Nanjing University of Traditional Chinese Medicine</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005189</affiliation-url><afid>60005189</afid><affilname>Nanjing University of Traditional Chinese Medicine</affilname><name-variant>Nanjing University of Traditional Chinese Medicine</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017763</affiliation-url><afid>60017763</afid><affilname>Ningxia Medical College</affilname><name-variant>Ningxia Medical University</name-variant><affiliation-city>Yinchuan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073489</affiliation-url><afid>60073489</afid><affilname>Changchun University</affilname><name-variant>Changchun University</name-variant><affiliation-city>Changchun</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:29167542600</author-url><authid>29167542600</authid><authname>Tao W.</authname><surname>Tao</surname><given-name>Weiwei</given-name><initials>W.</initials><afid>60005189</afid><afid>60005189</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:29167542600</author-url><authid>29167542600</authid><authname>Tao W.</authname><surname>Tao</surname><given-name>Weiwei</given-name><initials>W.</initials><afid>60005189</afid><afid>60005189</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56643940600</author-url><authid>56643940600</authid><authname>Su Q.</authname><surname>Su</surname><given-name>Qiang</given-name><initials>Q.</initials><afid>60005189</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56643434800</author-url><authid>56643434800</authid><authname>Wang H.</authname><surname>Wang</surname><given-name>Hanqin</given-name><initials>H.</initials><afid>60017763</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56643582700</author-url><authid>56643582700</authid><authname>Guo S.</authname><surname>Guo</surname><given-name>Shen</given-name><initials>S.</initials><afid>60005189</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36665991700</author-url><authid>36665991700</authid><authname>Chen Y.</authname><surname>Chen</surname><given-name>Yanyan</given-name><initials>Y.</initials><afid>60005189</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:25960050700</author-url><authid>25960050700</authid><authname>Duan J.</authname><surname>Duan</surname><given-name>Jinao</given-name><initials>J.</initials><afid>60005189</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56605732800</author-url><authid>56605732800</authid><authname>Wang S.</authname><surname>Wang</surname><given-name>Shumin</given-name><initials>S.</initials><afid>60073489</afid></author><authkeywords>Acute lung injury | Apoptosis | Inflammation | Platycodin D</authkeywords><intid>1785945176</intid><source-id>22432</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929376519"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929376519?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929376519&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929376519&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929376519</prism:url><dc:identifier>SCOPUS_ID:84929376519</dc:identifier><eid>2-s2.0-84929376519</eid><dc:title>Impact of leucine supplementation on exercise training induced anti-cardiac remodeling effect in heart failure mice</dc:title><dc:creator>Monteiro de Moraes W.</dc:creator><prism:publicationName>Nutrients</prism:publicationName><prism:eIssn>20726643</prism:eIssn><prism:volume>7</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>3751-3766</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.3390/nu7053751</prism:doi><dc:description>© 2015 by the authors; licensee MDPI, Basel, Switzerland. Leucine supplementation potentiates the effects of aerobic exercise training (AET) on skeletal muscle; however, its potential effects associated with AET on cardiac muscle have not been clarified yet. We tested whether leucine supplementation would potentiate the anti-cardiac remodeling effect of AET in a genetic model of sympathetic hyperactivity-induced heart failure in mice (α&lt;inf&gt;2A&lt;/inf&gt;/α&lt;inf&gt;2C&lt;/inf&gt;ARKO). Mice were assigned to five groups: wild type mice treated with placebo and sedentary (WT, n = 11), α&lt;inf&gt;2A&lt;/inf&gt;/α&lt;inf&gt;2C&lt;/inf&gt;ARKO treated with placebo and sedentary (KO, n = 9), α&lt;inf&gt;2A&lt;/inf&gt;/α&lt;inf&gt;2C&lt;/inf&gt;ARKO treated with leucine and sedentary (KOL, n = 11), α&lt;inf&gt;2A&lt;/inf&gt;/α&lt;inf&gt;2C&lt;/inf&gt;ARKO treated with placebo and AET (KOT, n = 12) or α&lt;inf&gt;2A&lt;/inf&gt;/α&lt;inf&gt;2C&lt;/inf&gt;ARKO treated with leucine and AET (KOLT, n = 12). AET consisted of four weeks on a treadmill with 60 min sessions (six days/week, 60% of maximal speed) and administration by gavage of leucine (1.35 g/kg/day) or placebo (distilled water). The AET significantly improved exercise capacity, fractional shortening and re-established cardiomyocytes’ diameter and collagen fraction in KOT. Additionally, AET significantly prevented the proteasome hyperactivity, increased misfolded proteins and HSP27 expression. Isolated leucine supplementation displayed no effect on cardiac function and structure (KOL), however, when associated with AET (KOLT), it increased exercise tolerance to a higher degree than isolated AET (KOT) despite no additional effects on AET induced anticardiac remodeling. Our results provide evidence for the modest impact of leucine supplementation on cardiac structure and function in exercised heart failure mice. Leucine supplementation potentiated AET effects on exercise tolerance, which might be related to its recognized impact on skeletal muscle.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014992</affiliation-url><afid>60014992</afid><affilname>Universidade Federal de Sao Paulo</affilname><name-variant>Federal University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112953958</affiliation-url><afid>112953958</afid><affilname>Nove de Julho University</affilname><name-variant>University Nove de Julho</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55094616800</author-url><authid>55094616800</authid><authname>de Moraes W.</authname><surname>de Moraes</surname><given-name>Wilson Max Almeida Monteiro</given-name><initials>W.M.A.M.</initials><afid>60014992</afid><afid>60008088</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55094616800</author-url><authid>55094616800</authid><authname>Monteiro de Moraes W.</authname><surname>Monteiro de Moraes</surname><given-name>Wilson Max Almeida</given-name><initials>W.M.A.</initials><afid>60014992</afid><afid>60008088</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56644885000</author-url><authid>56644885000</authid><authname>Melara T.</authname><surname>Melara</surname><given-name>Thaís Plasti</given-name><initials>T.P.</initials><afid>60008088</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56644965100</author-url><authid>56644965100</authid><authname>Moraes de Souza P.</authname><surname>Moraes de Souza</surname><given-name>Pamella Ramona</given-name><initials>P.R.</initials><afid>112953958</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56644181800</author-url><authid>56644181800</authid><authname>Guimarães F.</authname><surname>Guimarães</surname><given-name>Fabiana de Salvi</given-name><initials>F.d.S.</initials><afid>60008088</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:44460924300</author-url><authid>44460924300</authid><authname>Bozi L.</authname><surname>Bozi</surname><given-name>Luiz Henrique Marchesi</given-name><initials>L.H.M.</initials><afid>60008088</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35598683100</author-url><authid>35598683100</authid><authname>Brum P.</authname><surname>Brum</surname><given-name>Patricia Chakur</given-name><initials>P.C.</initials><afid>60008088</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:14522809600</author-url><authid>14522809600</authid><authname>Medeiros A.</authname><surname>Medeiros</surname><given-name>Alessandra</given-name><initials>A.</initials><afid>60014992</afid></author><authkeywords>Aerobic exercise training | Cardiac remodeling | Heart failure | Leucine</authkeywords><intid>2035938963</intid><source-id>19700188323</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929441325"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929441325?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929441325&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929441325&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929441325</prism:url><dc:identifier>SCOPUS_ID:84929441325</dc:identifier><eid>2-s2.0-84929441325</eid><dc:title>The Impact of Oral Intake of Dydrogesterone on Fetal Heart Development During Early Pregnancy</dc:title><dc:creator>Zaqout M.</dc:creator><prism:publicationName>Pediatric Cardiology</prism:publicationName><prism:issn>01720643</prism:issn><prism:eIssn>14321971</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00246-015-1190-9</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Congenital heart disease is the most frequent form of congenital anomaly in newborn infants and accounts for more than a quarter of all serious congenital afflictions worldwide. A genetic etiology is identified in &lt;20 % of cases of congenital heart defects, and in most cases the etiology remains a mystery. In the context of the health burden caused by congenital heart disease, the contribution of non-inherited risk factors is important especially if it turns out to be caused by a drug which can be avoided during pregnancy. We sought to determine whether maternal dydrogesterone treatment in early pregnancy is associated with congenital heart disease in the infant. We conducted a retrospective case–control study of birth defects and associated risk factors. Data were obtained and compared between 202 children born with congenital heart disease and a control group consisting of 200 children. All children were born in the period of 2010–2013. Dydrogesterone exposure was defined as any reported use during the first trimester of pregnancy. Exclusion criteria included stillbirths, children with chromosomal abnormalities and infants of mothers with chronic medical illnesses, e.g., diabetes. Binary logistic regression analyses were used to analyze the data and attempt to identify a causal relationship between drug exposure and congenital heart disease. Mothers of children born with congenital heart disease received more dydrogesterone during first trimester of pregnancy than mothers of children in the control group [adjusted odds ratio 2.71; (95 % CI 1.54–4.24); P = 0.001]. We identified a positive association between dydrogesterone usage during early pregnancy and congenital heart disease in the offspring. Nevertheless, further studies are needed to confirm these results.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068590</affiliation-url><afid>60068590</afid><affilname>University Hospital of Ghent</affilname><name-variant>University Hospital</name-variant><affiliation-city>Ghent</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114424677</affiliation-url><afid>114424677</afid><affilname>Abd Al Aziz Al Rantisi Specialist Pediatric Hospital</affilname><name-variant>Abd Al Aziz Al Rantisi Specialist Pediatric Hospital</name-variant><affiliation-city>Gaza</affiliation-city><affiliation-country>Palestine</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100330579</affiliation-url><afid>100330579</afid><affilname>Al-Quds University</affilname><name-variant>Al Quds University</name-variant><affiliation-city>Gaza</affiliation-city><affiliation-country>Palestine</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015150</affiliation-url><afid>60015150</afid><affilname>Imperial College London</affilname><name-variant>Imperial College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26538366400</author-url><authid>26538366400</authid><authname>Zaqout M.</authname><surname>Zaqout</surname><given-name>Mahmoud</given-name><initials>M.</initials><afid>60068590</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56418623200</author-url><authid>56418623200</authid><authname>Aslem E.</authname><surname>Aslem</surname><given-name>Emad</given-name><initials>E.</initials><afid>114424677</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55326970800</author-url><authid>55326970800</authid><authname>Abuqamar M.</authname><surname>Abuqamar</surname><given-name>Mazen</given-name><initials>M.</initials><afid>100330579</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56646629600</author-url><authid>56646629600</authid><authname>Abughazza O.</authname><surname>Abughazza</surname><given-name>Osama</given-name><initials>O.</initials><afid>60015150</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23502419700</author-url><authid>23502419700</authid><authname>Panzer J.</authname><surname>Panzer</surname><given-name>Joseph</given-name><initials>J.</initials><afid>60068590</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006456214</author-url><authid>7006456214</authid><authname>de Wolf D.</authname><surname>de Wolf</surname><given-name>Daniel</given-name><initials>D.</initials><afid>60068590</afid></author><authkeywords>Congenital heart disease | Dydrogesterone | Pregnancy</authkeywords><intid>1785955721</intid><source-id>20526</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929333810"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929333810?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929333810&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929333810&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929333810</prism:url><dc:identifier>SCOPUS_ID:84929333810</dc:identifier><eid>2-s2.0-84929333810</eid><dc:title>Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy</dc:title><dc:creator>Latus H.</dc:creator><prism:publicationName>Journal of Cardiovascular Magnetic Resonance</prism:publicationName><prism:issn>10976647</prism:issn><prism:eIssn>1532429X</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12968-015-0142-0</prism:doi><dc:description>© 2015 Latus et al.; licensee BioMed Central. Background: Different patterns of late gadolinium enhancement (LGE) including mid-wall fibrosis using cardiovascular magnetic resonance (CMR) have been reported in adult patients presenting with non-ischemic dilated cardiomyopathy (DCM). In these studies, LGE was associated with pronounced LV remodelling and predicted adverse cardiac outcomes. Accordingly, the purpose of our study was to determine the presence and patterns of LGE in children and adolescents with DCM. Methods: Patients &lt;18 years of age presenting with severe congestive heart failure who were admitted for evaluation of heart transplantation at our centre underwent CMR examination which consisted of ventricular functional analysis and assessment of LGE for detection of myocardial fibrosis. Ischemic DCM was excluded by coronary angiography, and right ventricular endomyocardial biopsies ruled out acute myocarditis. Results: Thirty-one patients (mean age 2.1±4.2 years) with severe LV dilatation (mean indexed LVEDV 136±48 ml/m&lt;sup&gt;2&lt;/sup&gt;) and LV dysfunction (mean LV-EF 23±8%) were examined. LGE was detected in 5 of the 31 patients (16%) appearing in various patterns characterized as mid-wall (n=1), focal patchy (n=1), RV insertion site (n=1) and transmural (n=2). Based on histopathological analysis, 4 of the 5 LGE positive patients had lymphocytic myocarditis, whereas one patient was diagnosed with idiopathic DCM. Conclusions: In children and adolescents with DCM, focal histologically proven myocardial fibrosis is rarely detected by LGE CMR despite marked LV dilatation and severely depressed LV function. LGE occurred in various patterns and mostly in patients with inflammatory cardiomyopathy. It remains unclear whether myocardial fibrosis in childhood DCM reflects different endogenous repair mechanisms that enable favourable reverse remodelling. Larger trials are needed to assess the prognostic implications of LGE in childhood DCM.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008248</affiliation-url><afid>60008248</afid><affilname>Universitatsklinikum Giessen und Marburg, Standort Giessen</affilname><affiliation-city>Giessen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022653</affiliation-url><afid>60022653</afid><affilname>Universitatsklinikum Tubingen Medizinische Fakultat</affilname><affiliation-city>Tubingen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26633946200</author-url><authid>26633946200</authid><authname>Latus H.</authname><surname>Latus</surname><given-name>Heiner</given-name><initials>H.</initials><afid>60008248</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55337954800</author-url><authid>55337954800</authid><authname>Gummel K.</authname><surname>Gummel</surname><given-name>Kerstin</given-name><initials>K.</initials><afid>60008248</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7007087642</author-url><authid>7007087642</authid><authname>Klingel K.</authname><surname>Klingel</surname><given-name>Karin</given-name><initials>K.</initials><afid>60022653</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6507047006</author-url><authid>6507047006</authid><authname>Moysich A.</authname><surname>Moysich</surname><given-name>Axel</given-name><initials>A.</initials><afid>60008248</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56640614200</author-url><authid>56640614200</authid><authname>Khalil M.</authname><surname>Khalil</surname><given-name>Markus</given-name><initials>M.</initials><afid>60008248</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56641537800</author-url><authid>56641537800</authid><authname>Mazhari N.</authname><surname>Mazhari</surname><given-name>Nona</given-name><initials>N.</initials><afid>60008248</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55844593900</author-url><authid>55844593900</authid><authname>Bauer J.</authname><surname>Bauer</surname><given-name>Juergen</given-name><initials>J.</initials><afid>60008248</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:23108841200</author-url><authid>23108841200</authid><authname>Kandolf R.</authname><surname>Kandolf</surname><given-name>Reinhard</given-name><initials>R.</initials><afid>60022653</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:19738177700</author-url><authid>19738177700</authid><authname>Schranz D.</authname><surname>Schranz</surname><given-name>Dietmar</given-name><initials>D.</initials><afid>60008248</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:14629837200</author-url><authid>14629837200</authid><authname>Apitz C.</authname><surname>Apitz</surname><given-name>Christian</given-name><initials>C.</initials><afid>60008248</afid></author><authkeywords>Childhood dilated cardiomyopathy | Late gadolinium enhancement | Myocardial fibrosis | Reverse ventricular remodelling</authkeywords><intid>2035940132</intid><article-number>34</article-number><source-id>23845</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929587355"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929587355?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929587355&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929587355&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929587355</prism:url><dc:identifier>SCOPUS_ID:84929587355</dc:identifier><eid>2-s2.0-84929587355</eid><dc:title>Family Caregiving for Immigrant Seniors Living With Heart Disease and Stroke: Chinese Canadian Perspective</dc:title><dc:creator>Liu L.</dc:creator><prism:publicationName>Health Care for Women International</prism:publicationName><prism:issn>07399332</prism:issn><prism:eIssn>10964665</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1080/07399332.2015.1038346</prism:doi><dc:description>2015 Copyright © Taylor &amp; Francis Group, LLC Heart disease and stroke are two leading causes of death and disability among older Canadians. Family support and caregiving are crucial to the positive functional recovery and psychological well-being of heart disease and stroke survivors. Based on focus groups and individual interviews with Chinese family caregivers in the Canadian province of Ontario, we explored the caregiver's experience, including the challenges, needs, and service gaps in providing care for immigrant seniors with heart disease and stroke. We found that caregiving practices and the strategies used to cope with caregiving challenges varied by gender, ethnicity, age, and length of migration. We provide recommendations for narrowing the gaps in caregiving at the end of the article.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024776</affiliation-url><afid>60024776</afid><affilname>University of Lethbridge</affilname><name-variant>University of Lethbridge</name-variant><affiliation-city>Lethbridge</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024776</affiliation-url><afid>60024776</afid><affilname>University of Lethbridge</affilname><name-variant>University of Lethbridge</name-variant><affiliation-city>Lethbridge</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56650341900</author-url><authid>56650341900</authid><authname>Liu L.</authname><surname>Liu</surname><given-name>Lichun Willa</given-name><initials>L.W.</initials><afid>60024776</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56650716000</author-url><authid>56650716000</authid><authname>McDaniel S.</authname><surname>McDaniel</surname><given-name>Susan A.</given-name><initials>S.A.</initials><afid>60024776</afid></author><intid>1535981551</intid><source-id>19543</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929428005"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929428005?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929428005&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929428005&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929428005</prism:url><dc:identifier>SCOPUS_ID:84929428005</dc:identifier><eid>2-s2.0-84929428005</eid><dc:title>Altered mechanical state in the embryonic heart results in time-dependent decreases in cardiac function</dc:title><dc:creator>Johnson B.</dc:creator><prism:publicationName>Biomechanics and Modeling in Mechanobiology</prism:publicationName><prism:issn>16177959</prism:issn><prism:eIssn>16177940</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10237-015-0681-1</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Proper blood flow patterns are critical for normal cardiac morphogenesis, a process that occurs rapidly in order to support further development of all tissue and organs. Previously, intracardiac fluid forces have been shown to play a critical role in cardiac morphogenesis. Altered blood flow in early development can result in an array of cardiac defects including ventricular septal defects, valve malformations, and impaired cardiac looping. However, given the dynamic and highly transient nature of cardiac morphogenesis, time dependency of the mechanical environment as an epigenetic factor in relation to intracardiac forces must be significant. Here, we show that abnormal cardiac loading adversely influences cardiac morphology only during certain time windows, thus confirming that mechanical factors are a time-dependent epigenetic factor. To illustrate this, groups of zebrafish embryos were spaced at 6-h increments from 24 to 48 h post-fertilization (hpf) in which embryos were centrifuged to generate a noninvasive alteration of cardiac preload in addition to an overall hypergravity environment. We found that earlier and later treatment groups responded with altered morphology and function, while the group with altered preload from 30 to 36 hpf had no effect. These results demonstrate the inherently time-dependent nature of epigenetic factors as pertaining to intracardiac forces and external mechanical factors. Further, it underscores the highly coupled nature of programmed biology and mechanical forces during cardiac morphogenesis. Future studies with respect to surgical correction during cardiac morphogenesis must consider timing to optimize therapeutic impact.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009226</affiliation-url><afid>60009226</afid><affilname>Colorado State University</affilname><name-variant>Colorado State University</name-variant><affiliation-city>Fort Collins</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009226</affiliation-url><afid>60009226</afid><affilname>Colorado State University</affilname><name-variant>Colorado State University</name-variant><affiliation-city>Fort Collins</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55694102700</author-url><authid>55694102700</authid><authname>Johnson B.</authname><surname>Johnson</surname><given-name>Brennan</given-name><initials>B.</initials><afid>60009226</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56646291500</author-url><authid>56646291500</authid><authname>Bark D.</authname><surname>Bark</surname><given-name>David</given-name><initials>D.</initials><afid>60009226</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56646504000</author-url><authid>56646504000</authid><authname>van Herck I.</authname><surname>van Herck</surname><given-name>Ilse</given-name><initials>I.</initials><afid>60009226</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:10043842800</author-url><authid>10043842800</authid><authname>Garrity D.</authname><surname>Garrity</surname><given-name>Deborah</given-name><initials>D.</initials><afid>60009226</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6506066591</author-url><authid>6506066591</authid><authname>Dasi L.</authname><surname>Dasi</surname><given-name>Lakshmi Prasad</given-name><initials>L.P.</initials><afid>60009226</afid></author><authkeywords>Congenital defects | Epigenetics | Heart tube | Mechanobiology | Morphogenesis | Peristalsis | Pumping | Zebrafish</authkeywords><intid>35954756</intid><source-id>16294</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930080800"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930080800?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930080800&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930080800&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930080800</prism:url><dc:identifier>SCOPUS_ID:84930080800</dc:identifier><eid>2-s2.0-84930080800</eid><dc:title>Accuracy and cutoff values of delayed heart to mediastinum ratio with &lt;sup&gt;123&lt;/sup&gt;I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses</dc:title><dc:creator>Lamotte G.</dc:creator><prism:publicationName>BMC Neurology</prism:publicationName><prism:eIssn>14712377</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>May 15, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12883-015-0338-9</prism:doi><dc:description>© 2015 Lamotte et al.; licensee BioMed Central. Background: Different studies have found diminished cardiac metaiodobenzylguanidine (MIBG) uptake in Lewy body (LB) related conditions (Parkinson's disease (PD) and Lewy body dementia (LBD)). However, delayed heart/mediastinum (d-H/M) ratio diagnostic cutoff points are debated in parkinsonian syndromes. Methods: We performed a monocentric retrospective analysis on 62 consecutive parkinsonian patients who underwent an &lt;sup&gt;123&lt;/sup&gt;I-MIBG scintigraphy, brain imaging and dopaminergic imaging using &lt;sup&gt;123&lt;/sup&gt;I-Ioflupane single photon emission computed tomography (SPECT) from 2009 to 2013. The optimal d-H/M ratio was determined from a Receiver Operating Characteristic (ROC) curve and the sensitivity (Se), specificity (Sp) and likelihood ratios (LR) were calculated. 42 patients were diagnosed with LB diseases (20 PD, 22 LBD) and 20 patients with other diseases. Results: &lt;sup&gt;123&lt;/sup&gt;I-MIBG scintigraphy helped to distinguish PD (p &lt; 0.001) and LBD (p = 0.03) from other diseases. The optimal d-H/M ratio was 1.48 (0.85 area under the ROC curve). Se and Sp were 83.3 %, and 85 % respectively with positive and negative LR of 5.5 and 0.2 respectively. Patients with LBD had a lower d-H/M ratio than patients with PD (result not statistically significant) and a cutoff point at 1.2 could help to differentiate the two diseases. We did not find any correlation between the d-H/M ratio and clinical or &lt;sup&gt;123&lt;/sup&gt;I-Ioflupane SPECT data. Conclusion: According to our population, the d-H/M ratio at 1.48 led to the best performance diagnosis with good Se, Sp and accuracy. In addition, a d-H/M ratio cutoff at 1.2 could help to differentiate PD from LBD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005384</affiliation-url><afid>60005384</afid><affilname>Centre Hospitalier Universitaire de Caen</affilname><name-variant>CHU</name-variant><affiliation-city>Caen</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032215</affiliation-url><afid>60032215</afid><affilname>Universite de Caen Basse Normandie</affilname><name-variant>Université de Caen</name-variant><affiliation-city>Caen</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005384</affiliation-url><afid>60005384</afid><affilname>Centre Hospitalier Universitaire de Caen</affilname><name-variant>CHU</name-variant><affiliation-city>Caen</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005384</affiliation-url><afid>60005384</afid><affilname>Centre Hospitalier Universitaire de Caen</affilname><name-variant>CHU</name-variant><affiliation-city>Caen</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55324417500</author-url><authid>55324417500</authid><authname>Lamotte G.</authname><surname>Lamotte</surname><given-name>Guillaume</given-name><initials>G.</initials><afid>60005384</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:14066516500</author-url><authid>14066516500</authid><authname>Morello R.</authname><surname>Morello</surname><given-name>Rémy</given-name><initials>R.</initials><afid>60005384</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56507434300</author-url><authid>56507434300</authid><authname>Lebasnier A.</authname><surname>Lebasnier</surname><given-name>Adrien</given-name><initials>A.</initials><afid>60005384</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:21644894500</author-url><authid>21644894500</authid><authname>Agostini D.</authname><surname>Agostini</surname><given-name>Denis</given-name><initials>D.</initials><afid>60005384</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006166181</author-url><authid>7006166181</authid><authname>Defer G.</authname><surname>Defer</surname><given-name>Gilles L.</given-name><initials>G.L.</initials><afid>60005384</afid><afid>60032215</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006166181</author-url><authid>7006166181</authid><authname>Defer G.</authname><surname>Defer</surname><given-name>Gilles L.</given-name><initials>G.L.</initials><afid>60005384</afid><afid>60032215</afid></author><authkeywords>Diagnosis | Lewy body dementia | MIBG | Myocardium | Parkinson's disease | parkinsonism | Sympathetic innervation</authkeywords><intid>1536060958</intid><source-id>14258</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929429244"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929429244?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929429244&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929429244&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929429244</prism:url><dc:identifier>SCOPUS_ID:84929429244</dc:identifier><eid>2-s2.0-84929429244</eid><dc:title>Screening Men with Coronary Heart Disease for Abdominal Aortic Aneurysm: A Prospective Cohort Study</dc:title><dc:creator>Vänni V.</dc:creator><prism:publicationName>World Journal of Surgery</prism:publicationName><prism:issn>03642313</prism:issn><prism:eIssn>14322323</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00268-015-3091-8</prism:doi><dc:description>© 2015 Société Internationale de Chirurgie Background: The prevalence of abdominal aortic aneurysms (AAA) is higher among patients with coronary heart disease (CHD) compared with control population. Objective: To assess and determine the prevalence of non-diagnosed AAA in men with CHD. Materials and methods: A total of 438 active male out-patients with CHD were screened for AAA by abdominal ultrasound (US) examination. The largest infrarenal aortic dimension was registered. The patient was regarded to have AAA when the aortic diameter was greater than 30 mm. Results: We found altogether 25 AAAs. The incidence of AAA was 5.7 %. One AAA patient was operated on, and the other AAA patients are under surveillance. Independent predictors for AAA among CHD patients were increased age, family history of AAA, and current or previous smoking. The screening process took on average 5 min per patient, and the cost of screening was 15€ ($18.50) per patient or €257 ($325) per found AAA. Conclusions: The prevalence of previously undiagnosed AAAs among patients with CHD is considerable. Screening of AAA should be considered among active patients with CHD. The most feasible and simplest option would be to perform the screening during any routine or elective cardiac US by a cardiologist, and we recommend to adopt it as a standard practice.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070302</affiliation-url><afid>60070302</afid><affilname>North Karelia Central Hospital</affilname><name-variant>North Karelia Central Hospital</name-variant><affiliation-city>Joensuu</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070302</affiliation-url><afid>60070302</afid><affilname>North Karelia Central Hospital</affilname><name-variant>North Karelia Central Hospital</name-variant><affiliation-city>Joensuu</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070302</affiliation-url><afid>60070302</afid><affilname>North Karelia Central Hospital</affilname><name-variant>North Karelia Central Hospital</name-variant><affiliation-city>Joensuu</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56646279700</author-url><authid>56646279700</authid><authname>Vänni V.</authname><surname>Vänni</surname><given-name>Ville</given-name><initials>V.</initials><afid>60070302</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56646016300</author-url><authid>56646016300</authid><authname>Hernesniemi J.</authname><surname>Hernesniemi</surname><given-name>Jussi</given-name><initials>J.</initials><afid>60070302</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6506416965</author-url><authid>6506416965</authid><authname>Turtiainen M.</authname><surname>Turtiainen</surname><given-name>Matti</given-name><initials>M.</initials><afid>60070302</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36647981200</author-url><authid>36647981200</authid><authname>Turtiainen J.</authname><surname>Turtiainen</surname><given-name>Johanna</given-name><initials>J.</initials><afid>60070302</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004299886</author-url><authid>7004299886</authid><authname>Hakala T.</authname><surname>Hakala</surname><given-name>Tapio</given-name><initials>T.</initials><afid>60070302</afid></author><intid>1785956842</intid><source-id>19301</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928255047"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928255047?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928255047&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928255047&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0024320514009023"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928255047</prism:url><dc:identifier>SCOPUS_ID:84928255047</dc:identifier><eid>2-s2.0-84928255047</eid><dc:title>Gap junctional regulation of pressure, fluid force, and electrical fields in the epigenetics of cardiac morphogenesis and remodeling</dc:title><dc:creator>Seki A.</dc:creator><prism:publicationName>Life Sciences</prism:publicationName><prism:issn>00243205</prism:issn><prism:eIssn>18790631</prism:eIssn><prism:volume>129</prism:volume><prism:pageRange>27-34</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.lfs.2014.10.022</prism:doi><pii>S0024320514009023</pii><dc:description>© 2014 Elsevier Inc. All rights reserved. Epigenetic factors of pressure load, fluid force, and electrical fields that occur during cardiac contraction affect cardiac development, morphology, function, and pathogenesis. These factors are orchestrated by intercellular communication mediated by gap junctions, which synchronize action potentials and second messengers. Misregulation of the gap junction protein connexin (Cx) alters cardiogenesis, and can be a pathogenic factor causing cardiac conduction disturbance, fatal arrhythmia, and cardiac remodeling in disease states such as hypertension and ischemia. Changes in Cx expression can occur even when the DNA sequence of the Cx gene itself is unaltered. Posttranslational modifications might reduce arrhythmogenic substrates, improve cardiac function, and promote remodeling in a diseased heart. In this review, we discuss the epigenetic features of gap junctions that regulate cardiac morphology and remodeling. We further discuss potential clinical applications of current knowledge of the structure and function of gap junctions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025639</affiliation-url><afid>60025639</afid><affilname>Tokyo Women's Medical University</affilname><name-variant>Tokyo Women's Medical University</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025639</affiliation-url><afid>60025639</afid><affilname>Tokyo Women's Medical University</affilname><name-variant>Tokyo Women's Medical University</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019916</affiliation-url><afid>60019916</afid><affilname>National Defense Medical College Tokorozawa</affilname><name-variant>National Defense Medical College</name-variant><affiliation-city>Tokorozawa</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7101909612</author-url><authid>7101909612</authid><authname>Seki A.</authname><surname>Seki</surname><given-name>Akiko</given-name><initials>A.</initials><afid>60025639</afid><afid>60025639</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7101909612</author-url><authid>7101909612</authid><authname>Seki A.</authname><surname>Seki</surname><given-name>Akiko</given-name><initials>A.</initials><afid>60025639</afid><afid>60025639</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56602477400</author-url><authid>56602477400</authid><authname>Nishii K.</authname><surname>Nishii</surname><given-name>Kiyomasa</given-name><initials>K.</initials><afid>60019916</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56539466000</author-url><authid>56539466000</authid><authname>Hagiwara N.</authname><surname>Hagiwara</surname><given-name>Nobuhisa</given-name><initials>N.</initials><afid>60025639</afid></author><authkeywords>Gap junction | Heart | Morphogenesis | Remodeling</authkeywords><intid>35753115</intid><source-id>20473</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929340188"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929340188?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929340188&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929340188&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929340188</prism:url><dc:identifier>SCOPUS_ID:84929340188</dc:identifier><eid>2-s2.0-84929340188</eid><dc:title>Cardiac development in zebrafish and human embryonic stem cells is inhibited by exposure to tobacco cigarettes and ecigarettes</dc:title><dc:creator>Palpant N.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0126259</prism:doi><dc:description>© 2015 Palpant et al. Background Maternal smoking is a risk factor for low birth weight and other adverse developmental outcomes. Objective We sought to determine the impact of standard tobacco cigarettes and e-cigarettes on heart development in vitro and in vivo. Methods Zebrafish (Danio rerio) were used to assess developmental effects in vivo and cardiac differentiation of human embryonic stem cells (hESCs) was used as a model for in vitro cardiac development. Results In zebrafish, exposure to both types of cigarettes results in broad, dose-dependent developmental defects coupled with severe heart malformation, pericardial edema and reduced heart function. Tobacco cigarettes are more toxic than e-cigarettes at comparable nicotine concentrations. During cardiac differentiation of hESCs, tobacco smoke exposure results in a delayed transition through mesoderm. Both types of cigarettes decrease expression of cardiac transcription factors in cardiac progenitor cells, suggesting a persistent delay in differentiation. In definitive human cardiomyocytes, both e-cigarette- and tobacco cigarette-treated samples showed reduced expression of sarcomeric genes such as MLC2v and MYL6. Furthermore, tobacco cigarette-treated samples had delayed onset of beating and showed low levels and aberrant localization of N-cadherin, reduced myofilament content with significantly reduced sarcomere length, and increased expression of the immature cardiac marker smooth muscle alpha-actin. Conclusion These data indicate a negative effect of both tobacco cigarettes and e-cigarettes on heart development in vitro and in vivo. Tobacco cigarettes are more toxic than E-cigarettes and exhibit a broader spectrum of cardiac developmental defects.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028548</affiliation-url><afid>60028548</afid><affilname>University of Washington School of Medicine</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028548</affiliation-url><afid>60028548</afid><affilname>University of Washington School of Medicine</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028548</affiliation-url><afid>60028548</afid><affilname>University of Washington School of Medicine</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028548</affiliation-url><afid>60028548</afid><affilname>University of Washington School of Medicine</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028548</affiliation-url><afid>60028548</afid><affilname>University of Washington School of Medicine</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">17</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:19934254600</author-url><authid>19934254600</authid><authname>Palpant N.</authname><surname>Palpant</surname><given-name>Nathan J.</given-name><initials>N.J.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:19934254600</author-url><authid>19934254600</authid><authname>Palpant N.</authname><surname>Palpant</surname><given-name>Nathan J.</given-name><initials>N.J.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:19934254600</author-url><authid>19934254600</authid><authname>Palpant N.</authname><surname>Palpant</surname><given-name>Nathan J.</given-name><initials>N.J.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55595942500</author-url><authid>55595942500</authid><authname>Hofsteen P.</authname><surname>Hofsteen</surname><given-name>Peter</given-name><initials>P.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55595942500</author-url><authid>55595942500</authid><authname>Hofsteen P.</authname><surname>Hofsteen</surname><given-name>Peter</given-name><initials>P.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55595942500</author-url><authid>55595942500</authid><authname>Hofsteen P.</authname><surname>Hofsteen</surname><given-name>Peter</given-name><initials>P.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:13105276800</author-url><authid>13105276800</authid><authname>Pabon L.</authname><surname>Pabon</surname><given-name>Lil</given-name><initials>L.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:13105276800</author-url><authid>13105276800</authid><authname>Pabon L.</authname><surname>Pabon</surname><given-name>Lil</given-name><initials>L.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:13105276800</author-url><authid>13105276800</authid><authname>Pabon L.</authname><surname>Pabon</surname><given-name>Lil</given-name><initials>L.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35511668800</author-url><authid>35511668800</authid><authname>Reinecke H.</authname><surname>Reinecke</surname><given-name>Hans</given-name><initials>H.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35511668800</author-url><authid>35511668800</authid><authname>Reinecke H.</authname><surname>Reinecke</surname><given-name>Hans</given-name><initials>H.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35511668800</author-url><authid>35511668800</authid><authname>Reinecke H.</authname><surname>Reinecke</surname><given-name>Hans</given-name><initials>H.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006341337</author-url><authid>7006341337</authid><authname>Murry C.</authname><surname>Murry</surname><given-name>Charles E.</given-name><initials>C.E.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006341337</author-url><authid>7006341337</authid><authname>Murry C.</authname><surname>Murry</surname><given-name>Charles E.</given-name><initials>C.E.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006341337</author-url><authid>7006341337</authid><authname>Murry C.</authname><surname>Murry</surname><given-name>Charles E.</given-name><initials>C.E.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006341337</author-url><authid>7006341337</authid><authname>Murry C.</authname><surname>Murry</surname><given-name>Charles E.</given-name><initials>C.E.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006341337</author-url><authid>7006341337</authid><authname>Murry C.</authname><surname>Murry</surname><given-name>Charles E.</given-name><initials>C.E.</initials><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid><afid>60028548</afid></author><intid>35943358</intid><article-number>0126259</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84917708552"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84917708552?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84917708552&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84917708552&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814614018834"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84917708552</prism:url><dc:identifier>SCOPUS_ID:84917708552</dc:identifier><eid>2-s2.0-84917708552</eid><dc:title>Fatty acid composition of Swedish bakery products, with emphasis on trans-fatty acids</dc:title><dc:creator>Trattner S.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>175</prism:volume><prism:pageRange>423-430</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2014.11.145</prism:doi><pii>S0308814614018834</pii><dc:description>© 2014 The Authors. Trans-fatty acids (TFA) have been associated with increased risk of coronary heart disease, by affecting blood lipids and inflammation factors. Current nutrition recommendations emphasise a limitation of dietary TFA intake. The aim of this study was to investigate fatty acid composition in sweet bakery products, with emphasis on TFA, on the Swedish market and compare fatty acid composition over time. Products were sampled in 2001, 2006 and 2007 and analysed for fatty acid composition by using GC. Mean TFA levels were 0.7% in 2007 and 5.9% in 2001 of total fatty acids. In 1995-97, mean TFA level was 14.3%. In 2007, 3 of 41 products had TFA levels above 2% of total fatty acids. TFA content had decreased in this product category, while the proportion of saturated (SFA) and polyunsaturated (PUFA) fatty acids had increased, mostly through increased levels of 16:0 and 18:2 n-6, respectively. The total fat content remained largely unchanged.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105640768</affiliation-url><afid>105640768</afid><affilname>National Food Agency</affilname><name-variant>National Food Agency</name-variant><affiliation-city>Uppsala</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027152</affiliation-url><afid>60027152</afid><affilname>Sveriges lantbruksuniversitet</affilname><name-variant>Swedish University of Agricultural Sciences</name-variant><affiliation-city>Uppsala</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23006580400</author-url><authid>23006580400</authid><authname>Trattner S.</authname><surname>Trattner</surname><given-name>Sofia</given-name><initials>S.</initials><afid>105640768</afid><afid>60027152</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23006580400</author-url><authid>23006580400</authid><authname>Trattner S.</authname><surname>Trattner</surname><given-name>Sofia</given-name><initials>S.</initials><afid>105640768</afid><afid>60027152</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56446245500</author-url><authid>56446245500</authid><authname>Becker W.</authname><surname>Becker</surname><given-name>Wulf</given-name><initials>W.</initials><afid>105640768</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6505506309</author-url><authid>6505506309</authid><authname>Wretling S.</authname><surname>Wretling</surname><given-name>Sören</given-name><initials>S.</initials><afid>105640768</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:23767347000</author-url><authid>23767347000</authid><authname>Öhrvik V.</authname><surname>Öhrvik</surname><given-name>Veronica</given-name><initials>V.</initials><afid>105640768</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701350991</author-url><authid>6701350991</authid><authname>Mattisson I.</authname><surname>Mattisson</surname><given-name>Irene</given-name><initials>I.</initials><afid>105640768</afid></author><authkeywords>Bakery products | Cakes | Cookies | Fat content | Trans fatty acids</authkeywords><intid>1034016585</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929359759"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929359759?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929359759&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929359759&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929359759</prism:url><dc:identifier>SCOPUS_ID:84929359759</dc:identifier><eid>2-s2.0-84929359759</eid><dc:title>Whole-body endothermy in a mesopelagic fish, the opah, Lampris guttatus</dc:title><dc:creator>Wegner N.</dc:creator><prism:publicationName>Science</prism:publicationName><prism:issn>00368075</prism:issn><prism:eIssn>10959203</prism:eIssn><prism:volume>348</prism:volume><prism:issueIdentifier>6236</prism:issueIdentifier><prism:pageRange>786-789</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1126/science.aaa8902</prism:doi><dc:description>© 2015 by the American Association for the Advancement of Science; all rights reserved. Endothermy (the metabolic production and retention of heat to warm body temperature above ambient) enhances physiological function, and whole-body endothermy generally sets mammals and birds apart from other animals. Here, we describe a whole-body form of endothermy in a fish, the opah (Lampris guttatus), that produces heat through the constant "flapping" of wing-like pectoral fins and minimizes heat loss through a series of counter-current heat exchangers within its gills. Unlike other fish, opah distribute warmed blood throughout the body, including to the heart, enhancing physiological performance and buffering internal organ function while foraging in the cold, nutrient-rich waters below the ocean thermocline.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109607195</affiliation-url><afid>109607195</afid><affilname>National Marine Fisheries Service (NMFS)</affilname><name-variant>National Marine Fisheries Service (NMFS)</name-variant><affiliation-city>Carlsbad</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100654840</affiliation-url><afid>100654840</afid><affilname>NMFS/NOAA</affilname><name-variant>NMFS/NOAA</name-variant><affiliation-city>Beaufort</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:9943338600</author-url><authid>9943338600</authid><authname>Wegner N.</authname><surname>Wegner</surname><given-name>Nicholas C.</given-name><initials>N.C.</initials><afid>109607195</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55372248800</author-url><authid>55372248800</authid><authname>Snodgrass O.</authname><surname>Snodgrass</surname><given-name>Owyn E.</given-name><initials>O.E.</initials><afid>100654840</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006628512</author-url><authid>7006628512</authid><authname>Dewar H.</authname><surname>Dewar</surname><given-name>Heidi</given-name><initials>H.</initials><afid>109607195</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15032890000</author-url><authid>15032890000</authid><authname>Hyde J.</authname><surname>Hyde</surname><given-name>John R.</given-name><initials>J.R.</initials><afid>109607195</afid></author><intid>2035941271</intid><source-id>23571</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929603533"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929603533?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929603533&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929603533&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929603533</prism:url><dc:identifier>SCOPUS_ID:84929603533</dc:identifier><eid>2-s2.0-84929603533</eid><dc:title>Athorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects</dc:title><dc:creator>Adar L.</dc:creator><prism:publicationName>Drug Design, Development and Therapy</prism:publicationName><prism:issn>11778881</prism:issn><prism:eIssn>11778881</prism:eIssn><prism:volume>9</prism:volume><prism:pageRange>2653-2662</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.2147/DDDT.S81799</prism:doi><dc:description>© 2015 Adar et al. Tbo-filgrastim is a recombinant human granulocyte colony-stimulating factor approved by the US Food and Drug Administration to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. We assessed the effect of tbo-filgrastim on cardiac conduction and repolarization in healthy subjects. A three-arm, parallel-group, active- and placebo-controlled, double-blind study randomized healthy adults to a single 5 μg/kg intravenous tbo-filgrastim infusion, a single intravenous placebo infusion, or a single 400 mg moxifloxacin oral dose. The primary end point was placebo-corrected time-matched change from baseline in QT interval corrected using a QT individual correction (QTcI) method. Secondary end points included heart rate, PR interval, QRS duration, change in electrocardiogram patterns, correlation between QTcI change from baseline (milliseconds) and tbo-filgrastim serum concentrations, and safety variables. A total of 145 subjects were enrolled (50 tbo-filgrastim, 50 placebo, 45 moxifloxacin). Peak placebo-corrected change from baseline for QTcI with tbo-filgrastim was 3.5 milliseconds, with a two-sided 95% upper confidence interval of 7.2 milliseconds, demonstrating no signal for any tbo-filgrastim effect on QTc. Concentration-effect modeling showed no evidence of an effect of tbo-filgrastim on cardiac repolarization. Tbo-filgrastim produced no clinically significant changes in other electrocardiogram parameters. Tbo-filgrastim was well tolerated.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088746</affiliation-url><afid>60088746</afid><affilname>Teva Pharmaceutical Industries Ltd.</affilname><name-variant>Teva Pharmaceuticals</name-variant><affiliation-city>Petah Tiqwa</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60087917</affiliation-url><afid>60087917</afid><affilname>Merckle GmbH</affilname><name-variant>Merckle GmbH</name-variant><affiliation-city>Ulm</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112768650</affiliation-url><afid>112768650</afid><affilname>EResearchTechnology Inc.</affilname><name-variant>ERT (eResearch Technology, Inc)</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6506681707</author-url><authid>6506681707</authid><authname>Adar L.</authname><surname>Adar</surname><given-name>Liat</given-name><initials>L.</initials><afid>60088746</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507754002</author-url><authid>6507754002</authid><authname>Avisar N.</authname><surname>Avisar</surname><given-name>Noa</given-name><initials>N.</initials><afid>60088746</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56436862100</author-url><authid>56436862100</authid><authname>Lammerich A.</authname><surname>Lammerich</surname><given-name>Andreas</given-name><initials>A.</initials><afid>60087917</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005828458</author-url><authid>7005828458</authid><authname>Kleiman R.</authname><surname>Kleiman</surname><given-name>Robert B.</given-name><initials>R.B.</initials><afid>112768650</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701424420</author-url><authid>6701424420</authid><authname>Spiegelstein O.</authname><surname>Spiegelstein</surname><given-name>Ofer</given-name><initials>O.</initials><afid>60088746</afid></author><authkeywords>Electrocardiogram | Granulocyte colony-stimulating factor | QT interval | Tbo-filgrastim</authkeywords><intid>2035976931</intid><source-id>19700175230</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929401875"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929401875?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929401875&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929401875&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929401875</prism:url><dc:identifier>SCOPUS_ID:84929401875</dc:identifier><eid>2-s2.0-84929401875</eid><dc:title>Effect of laser acupuncture on obesity: Study protocol for a randomized controlled trial</dc:title><dc:creator>Tseng C.</dc:creator><prism:publicationName>Trials</prism:publicationName><prism:eIssn>17456215</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>May 15, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13063-015-0748-4</prism:doi><dc:description>© 2015 Tseng et al.; licensee BioMed Central. Background: Obesity-related diseases have a profound economic impact on health care systems. Laser acupuncture has been shown to have beneficial effects on obesity. However, to our knowledge, those trials were either non-randomized, non-blinded or included low-calorie diet control. We have, therefore, designed a patient-assessor-blinded, randomized, sham-controlled crossover trial to investigate the significance of laser acupuncture on obesity. Methods/Design: 104 subjects above 20 years of age with a body mass index (BMI) of over 25 kg/m&lt;sup&gt;2&lt;/sup&gt; will be divided into 2 groups: experimental and control. Each subject will receive the treatment relevant to their group 3 times a week for 8 weeks. After 8 weeks of treatment the subject will enter a 2-week washout period, after which the subjects will switch groups. Measurements will include BMI, body fat percentage, waist-to-hip ratio (WHR), waist circumference, hip circumference, skinfold thickness, thigh circumference, body fat, blood pressure, heart rate, hunger and the 36-item Short-Form Health Survey (SF-36). Discussion: The results of this study will provide the basis for future large-scale multicenter trials investigating the effects of laser acupuncture on obesity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031913</affiliation-url><afid>60031913</afid><affilname>Chang Gung Memorial Hospital</affilname><name-variant>Chang Gung Memorial Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020351</affiliation-url><afid>60020351</afid><affilname>Chang Gung University</affilname><name-variant>Chang Gung University</name-variant><affiliation-city>Taoyuan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090105</affiliation-url><afid>60090105</afid><affilname>Chang Gung University of Science and Technology</affilname><name-variant>Chang-Gung Institute of Technology</name-variant><affiliation-city>Taoyuan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090105</affiliation-url><afid>60090105</afid><affilname>Chang Gung University of Science and Technology</affilname><name-variant>Chang-Gung Institute of Technology</name-variant><affiliation-city>Taoyuan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645545300</author-url><authid>56645545300</authid><authname>Tseng C.</authname><surname>Tseng</surname><given-name>Chi Chuan</given-name><initials>C.C.</initials><afid>60031913</afid><afid>60020351</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645545300</author-url><authid>56645545300</authid><authname>Tseng C.</authname><surname>Tseng</surname><given-name>Chi Chuan</given-name><initials>C.C.</initials><afid>60031913</afid><afid>60020351</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56645993200</author-url><authid>56645993200</authid><authname>Tseng A.</authname><surname>Tseng</surname><given-name>Alan</given-name><initials>A.</initials><afid>60016849</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35073552600</author-url><authid>35073552600</authid><authname>Chang C.</authname><surname>Chang</surname><given-name>Chia Hao</given-name><initials>C.H.</initials><afid>60090105</afid><afid>60090105</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35073552600</author-url><authid>35073552600</authid><authname>Chang C.</authname><surname>Chang</surname><given-name>Chia Hao</given-name><initials>C.H.</initials><afid>60090105</afid><afid>60090105</afid></author><authkeywords>Body mass index | Laser acupuncture | Obesity</authkeywords><intid>1785956785</intid><article-number>217</article-number><source-id>4700151726</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929378555"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929378555?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929378555&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929378555&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929378555</prism:url><dc:identifier>SCOPUS_ID:84929378555</dc:identifier><eid>2-s2.0-84929378555</eid><dc:title>Carbohydrate electrolyte solutions enhance endurance capacity in active females</dc:title><dc:creator>Sun F.</dc:creator><prism:publicationName>Nutrients</prism:publicationName><prism:eIssn>20726643</prism:eIssn><prism:volume>7</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>3739-3750</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.3390/nu7053739</prism:doi><dc:description>© 2015 by the authors; licensee MDPI, Basel, Switzerland. The purpose of the present study was to investigate the effects of supplementation with a carbohydrate-electrolyte solution (CES) in active females during a prolonged session of submaximal running to exhaustion. Eight healthy active females volunteered to perform a session of open-ended running to exhaustion at 70% of their maximal oxygen consumption on a treadmill during the follicular phase of their menstrual cycle on two occasions. During each run, the subjects consumed either 3mL·kg&lt;sup&gt;−1&lt;/sup&gt; body mass of a 6% CES or a placebo drink (PL) every 20 min during exercise. The trials were administered in a randomized double-blind, cross-over design. During the run, the subjects ingested similar volumes of fluid in two trials (CES: 644 ± 75 mL vs. PL: 593 ± 66 mL, p &gt; 0.05). The time to exhaustion was 16% longer during the CES trial (106.2 ± 9.4 min) than during the PL trial (91.6 ± 5.9 min) (p &lt; 0.05). At 45 min during exercise, the plasma glucose concentration in the CES trial was higher than that in PL trial. No differences were observed in the plasma lactate level, respiratory exchange ratio, heart rate, perceived rate of exertion, sensation of thirst, or abdominal discomfort between the two trials (p &gt; 0.05). The results of the present study confirm that CES supplementation improves the moderate intensity endurance capacity of active females during the follicular phases of the menstrual cycle. However, the exogenous oxidation of carbohydrate does not seem to explain the improved capacity after CES supplementation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017919</affiliation-url><afid>60017919</afid><affilname>Hong Kong Institute of Education</affilname><name-variant>The Hong Kong Institute of Education</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002798</affiliation-url><afid>60002798</afid><affilname>Chinese University of Hong Kong</affilname><name-variant>The Chinese University of Hong Kong</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36025864300</author-url><authid>36025864300</authid><authname>Sun F.</authname><surname>Sun</surname><given-name>Feng Hua</given-name><initials>F.H.</initials><afid>60017919</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56203982700</author-url><authid>56203982700</authid><authname>Wong S.</authname><surname>Wong</surname><given-name>Stephen Heung Sang</given-name><initials>S.H.S.</initials><afid>60002798</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56643652200</author-url><authid>56643652200</authid><authname>Chen S.</authname><surname>Chen</surname><given-name>Shi Hui</given-name><initials>S.H.</initials><afid>60017919</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56644262200</author-url><authid>56644262200</authid><authname>Poon T.</authname><surname>Poon</surname><given-name>Tsz Chun</given-name><initials>T.C.</initials><afid>60002798</afid></author><authkeywords>Exercise to exhaustion | Follicular phase | Running</authkeywords><intid>1785946645</intid><source-id>19700188323</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929430792"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929430792?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929430792&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929430792&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929430792</prism:url><dc:identifier>SCOPUS_ID:84929430792</dc:identifier><eid>2-s2.0-84929430792</eid><dc:title>Heart disease: Stimulating cardiomyocyte regeneration after heart failure</dc:title><dc:creator>Crunkhorn S.</dc:creator><prism:publicationName>Nature Reviews Drug Discovery</prism:publicationName><prism:issn>14741776</prism:issn><prism:eIssn>14741784</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1038/nrd4654</prism:doi><citedby-count>0</citedby-count><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56446600000</author-url><authid>56446600000</authid><authname>Crunkhorn S.</authname><surname>Crunkhorn</surname><given-name>Sarah</given-name><initials>S.</initials></author><intid>35955437</intid><source-id>20425</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929440524"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929440524?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929440524&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929440524&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929440524</prism:url><dc:identifier>SCOPUS_ID:84929440524</dc:identifier><eid>2-s2.0-84929440524</eid><dc:title>Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature</dc:title><dc:creator>Jacobson A.</dc:creator><prism:publicationName>Journal of Nuclear Cardiology</prism:publicationName><prism:issn>10713581</prism:issn><prism:eIssn>15326551</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12350-015-0170-z</prism:doi><dc:description>© 2015 American Society of Nuclear Cardiology Background: A critical review of the literature on drug interactions with mIBG uptake was performed to allow formulation of contemporary guidance regarding withholding medications prior to clinical imaging studies. Methods: Published information was extracted on the experimental system used, the quantitative characteristics of the measurements, and whether any data directly examining cardiac tissues were included. Level of evidence for each medication category was assessed on a qualitative scale of very low, low, medium, or high. Strength of medication effect for inhibition of mIBG uptake was judged as none, weak, moderate, or strong. Results: The only medications for which level of evidence was judged high were labetalol and reserpine. Level of evidence was judged medium for tricyclic antidepressants, calcium channel blockers, and antiarrhythmics (specifically amiodarone). Evidence was judged sufficient to recommend withholding labetalol and the tricyclic antidepressants prior to mIBG cardiac imaging. Mechanistic evidence was sufficient to suggest consideration of withdrawal of sympathomimetic amines and serotonin-norepinephrine reuptake inhibitors (SNRIs). Conclusions: As there is strong evidence for inhibition of mIBG uptake in only a small number of compounds, clinical decisions regarding withdrawal of concomitant medications should be individualized by considering the potential consequences of a false-positive (artificially low cardiac uptake) imaging result.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115245320</affiliation-url><afid>115245320</afid><affilname>Diagram Consulting</affilname><name-variant>Diagram Consulting</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002388</affiliation-url><afid>60002388</afid><affilname>Albert Einstein College of Medicine of Yeshiva University</affilname><name-variant>Albert Einstein College of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645747400</author-url><authid>56645747400</authid><authname>Jacobson A.</authname><surname>Jacobson</surname><given-name>Arnold F.</given-name><initials>A.F.</initials><afid>115245320</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003313449</author-url><authid>7003313449</authid><authname>Travin M.</authname><surname>Travin</surname><given-name>Mark I.</given-name><initials>M.I.</initials><afid>60002388</afid></author><authkeywords>mIBG | myocardial scintigraphy | norepinephrine</authkeywords><intid>535955966</intid><source-id>17229</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929326386"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929326386?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929326386&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929326386&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929326386</prism:url><dc:identifier>SCOPUS_ID:84929326386</dc:identifier><eid>2-s2.0-84929326386</eid><dc:title>Left ventricular global longitudinal strain (GLS) is a superior predictor of all-cause and cardiovascular mortality when compared to ejection fraction in advanced Chronic Kidney Disease</dc:title><dc:creator>Krishnasamy R.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0127044</prism:doi><dc:description>© 2015 Krishnasamy et al. Background: Echocardiographic global longitudinal strain (GLS) is increasingly recognised as a more effective technique than conventional ejection fraction (EF) in detecting subtle changes in left ventricular (LV) function. This study investigated the prognostic value of GLS over EF in patients with advanced Chronic Kidney Disease (CKD). Methods: The study included 183 patients (57% male, 63% on dialysis) with CKD stage 4, 5 and 5Dialysis (D). 112 (61%) of patients died in a follow up of 7.8 ± 4.4 years and 41% of deaths were due to cardiovascular (CV) disease. GLS was calculated using 2-dimensional speckle tracking and EF was measured using Simpson's biplane method. Cox proportional hazard models were used to assess the association of measures of LV function and all- cause and CV mortality. Results: The mean GLS at baseline was -13.6 ± 4.3% and EF was 45 ± 11%. GLS was a significant predictor of all-cause [Hazard Ratio (HR) 1.09 95%; Confidence Interval (CI) 1.02-1.16; p = 0.01] and CV mortality (HR 1.16 95%; CI 1.04-1.30; p = 0.008) following adjustment for relevant clinical variables including LV mass index (LVMI) and EF. GLS also had greater predictive power for both all- cause and CV mortality compared to EF. Impaired GLS (&gt;-16%) was associated with a 5.6-fold increased unadjusted risk of CV mortality in patients with preserved EF. Conclusions: In this cohort of patients with advanced CKD, GLS is a more sensitive predictor of overall and CV mortality compared to EF. Studies of larger populations in CKD are required to confirm that GLS provides additive prognostic value in patients with preserved EF.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031004</affiliation-url><afid>60031004</afid><affilname>University of Queensland</affilname><name-variant>The University of Queensland</name-variant><affiliation-city>Brisbane</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031004</affiliation-url><afid>60031004</afid><affilname>University of Queensland</affilname><name-variant>The University of Queensland</name-variant><affiliation-city>Brisbane</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031004</affiliation-url><afid>60031004</afid><affilname>University of Queensland</affilname><name-variant>The University of Queensland</name-variant><affiliation-city>Brisbane</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015356</affiliation-url><afid>60015356</afid><affilname>University of Tasmania</affilname><name-variant>University of Tasmania</name-variant><affiliation-city>Hobart</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54787960900</author-url><authid>54787960900</authid><authname>Krishnasamy R.</authname><surname>Krishnasamy</surname><given-name>Rathika</given-name><initials>R.</initials><afid>60031004</afid><afid>60031004</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54787960900</author-url><authid>54787960900</authid><authname>Krishnasamy R.</authname><surname>Krishnasamy</surname><given-name>Rathika</given-name><initials>R.</initials><afid>60031004</afid><afid>60031004</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35454123200</author-url><authid>35454123200</authid><authname>Isbel N.</authname><surname>Isbel</surname><given-name>Nicole M.</given-name><initials>N.M.</initials><afid>60031004</afid><afid>60031004</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35454123200</author-url><authid>35454123200</authid><authname>Isbel N.</authname><surname>Isbel</surname><given-name>Nicole M.</given-name><initials>N.M.</initials><afid>60031004</afid><afid>60031004</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35444599100</author-url><authid>35444599100</authid><authname>Hawley C.</authname><surname>Hawley</surname><given-name>Carmel M.</given-name><initials>C.M.</initials><afid>60031004</afid><afid>60031004</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35444599100</author-url><authid>35444599100</authid><authname>Hawley C.</authname><surname>Hawley</surname><given-name>Carmel M.</given-name><initials>C.M.</initials><afid>60031004</afid><afid>60031004</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:13806558100</author-url><authid>13806558100</authid><authname>Pascoe E.</authname><surname>Pascoe</surname><given-name>Elaine M.</given-name><initials>E.M.</initials><afid>60031004</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56644532700</author-url><authid>56644532700</authid><authname>Burrage M.</authname><surname>Burrage</surname><given-name>Matthew</given-name><initials>M.</initials><afid>60031004</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602410007</author-url><authid>6602410007</authid><authname>Leano R.</authname><surname>Leano</surname><given-name>Rodel</given-name><initials>R.</initials><afid>60031004</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602475735</author-url><authid>6602475735</authid><authname>Haluska B.</authname><surname>Haluska</surname><given-name>Brian A.</given-name><initials>B.A.</initials><afid>60031004</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56593723500</author-url><authid>56593723500</authid><authname>Marwick T.</authname><surname>Marwick</surname><given-name>Thomas H.</given-name><initials>T.H.</initials><afid>60015356</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7101872561</author-url><authid>7101872561</authid><authname>Stanton T.</authname><surname>Stanton</surname><given-name>Tony</given-name><initials>T.</initials><afid>60031004</afid></author><intid>1785944699</intid><article-number>0127044</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929172090"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929172090?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929172090&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929172090&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929172090</prism:url><dc:identifier>SCOPUS_ID:84929172090</dc:identifier><eid>2-s2.0-84929172090</eid><dc:title>Sports in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy and desmosomal mutations | Sport bei Patienten mit arrhythmogener rechtsventrikulärer Dysplasie/Kardiomyopathie und desmosomalen Mutationen</dc:title><dc:creator>Sawant A.</dc:creator><prism:publicationName>Herz</prism:publicationName><prism:issn>03409937</prism:issn><prism:eIssn>16156692</prism:eIssn><prism:volume>40</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>402-409</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00059-015-4223-5</prism:doi><dc:description>© 2015, Urban &amp; Vogel. Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a rare cardiomyopathy associated with life-threatening arrhythmias and an increased risk of sudden cardiac death. In addition to mutations in desmosomal genes, environmental factors such as exercise and sport have been implicated in the pathogenesis of the disease. Recent studies have shown that exercise may be associated with adverse outcomes in patients with ARVD/C. On the basis of current evidence, patients with ARVD/C are recommended to limit exercise irrespective of their mutation status. Some studies have suggested the presence of an entirely acquired form of the disease caused by exercise, which has been dubbed “exercise-induced ARVD/C.”</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001555</affiliation-url><afid>60001555</afid><affilname>Johns Hopkins Hospital</affilname><name-variant>Johns Hopkins Hospital</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56562664500</author-url><authid>56562664500</authid><authname>Sawant A.</authname><surname>Sawant</surname><given-name>A. C.</given-name><initials>A.C.</initials><afid>60001555</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26643092500</author-url><authid>26643092500</authid><authname>Calkins H.</authname><surname>Calkins</surname><given-name>H.</given-name><initials>H.</initials><afid>60001555</afid></author><authkeywords>Arrhythmia | Arrhythmogenic right ventricular dysplasia/cardiomyopathy | Desmosome | Exercise | Sudden cardiac death</authkeywords><intid>2035910756</intid><source-id>23251</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929180185"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929180185?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929180185&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929180185&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929180185</prism:url><dc:identifier>SCOPUS_ID:84929180185</dc:identifier><eid>2-s2.0-84929180185</eid><dc:title>Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy</dc:title><dc:creator>Latus H.</dc:creator><prism:publicationName>Journal of Cardiovascular Magnetic Resonance</prism:publicationName><prism:issn>10976647</prism:issn><prism:eIssn>1532429X</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>May 15, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12968-015-0142-0</prism:doi><dc:description>© 2015 Latus et al.; licensee BioMed Central. Background: Different patterns of late gadolinium enhancement (LGE) including mid-wall fibrosis using cardiovascular magnetic resonance (CMR) have been reported in adult patients presenting with non-ischemic dilated cardiomyopathy (DCM). In these studies, LGE was associated with pronounced LV remodelling and predicted adverse cardiac outcomes. Accordingly, the purpose of our study was to determine the presence and patterns of LGE in children and adolescents with DCM. Methods: Patients &lt;18 years of age presenting with severe congestive heart failure who were admitted for evaluation of heart transplantation at our centre underwent CMR examination which consisted of ventricular functional analysis and assessment of LGE for detection of myocardial fibrosis. Ischemic DCM was excluded by coronary angiography, and right ventricular endomyocardial biopsies ruled out acute myocarditis. Results: Thirty-one patients (mean age 2.1 ± 4.2 years) with severe LV dilatation (mean indexed LVEDV 136 ± 48 ml/m&lt;sup&gt;2&lt;/sup&gt;) and LV dysfunction (mean LV-EF 23 ± 8%) were examined. LGE was detected in 5 of the 31 patients (16%) appearing in various patterns characterized as mid-wall (n = 1), focal patchy (n = 1), RV insertion site (n = 1) and transmural (n = 2). Based on histopathological analysis, 4 of the 5 LGE positive patients had lymphocytic myocarditis, whereas one patient was diagnosed with idiopathic DCM. Conclusions: In children and adolescents with DCM, focal histologically proven myocardial fibrosis is rarely detected by LGE CMR despite marked LV dilatation and severely depressed LV function. LGE occurred in various patterns and mostly in patients with inflammatory cardiomyopathy. It remains unclear whether myocardial fibrosis in childhood DCM reflects different endogenous repair mechanisms that enable favourable reverse remodelling. Larger trials are needed to assess the prognostic implications of LGE in childhood DCM.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008248</affiliation-url><afid>60008248</afid><affilname>Universitatsklinikum Giessen und Marburg, Standort Giessen</affilname><affiliation-city>Giessen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022653</affiliation-url><afid>60022653</afid><affilname>Universitatsklinikum Tubingen Medizinische Fakultat</affilname><affiliation-city>Tubingen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26633946200</author-url><authid>26633946200</authid><authname>Latus H.</authname><surname>Latus</surname><given-name>Heiner</given-name><initials>H.</initials><afid>60008248</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55337954800</author-url><authid>55337954800</authid><authname>Gummel K.</authname><surname>Gummel</surname><given-name>Kerstin</given-name><initials>K.</initials><afid>60008248</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7007087642</author-url><authid>7007087642</authid><authname>Klingel K.</authname><surname>Klingel</surname><given-name>Karin</given-name><initials>K.</initials><afid>60022653</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6507047006</author-url><authid>6507047006</authid><authname>Moysich A.</authname><surname>Moysich</surname><given-name>Axel</given-name><initials>A.</initials><afid>60008248</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56640614200</author-url><authid>56640614200</authid><authname>Khalil M.</authname><surname>Khalil</surname><given-name>Markus</given-name><initials>M.</initials><afid>60008248</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56641537800</author-url><authid>56641537800</authid><authname>Mazhari N.</authname><surname>Mazhari</surname><given-name>Nona</given-name><initials>N.</initials><afid>60008248</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55844593900</author-url><authid>55844593900</authid><authname>Bauer J.</authname><surname>Bauer</surname><given-name>Juergen</given-name><initials>J.</initials><afid>60008248</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:23108841200</author-url><authid>23108841200</authid><authname>Kandolf R.</authname><surname>Kandolf</surname><given-name>Reinhard</given-name><initials>R.</initials><afid>60022653</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:19738177700</author-url><authid>19738177700</authid><authname>Schranz D.</authname><surname>Schranz</surname><given-name>Dietmar</given-name><initials>D.</initials><afid>60008248</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:14629837200</author-url><authid>14629837200</authid><authname>Apitz C.</authname><surname>Apitz</surname><given-name>Christian</given-name><initials>C.</initials><afid>60008248</afid></author><authkeywords>Childhood dilated cardiomyopathy | Late gadolinium enhancement | Myocardial fibrosis | Reverse ventricular remodelling</authkeywords><intid>2035912232</intid><source-id>23845</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929448460"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929448460?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929448460&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929448460&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929448460</prism:url><dc:identifier>SCOPUS_ID:84929448460</dc:identifier><eid>2-s2.0-84929448460</eid><dc:title>Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension</dc:title><dc:creator>Fenster B.</dc:creator><prism:publicationName>Heart and Vessels</prism:publicationName><prism:issn>09108327</prism:issn><prism:eIssn>16152573</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00380-015-0691-z</prism:doi><dc:description>© 2015 Springer Japan The response of the right ventricle (RV) to pulmonary arterial hypertension (PAH) involves changes in contractile function, chamber size, hypertrophy, and extracellular matrix (ECM). Galectin-3 (Gal-3) is a mediator of myocardial ECM metabolism and biomarker for left heart remodeling, yet its ability to reflect RV remodeling is unknown. We hypothesized that serum Gal-3 levels correlate with RV morphology and function in PAH, and that Gal-3 is associated with circulating markers of ECM. Fifteen subjects with PAH and 10 age-matched controls underwent same-day echocardiography, cardiac magnetic resonance (CMR) imaging, and phlebotomy for Gal-3 and ECM biomarkers including N-terminal propeptide of type III collagen type (PIIINP), tissue inhibitor of metalloproteinase-1 (TIMP-1), and hyaluronic acid (HA). RV ejection fraction, end diastolic volume index, end systolic volume index, and mass index were calculated using CMR. Echocardiography was used to estimate RV systolic pressure and measure RV strain. Serum Gal-3, TIMP-1, and HA levels were all significantly increased in PAH subjects when compared to controls. Gal-3 correlated with RV ejection fraction (ρ −0.44, p 0.03), end diastolic volume index (ρ 0.42, p 0.03), end systolic volume index (ρ 0.44, p 0.027), mass index (ρ 0.47, p 0.016), systolic pressure (ρ 0.55, p &lt; 0.001), and strain (ρ 0.43, p 0.03). Gal-3 levels positively correlated with the ECM markers TIMP-1 and HA but not with PIIINP. In conclusion, Gal-3 levels are associated with multiple indices of RV function and morphology. Gal-3 may represent a novel biomarker for RV remodeling and associated ECM turnover in PAH.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102305</affiliation-url><afid>60102305</afid><affilname>National Jewish Health</affilname><name-variant>National Jewish Health</name-variant><affiliation-city>Denver</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60097019</affiliation-url><afid>60097019</afid><affilname>Siemens Healthcare Diagnostics Inc.</affilname><name-variant>Siemens Healthcare Diagnostics</name-variant><affiliation-city>Deerfield</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102305</affiliation-url><afid>60102305</afid><affilname>National Jewish Health</affilname><name-variant>National Jewish Health</name-variant><affiliation-city>Denver</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102305</affiliation-url><afid>60102305</afid><affilname>National Jewish Health</affilname><name-variant>National Jewish Health</name-variant><affiliation-city>Denver</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102305</affiliation-url><afid>60102305</afid><affilname>National Jewish Health</affilname><name-variant>National Jewish Health</name-variant><affiliation-city>Denver</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7801345259</author-url><authid>7801345259</authid><authname>Fenster B.</authname><surname>Fenster</surname><given-name>Brett E.</given-name><initials>B.E.</initials><afid>60102305</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55568828400</author-url><authid>55568828400</authid><authname>Lasalvia L.</authname><surname>Lasalvia</surname><given-name>Luis</given-name><initials>L.</initials><afid>60097019</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56061776600</author-url><authid>56061776600</authid><authname>Schroeder J.</authname><surname>Schroeder</surname><given-name>Joyce D.</given-name><initials>J.D.</initials><afid>60102305</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56063422300</author-url><authid>56063422300</authid><authname>Smyser J.</authname><surname>Smyser</surname><given-name>Jamey</given-name><initials>J.</initials><afid>60102305</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8053681900</author-url><authid>8053681900</authid><authname>Silveira L.</authname><surname>Silveira</surname><given-name>Lori J.</given-name><initials>L.J.</initials><afid>60102305</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55405484100</author-url><authid>55405484100</authid><authname>Buckner J.</authname><surname>Buckner</surname><given-name>J. Kern</given-name><initials>J.K.</initials><afid>60102305</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7404381931</author-url><authid>7404381931</authid><authname>Brown K.</authname><surname>Brown</surname><given-name>Kevin K.</given-name><initials>K.K.</initials><afid>60102305</afid></author><authkeywords>Biomarker | Cardiac magnetic resonance imaging | Myocardial fibrosis | Pulmonary hypertension | Right ventricle</authkeywords><intid>1535956081</intid><source-id>23221</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929162713"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929162713?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929162713&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929162713&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929162713</prism:url><dc:identifier>SCOPUS_ID:84929162713</dc:identifier><eid>2-s2.0-84929162713</eid><dc:title>Sudden cardiac death in athletes and its prevention | Plötzlicher Herztod bei Sportlern und dessen Prävention</dc:title><dc:creator>Tönnis T.</dc:creator><prism:publicationName>Herz</prism:publicationName><prism:issn>03409937</prism:issn><prism:eIssn>16156692</prism:eIssn><prism:volume>40</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>379-385</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00059-015-4225-3</prism:doi><dc:description>© 2015, Urban &amp; Vogel. Athletes and especially elite athletes are predominantly young people and are not associated with high health risks, apart from traumatic injuries. Nevertheless, there is a significantly high incidence of sudden cardiac death (SCD), which ranges from 0.6 to 3.0/100,000 athletes per year. Often the SCD is the first manifestation of an underlying cardiac disease. Distinct structural cardiac disorders, such as hypertrophic cardiomyopathy, coronary artery anomalies (17 %), inflammatory disorders (6 %) and arrhythmogenic right ventricular cardiomyopathy as well as conditions without structural cardiac abnormalities, such as primary electrical diseases (channelopathies) are important causes of sudden death. A simple screening can help to identify athletes with these diseases and allow specific therapies or precautionary measures to be initiated.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022215</affiliation-url><afid>60022215</afid><affilname>Asklepios Klinik St. Georg</affilname><name-variant>Asklepios Klinik St. Georg</name-variant><affiliation-city>Hamburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115235559</affiliation-url><afid>115235559</afid><affilname>Herzpraxis Lübeck</affilname><name-variant>Herzpraxis Lübeck</name-variant><affiliation-city>Lubeck</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:9747436000</author-url><authid>9747436000</authid><authname>Tönnis T.</authname><surname>Tönnis</surname><given-name>T.</given-name><initials>T.</initials><afid>60022215</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56641013600</author-url><authid>56641013600</authid><authname>Tack C.</authname><surname>Tack</surname><given-name>C.</given-name><initials>C.</initials><afid>115235559</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56425407100</author-url><authid>56425407100</authid><authname>Kuck K.</authname><surname>Kuck</surname><given-name>K. H.</given-name><initials>K.H.</initials><afid>60022215</afid></author><authkeywords>Channelopathies | Screening | Sports | Structural cardiac disorders | Sudden cardiac death</authkeywords><intid>2035913208</intid><source-id>23251</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929160844"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929160844?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929160844&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929160844&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929160844</prism:url><dc:identifier>SCOPUS_ID:84929160844</dc:identifier><eid>2-s2.0-84929160844</eid><dc:title>Pulmonary hypertension: Possible genetic causes and therapeutic options | Pulmonale Hypertonie: Mögliche genetische Ursachen und therapeutische Optionen</dc:title><dc:creator>Grünig E.</dc:creator><prism:publicationName>Herz</prism:publicationName><prism:issn>03409937</prism:issn><prism:eIssn>16156692</prism:eIssn><prism:volume>40</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>457-470</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00059-015-4230-6</prism:doi><dc:description>© 2015, Urban &amp; Vogel. Pulmonary hypertension (PH) is a severe disease, which is usually only recognized at a late stage. It is characterized by dyspnea and right heart insufficiency. In some forms of pulmonary hypertension, such as the rare pulmonary arterial hypertension (PAH) and PAH associated with congenital heart defects, genetic factors have been identified. This article summarizes the general and supportive therapies for PH, targeted pharmaceutical treatment for PAH and non-operable chronic thromboembolic pulmonary hypertension. To achieve acceptable survival rates, it is essential to transfer patients to an expert center at an early stage for further differential diagnostics and therapy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003280</affiliation-url><afid>60003280</afid><affilname>Universitatsklinikum Heidelberg</affilname><affiliation-city>Heidelberg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005036</affiliation-url><afid>60005036</afid><affilname>Universitatsklinikum Hamburg-Eppendorf und Medizinische Fakultat</affilname><name-variant>University Medical Center Hamburg-Eppendorf</name-variant><affiliation-city>Hamburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072281</affiliation-url><afid>60072281</afid><affilname>Kerckhoff-Klinik</affilname><name-variant>Kerckhoff Heart Center</name-variant><affiliation-city>Bad Nauheim</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603702994</author-url><authid>6603702994</authid><authname>Grünig E.</authname><surname>Grünig</surname><given-name>E.</given-name><initials>E.</initials><afid>60003280</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56151065000</author-url><authid>56151065000</authid><authname>Eichstaedt C.</authname><surname>Eichstaedt</surname><given-name>C. A.</given-name><initials>C.A.</initials><afid>60003280</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14830085800</author-url><authid>14830085800</authid><authname>Ehlken N.</authname><surname>Ehlken</surname><given-name>N.</given-name><initials>N.</initials><afid>60003280</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35464975900</author-url><authid>35464975900</authid><authname>Mayer E.</authname><surname>Mayer</surname><given-name>E.</given-name><initials>E.</initials><afid>60005036</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24328463600</author-url><authid>24328463600</authid><authname>Klose H.</authname><surname>Klose</surname><given-name>H.</given-name><initials>H.</initials><afid>60072281</afid></author><authkeywords>Combination therapy | Genetic factors | Pharmaceutical treatment | Prognosis | Pulmonary hypertension</authkeywords><intid>535919729</intid><source-id>23251</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927918582"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927918582?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927918582&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927918582&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S094471131500080X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927918582</prism:url><dc:identifier>SCOPUS_ID:84927918582</dc:identifier><eid>2-s2.0-84927918582</eid><dc:title>Comparative studies of polydatin and resveratrol on mutual transformation and antioxidative effect in vivo</dc:title><dc:creator>Wang H.</dc:creator><prism:publicationName>Phytomedicine</prism:publicationName><prism:issn>09447113</prism:issn><prism:eIssn>1618095X</prism:eIssn><prism:volume>22</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>553-559</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.phymed.2015.03.014</prism:doi><pii>S094471131500080X</pii><dc:description>© 2015 Elsevier GmbH. All rights reserved. Background Polydatin and resveratrol are extractives of radix or rhizoma of Polygonum cuspidatum, and as the glycoside forms, it is a natural precursor of resveratrol. Purpose In this study, we aimed to explore the mutual transformation between polydatin and resveratrol in rats, and to compare the antioxidative effect of them in vivo. Study design In this study, we analyzed the serum molar concentration of polydatin and resveratrol after oral administration in rats and evaluated the anti-oxidative stress effects of them using a mouse model. Methods Rats were orally administered polydatin or resveratrol and the concentration of them in serum were analyzed by high performance liquid chromatography (HPLC). Their antioxidative effect was compared in mice with oxidative stress cardiomyopathy induced by doxorubicin (DOX). Results The results showed that polydatin and resveratrol could mutually transform in vivo, the molar concentration of polydatin in serum was always averagely 3.35 and 4.28 times as much as resveratrol after oral administration of polydatin and resveratrol at 200 mg/kg, respectively. Both polydatin and resveratrol could significantly decrease the content of malonydialdehyde (MDA), promote the activities of total superoxide dismutase (T-SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) in plasma, and increase the content of glutathione (GSH) in myocardial tissue. The effect of polydatin surpassed resveratrol, particularly embodied in increasing the activities of T-SOD and CAT, and the content of GSH. Conclusion It illustrates that polydatin is the main substance in serum after intragastric administration with polydatin or resveratrol, and the mutual transformation between polydatin and resveratrol keeps balance; they both have the ability of antioxidative stress in vivo, and polydatin has a better effect than resveratrol, which hints that polydatin may be a substitute for resveratrol in antioxidant for clinical use.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010170</affiliation-url><afid>60010170</afid><affilname>Shanghai University of Traditional Chinese Medicine</affilname><name-variant>Shanghai University of Traditional Chinese Medicine</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009246</affiliation-url><afid>60009246</afid><affilname>Shanghai Institute of Technology</affilname><name-variant>Shanghai Institute of Technology</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56278801800</author-url><authid>56278801800</authid><authname>Wang H.</authname><surname>Wang</surname><given-name>Hui Lin</given-name><initials>H.L.</initials><afid>60010170</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56278330500</author-url><authid>56278330500</authid><authname>Gao J.</authname><surname>Gao</surname><given-name>Jian Ping</given-name><initials>J.P.</initials><afid>60010170</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56595863500</author-url><authid>56595863500</authid><authname>Han Y.</authname><surname>Han</surname><given-name>Yu Liang</given-name><initials>Y.L.</initials><afid>60009246</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55706196500</author-url><authid>55706196500</authid><authname>Xu X.</authname><surname>Xu</surname><given-name>Xu</given-name><initials>X.</initials><afid>60009246</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56326139100</author-url><authid>56326139100</authid><authname>Wu R.</authname><surname>Wu</surname><given-name>Rong</given-name><initials>R.</initials><afid>60010170</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56326188500</author-url><authid>56326188500</authid><authname>Gao Y.</authname><surname>Gao</surname><given-name>Yan</given-name><initials>Y.</initials><afid>60010170</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56595970900</author-url><authid>56595970900</authid><authname>Cui X.</authname><surname>Cui</surname><given-name>Xiao Hua</given-name><initials>X.H.</initials><afid>60010170</afid></author><authkeywords>Antioxidative stress | Mutual transformation | Polydatin | Resveratrol</authkeywords><intid>35701444</intid><source-id>17067</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929157857"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929157857?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929157857&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929157857&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929157857</prism:url><dc:identifier>SCOPUS_ID:84929157857</dc:identifier><eid>2-s2.0-84929157857</eid><dc:title>Isolated interrupted aortic arch in adulthood: A case report | Isolierter unterbrochener Aortenbogen beim Erwachsenen: Fallbericht</dc:title><dc:creator>Rencuzogullari I.</dc:creator><prism:publicationName>Herz</prism:publicationName><prism:issn>03409937</prism:issn><prism:eIssn>16156692</prism:eIssn><prism:volume>40</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>549-551</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00059-013-4023-8</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113034061</affiliation-url><afid>113034061</afid><affilname>Mugla Sitki Kocman University</affilname><name-variant>Muǧla Sitki Koçman University</name-variant><affiliation-city>Mugla</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088370</affiliation-url><afid>60088370</afid><affilname>Mersin Universitesi Tip Fakultesi</affilname><name-variant>Mersin University Medical Faculty</name-variant><affiliation-city>Mersin</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55777278900</author-url><authid>55777278900</authid><authname>Rencuzogullari I.</authname><surname>Rencuzogullari</surname><given-name>I.</given-name><initials>I.</initials><afid>113034061</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603658114</author-url><authid>6603658114</authid><authname>Ozcan I.</authname><surname>Ozcan</surname><given-name>I. T.</given-name><initials>I.T.</initials><afid>60088370</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6504364916</author-url><authid>6504364916</authid><authname>Cirit A.</authname><surname>Cirit</surname><given-name>A.</given-name><initials>A.</initials><afid>60088370</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56480238700</author-url><authid>56480238700</authid><authname>Ayhan S.</authname><surname>Ayhan</surname><given-name>S.</given-name><initials>S.</initials><afid>60088370</afid></author><intid>1035912375</intid><source-id>23251</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925089002"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925089002?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925089002&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925089002&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915001624"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925089002</prism:url><dc:identifier>SCOPUS_ID:84925089002</dc:identifier><eid>2-s2.0-84925089002</eid><dc:title>A step ahead of PPARγ full agonists to PPARγ partial agonists: Therapeutic perspectives in the management of diabetic insulin resistance</dc:title><dc:creator>Chigurupati S.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>755</prism:volume><prism:pageRange>50-57</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.02.043</prism:doi><pii>S0014299915001624</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Abstract Described since long as a member of the nuclear receptor superfamily, peroxisome proliferator-activated receptors (PPARs) regulate the gene expression of proteins involved in glucose and lipid metabolism. PPARs indeed regulate several physiologic processes, including lipid homeostasis, adipogenesis, inflammation, and wound healing. PPARs bind natural or synthetic PPAR ligands can function as cellular sensors to regulate the gene transcription. Dyslipidemia, and type 2 diabetes mellitus (T2DM) with insulin resistance are treated using agonists of PPARα and PPARγ, respectively. The PPARγ is a key regulator of insulin sensitization and glucose metabolism, and therefore is considered as an imperative pharmacological target to combat diabetic metabolic disease and insulin resistance. Of note, currently available PPARγ full agonists like rosiglitazone display serious adverse effects such as fluid retention/oedema, weight gain, and increased incidence of cardiovascular events. On the other hand, PPARγ partial agonists are being suggested to devoid or having less incidence of these undesirable events, and are under developmental stages. Current research is on the way for the development of novel PPARγ partial agonists with enhanced therapeutic efficacy and reduced adverse effects. This review sheds lights on the current status of development of PPARγ partial agonists, for the management of T2DM, having comparatively less or no adverse effects to that of PPARγ full agonists.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105231859</affiliation-url><afid>105231859</afid><affilname>AIMST University</affilname><name-variant>AIMST University</name-variant><affiliation-city>Bedong</affiliation-city><affiliation-country>Malaysia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105231859</affiliation-url><afid>105231859</afid><affilname>AIMST University</affilname><name-variant>AIMST University</name-variant><affiliation-city>Bedong</affiliation-city><affiliation-country>Malaysia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105231859</affiliation-url><afid>105231859</afid><affilname>AIMST University</affilname><name-variant>AIMST University</name-variant><affiliation-city>Bedong</affiliation-city><affiliation-country>Malaysia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56283198100</author-url><authid>56283198100</authid><authname>Chigurupati S.</authname><surname>Chigurupati</surname><given-name>Sridevi</given-name><initials>S.</initials><afid>105231859</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55922568900</author-url><authid>55922568900</authid><authname>Dhanaraj S.</authname><surname>Dhanaraj</surname><given-name>Sokkalingam A.</given-name><initials>S.A.</initials><afid>105231859</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14625937600</author-url><authid>14625937600</authid><authname>Balakumar P.</authname><surname>Balakumar</surname><given-name>Pitchai</given-name><initials>P.</initials><afid>105231859</afid></author><authkeywords>Adverse effects | Cardiovascular events | Diabetes mellitus | PPARγ full agonists | PPARγ partial agonists</authkeywords><intid>2035260707</intid><article-number>69790</article-number><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929359773"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929359773?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929359773&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929359773&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929359773</prism:url><dc:identifier>SCOPUS_ID:84929359773</dc:identifier><eid>2-s2.0-84929359773</eid><dc:title>Sodium-calcium exchanger 1 regulates epithelial cell migration via calcium-dependent extracellular signal-regulated kinase signaling</dc:title><dc:creator>Balasubramaniam S.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>20</prism:issueIdentifier><prism:pageRange>12463-12473</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M114.629519</prism:doi><dc:description>© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Na&lt;sup&gt;+&lt;/sup&gt;/Ca&lt;sup&gt;2+&lt;/sup&gt; exchanger-1 (NCX1) is a major calcium extrusion mechanism in renal epithelial cells enabling the efflux of one Ca&lt;sup&gt;2+&lt;/sup&gt; ion and the influx of three Na&lt;sup&gt;+&lt;/sup&gt; ions. The gradient for this exchange activity is provided by Na, K-ATPase, a hetero-oligomer consisting of a catalytic α-subunit and a regulatory β-subunit (Na, K-β) that also functions as a motility and tumor suppressor. We showed earlier that mice with heart-specific ablation (KO) of Na, K-β had a specific reduction in NCX1 protein and were ouabain-insensitive. Here, we demonstrate that Na, K-β associates with NCX1 and regulates its localization to the cell surface. Madin-Darby canine kidney cells with Na, K-β knockdown have reduced NCX1 protein and function accompanied by 2.1-fold increase in free intracellular calcium and a corresponding increase in the rate of cell migration. Increased intracellular calcium up-regulated ERK1/2 via calmodulin-dependent activation of PI3K. Both myosin light chain kinase and Rho-associated kinase acted as mediators of ERK1/2-dependent migration. Restoring NCX1 expression in β-KD cells reduced migration rate and ERK1/2 activation, suggesting that NCX1 functions downstream of Na, K-β in regulating cell migration. In parallel, inhibition of NCX1 by KB-R7943 in Madin-Darby canine kidney cells, LLC-PK1, and human primary renal epithelial cells (HREpiC) increased ERK1/2 activation and cell migration. This increased migration was associated with high myosin light chain phosphorylation by PI3K/ERK-dependent mechanism in HREpiC cells. These data confirm the role of NCX1 activity in regulating renal epithelial cell migration.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018141</affiliation-url><afid>60018141</afid><affilname>Alfred I. duPont Hospital for Children</affilname><name-variant>Alfred I. DuPont Hospital for Children</name-variant><affiliation-city>Wilmington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023004</affiliation-url><afid>60023004</afid><affilname>University of Delaware</affilname><name-variant>University of Delaware</name-variant><affiliation-city>Newark</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56644280900</author-url><authid>56644280900</authid><authname>Balasubramaniam S.</authname><surname>Balasubramaniam</surname><given-name>Sona Lakshme</given-name><initials>S.L.</initials><afid>60018141</afid><afid>60023004</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56644280900</author-url><authid>56644280900</authid><authname>Balasubramaniam S.</authname><surname>Balasubramaniam</surname><given-name>Sona Lakshme</given-name><initials>S.L.</initials><afid>60018141</afid><afid>60023004</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:25960037400</author-url><authid>25960037400</authid><authname>Gopalakrishnapillai A.</authname><surname>Gopalakrishnapillai</surname><given-name>Anilkumar</given-name><initials>A.</initials><afid>60018141</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56092594300</author-url><authid>56092594300</authid><authname>Gangadharan V.</authname><surname>Gangadharan</surname><given-name>Vimal</given-name><initials>V.</initials><afid>60023004</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56479927400</author-url><authid>56479927400</authid><authname>Duncan R.</authname><surname>Duncan</surname><given-name>Randall L.</given-name><initials>R.L.</initials><afid>60023004</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:9744096900</author-url><authid>9744096900</authid><authname>Barwe S.</authname><surname>Barwe</surname><given-name>Sonali P.</given-name><initials>S.P.</initials><afid>60018141</afid><afid>60023004</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:9744096900</author-url><authid>9744096900</authid><authname>Barwe S.</authname><surname>Barwe</surname><given-name>Sonali P.</given-name><initials>S.P.</initials><afid>60018141</afid><afid>60023004</afid></author><intid>2035940051</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929379485"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929379485?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929379485&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929379485&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929379485</prism:url><dc:identifier>SCOPUS_ID:84929379485</dc:identifier><eid>2-s2.0-84929379485</eid><dc:title>Short-term outcomes of hip fractures in patients aged 90 years old and over receiving surgical intervention</dc:title><dc:creator>Lin W.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0125496</prism:doi><dc:description>© 2015 Lin et al. Background: The knowledge about short-term outcomes of nonagenarians undergoing surgery for hip fracture in Asian is limited. Methods: The patients with hip fractures who underwent hip hemiarthroplasty and open reduction with internal fixation (ORIF) for management during the period from 2008 to 2012 were identified and their medical record was retrospectively reviewed. Results: During the study period, a total of 101 patients underwent surgery formanagement of hip fractures, and the age of patients ranged from 90 to 96 years. The sites of hip fracture were intertrochanteric (n = 57, 56.4%) and the neck of the femur (n = 44, 43.6%). Most of the patients had American Society of Anesthesiologists scores of 3(n = 55) or 4 (in 44 patients). 80.2%(n = 81) underwent the operation within one day after admission; however, there were 13 patients (12.9%) that underwent surgery 48 or more hours later. ORIF and hemiarthroplasty were performed for 63 (62.4%) and 38 (37.6%) patients, respectively. Overall, the 30-day and 1-year mortality rates were 9.9%(10/101) and 17.3%(13/75), respectively. Multivariate analysis showed that the 30-day mortality was significantly associated only with end-stage renal disease (ESRD) (Odds ratio, 11.13, 95%confidence interval, 1.275-97.881, P =.029). Conclusions: The short-term outcome of surgical management for Asian nonagenarians with hip fractures is favorable in selected patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090111</affiliation-url><afid>60090111</afid><affilname>Chi Mei Medical Center</affilname><name-variant>Chi-Mei Medical Center</name-variant><affiliation-city>Tainan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012256</affiliation-url><afid>60012256</afid><affilname>Kaohsiung Medical University</affilname><name-variant>Kaohsiung Medical University</name-variant><affiliation-city>Kaohsiung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090111</affiliation-url><afid>60090111</afid><affilname>Chi Mei Medical Center</affilname><name-variant>Chi-Mei Medical Center</name-variant><affiliation-city>Tainan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105590450</affiliation-url><afid>105590450</afid><affilname>Min-Hwei College of Health Care Management</affilname><name-variant>Min-Hwei College of Health Care Management</name-variant><affiliation-city>Tainan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090111</affiliation-url><afid>60090111</afid><affilname>Chi Mei Medical Center</affilname><name-variant>Chi-Mei Medical Center</name-variant><affiliation-city>Tainan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643490500</author-url><authid>56643490500</authid><authname>Lin W.</authname><surname>Lin</surname><given-name>Wei Ting</given-name><initials>W.T.</initials><afid>60090111</afid><afid>60012256</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643490500</author-url><authid>56643490500</authid><authname>Lin W.</authname><surname>Lin</surname><given-name>Wei Ting</given-name><initials>W.T.</initials><afid>60090111</afid><afid>60012256</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37046674500</author-url><authid>37046674500</authid><authname>Chao C.</authname><surname>Chao</surname><given-name>Chien Ming</given-name><initials>C.M.</initials><afid>60090111</afid><afid>105590450</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37046674500</author-url><authid>37046674500</authid><authname>Chao C.</authname><surname>Chao</surname><given-name>Chien Ming</given-name><initials>C.M.</initials><afid>60090111</afid><afid>105590450</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56643585700</author-url><authid>56643585700</authid><authname>Liu H.</authname><surname>Liu</surname><given-name>Hsuan Chih</given-name><initials>H.C.</initials><afid>60090111</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:54882785700</author-url><authid>54882785700</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yi Ju</given-name><initials>Y.J.</initials><afid>60090111</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56643345200</author-url><authid>56643345200</authid><authname>Lee W.</authname><surname>Lee</surname><given-name>Wei Jing</given-name><initials>W.J.</initials><afid>60090111</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7403086515</author-url><authid>7403086515</authid><authname>Lai C.</authname><surname>Lai</surname><given-name>Chih Cheng</given-name><initials>C.C.</initials><afid>60090111</afid></author><intid>1535943943</intid><article-number>e0125496</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929377692"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929377692?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929377692&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929377692&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929377692</prism:url><dc:identifier>SCOPUS_ID:84929377692</dc:identifier><eid>2-s2.0-84929377692</eid><dc:title>Accuracy of pulse oximeters in detecting hypoxemia in patients with chronic thromboembolic pulmonary hypertension</dc:title><dc:creator>Kohyama T.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0126979</prism:doi><dc:description>© 2015 Kohyama et al. Purpose: Pulse oximetry is routinely used to continuously and non-invasively monitor arterial oxygen saturation (SaO&lt;inf&gt;2&lt;/inf&gt;). When oxygen saturation by pulse oximeter (SpO&lt;inf&gt;2&lt;/inf&gt;) overestimates SaO&lt;inf&gt;2&lt;/inf&gt;, hypoxemia may be overlooked. We compared the SpO&lt;inf&gt;2&lt;/inf&gt; - SaO&lt;inf&gt;2&lt;/inf&gt; differences among three pulse oximeters in patients with chronic thromboembolic pulmonary hypertension (CTEPH) who spent their daily lives in a poor oxygen state. Material and Method: This prospective observational study recruited 32 patients with CTEPH undergoing elective cardiac catheterization. As we collected arterial blood samples in the catheter laboratory, SpO&lt;inf&gt;2&lt;/inf&gt; values were simultaneously recorded. Three pulse oximeters were used on each patient, and SpO&lt;inf&gt;2&lt;/inf&gt; values were compared with oximetry readings using a blood gas analyzer. To determine the optimal SpO&lt;inf&gt;2&lt;/inf&gt; value by which to detect hypoxemia (SaO&lt;inf&gt;2&lt;/inf&gt;≤90%), we generated receiver operating characteristic (ROC) curves for each pulse oximeter. Result: The root mean square of each pulse oximeter was 1.79 (OLV-3100), 1.64 (N-BS), and 2.50 (Masimo Radical). The mean bias (SpO&lt;inf&gt;2&lt;/inf&gt; - SaO&lt;inf&gt;2&lt;/inf&gt;) for the 90%-95% saturation range was significantly higher for Masimo Radical (0.19 +/- 1.78% [OLV-3100], 0.18 +/- 1.63% [N-BS], and 1.61 +/- 1.91%[Masimo Radical]; p&lt;0.0001). The optimal SpO&lt;inf&gt;2&lt;/inf&gt; value to detect hypoxemia (SaO&lt;inf&gt;2&lt;/inf&gt;≤90%) was 89% for OLV-3100, 90% for N-BS, and 92% for Masimo Radical. Conclusion: We found that the biases and precision with which to detect hypoxemia differed among the three pulse oximeters. To avoid hypoxemia, the optimal SpO&lt;inf&gt;2&lt;/inf&gt; should be determined for each pulse oximeter.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020028</affiliation-url><afid>60020028</afid><affilname>Kyorin University</affilname><name-variant>Kyorin University</name-variant><affiliation-city>Mitaka</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019092</affiliation-url><afid>60019092</afid><affilname>Kyorin University School of Medicine</affilname><name-variant>Kyorin University School of Medicine</name-variant><affiliation-city>Mitaka</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55433851900</author-url><authid>55433851900</authid><authname>Kohyama T.</authname><surname>Kohyama</surname><given-name>Tomoki</given-name><initials>T.</initials><afid>60020028</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7103037122</author-url><authid>7103037122</authid><authname>Moriyama K.</authname><surname>Moriyama</surname><given-name>Kiyoshi</given-name><initials>K.</initials><afid>60020028</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56446520800</author-url><authid>56446520800</authid><authname>Kanai R.</authname><surname>Kanai</surname><given-name>Riichiro</given-name><initials>R.</initials><afid>60020028</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56644191100</author-url><authid>56644191100</authid><authname>Kotani M.</authname><surname>Kotani</surname><given-name>Mariko</given-name><initials>M.</initials><afid>60020028</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56644338300</author-url><authid>56644338300</authid><authname>Uzawa K.</authname><surname>Uzawa</surname><given-name>Kohji</given-name><initials>K.</initials><afid>60020028</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56489383500</author-url><authid>56489383500</authid><authname>Satoh T.</authname><surname>Satoh</surname><given-name>Toru</given-name><initials>T.</initials><afid>60019092</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004844828</author-url><authid>7004844828</authid><authname>Yorozu T.</authname><surname>Yorozu</surname><given-name>Tomoko</given-name><initials>T.</initials><afid>60020028</afid></author><intid>2035941039</intid><article-number>0126979</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929429153"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929429153?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929429153&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929429153&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929429153</prism:url><dc:identifier>SCOPUS_ID:84929429153</dc:identifier><eid>2-s2.0-84929429153</eid><dc:title>Ligand specific variation in cardiac response to stimulation of peroxisome proliferator-activated receptor-alpha in spontaneously hypertensive rat</dc:title><dc:creator>Ismael S.</dc:creator><prism:publicationName>Molecular and Cellular Biochemistry</prism:publicationName><prism:issn>03008177</prism:issn><prism:eIssn>15734919</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11010-015-2435-x</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Left ventricular hypertrophy (LVH) is an independent risk factor for cardiac failure. Reduction of LVH has beneficial effects on the heart. LVH is associated with shift in energy substrate preference from fatty acid to glucose, mediated by down regulation of peroxisome proliferator-activated receptor-alpha (PPAR-α). As long-term dependence on glucose can promote adverse cardiac remodeling, it was hypothesized that, prevention of metabolic shift by averting down regulation of PPAR-α can reduce cardiac remodeling in spontaneously hypertensive rat (SHR). Cardiac response to stimulation of PPAR-α presumably depends on the type of ligand used. Therefore, the study was carried out in SHR, using two different PPAR-α ligands. SHR were treated with either fenofibrate (100 mg/kg/day) or medium-chain triglyceride (MCT) Tricaprylin (5 % of diet) for 4 months. Expression of PPAR-α and medium-chain acylCoA dehydrogenase served as markers, for stimulation of PPAR-α. Both ligands stimulated PPAR-α. Decrease of blood pressure was observed only with fenofibrate. LVH was assessed from heart-weight/body weight ratio, histology and brain natriuretic peptide expression. As oxidative stress is linked with hypertrophy, serum and cardiac malondialdehyde and cardiac 3-nitrotyrosine levels were determined. Compared to untreated SHR, LVH and oxidative stress were lower on supplementation with MCT, but higher on treatment with fenofibrate. The observations indicate that reduction of blood pressure is not essentially accompanied by reduction of LVH, and that, progressive cardiac remodeling can be prevented with decrease in oxidative stress. Contrary to the notion that reactivation of PPAR-α is detrimental; the study substantiates that cardiac response to stimulation of PPAR-α is ligand specific.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027039</affiliation-url><afid>60027039</afid><affilname>Sree Chitra Tirunal Institute for Medical Sciences and Technology</affilname><name-variant>Sree Chitra Tirunal Institute for Medical Sciences and Technology</name-variant><affiliation-city>Thiruvananthapuram</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027039</affiliation-url><afid>60027039</afid><affilname>Sree Chitra Tirunal Institute for Medical Sciences and Technology</affilname><name-variant>Sree Chitra Tirunal Institute for Medical Sciences and Technology</name-variant><affiliation-city>Thiruvananthapuram</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56646182800</author-url><authid>56646182800</authid><authname>Ismael S.</authname><surname>Ismael</surname><given-name>Saifudeen</given-name><initials>S.</initials><afid>60027039</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:49962016100</author-url><authid>49962016100</authid><authname>Purushothaman S.</authname><surname>Purushothaman</surname><given-name>Sreeja</given-name><initials>S.</initials><afid>60027039</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8416748900</author-url><authid>8416748900</authid><authname>Harikrishnan V.</authname><surname>Harikrishnan</surname><given-name>V. S.</given-name><initials>V.S.</initials><afid>60027039</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202192317</author-url><authid>7202192317</authid><authname>Nair R.</authname><surname>Nair</surname><given-name>R. Renuka</given-name><initials>R.R.</initials><afid>60027039</afid></author><authkeywords>Cardiac remodeling | Fenofibrate | Medium chain triglyceride | Metabolic shift | Oxidative stress | Stimulation of PPAR-α</authkeywords><intid>2035950962</intid><source-id>14134</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929359095"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929359095?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929359095&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929359095&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929359095</prism:url><dc:identifier>SCOPUS_ID:84929359095</dc:identifier><eid>2-s2.0-84929359095</eid><dc:title>Potential transmission pathways of Streptococcus gallolyticus subsp. gallolyticus</dc:title><dc:creator>Dumke J.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0126507</prism:doi><dc:description>© 2015 Dumke et al. Streptococcus gallolyticus subsp. gallolyticus (S. gallolyticus subsp. gallolyticus), a member of group D streptococci, is an inhabitant of the animal and human gastrointestinal tract. Furthermore, it is a facultative pathogen which causes e.g. endocarditis, septicemia and mastitis. S. gallolyticus subsp. gallolyticus may be transmitted either directly or indirectly between animals and humans. However, the transmission routes are an unsolved issue. In this study, we present systematic analyses of an S. gallolyticus subsp. gallolyticus isolate of an infective endocarditis patient in relation to isolates of his laying hen flock. Isolates from pooled droppings of laying hens, pooled dust samples and human blood culture were characterized by using multilocus sequence typing (MLST) and DNA fingerprinting. MLST revealed the same allelic profile of isolates from the human blood culture and from the droppings of laying hens. In addition, these isolates showed clonal identity regarding a similar DNA fingerprinting pattern. For the first time, we received a hint that transmission of S. gallolyticus subsp. gallolyticus between poultry and humans may occur. This raises the question about the zoonotic potential of isolates from poultry and should be considered in future studies.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005322</affiliation-url><afid>60005322</afid><affilname>Universitat Bochum</affilname><name-variant>Ruhr-Universität Bochum</name-variant><affiliation-city>Bochum</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011610</affiliation-url><afid>60011610</afid><affilname>Tierarztliche Hochschule Hannover</affilname><name-variant>University of Veterinary Medicine Hannover</name-variant><affiliation-city>Hannover</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56246849500</author-url><authid>56246849500</authid><authname>Dumke J.</authname><surname>Dumke</surname><given-name>Jessika</given-name><initials>J.</initials><afid>60005322</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35776614900</author-url><authid>35776614900</authid><authname>Hinse D.</authname><surname>Hinse</surname><given-name>Dennis</given-name><initials>D.</initials><afid>60005322</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:25226345000</author-url><authid>25226345000</authid><authname>Vollmer T.</authname><surname>Vollmer</surname><given-name>Tanja</given-name><initials>T.</initials><afid>60005322</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:10938808700</author-url><authid>10938808700</authid><authname>Schulz J.</authname><surname>Schulz</surname><given-name>Jochen</given-name><initials>J.</initials><afid>60011610</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003640475</author-url><authid>7003640475</authid><authname>Knabbe C.</authname><surname>Knabbe</surname><given-name>Cornelius</given-name><initials>C.</initials><afid>60005322</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005119281</author-url><authid>7005119281</authid><authname>Dreier J.</authname><surname>Dreier</surname><given-name>Jens</given-name><initials>J.</initials><afid>60005322</afid></author><intid>1035939130</intid><article-number>e0126507</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929573842"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929573842?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929573842&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929573842&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929573842</prism:url><dc:identifier>SCOPUS_ID:84929573842</dc:identifier><eid>2-s2.0-84929573842</eid><dc:title>The usefulness of ozone treatment in spinal pain</dc:title><dc:creator>Bocci V.</dc:creator><prism:publicationName>Drug Design, Development and Therapy</prism:publicationName><prism:issn>11778881</prism:issn><prism:eIssn>11778881</prism:eIssn><prism:volume>9</prism:volume><prism:pageRange>2677-2685</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.2147/DDDT.S74518</prism:doi><dc:description>© 2015 Bocci et al. Objective: The aim of this review is to elucidate the biochemical, molecular, immunological, and pharmaceutical mechanisms of action of ozone dissolved in biological fluids. Studies performed during the last two decades allow the drawing of a comprehensive framework for understanding and recommending the integration of ozone therapy for spinal pain. Methods: An in-depth screening of primary sources of information online – via SciFinder Scholar, Google Scholar, and Scopus databases as well as Embase, PubMed, and the Cochrane Database of Systemic Reviews – was performed. In this review, the most significant papers of the last 25 years are presented and their proposals critically evaluated, regardless of the bibliometric impact of the journals. Results: The efficacy of standard treatments combined with the unique capacity of ozone therapy to reactivate the innate antioxidant system is the key to correcting the oxidative stress typical of chronic inflammatory diseases. Pain pathways and control systems of algesic signals after ozone administration are described. Conclusion: This paper finds favors the full insertion of ozone therapy into pharmaceutical sciences, rather than as either an alternative or an esoteric approach.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002838</affiliation-url><afid>60002838</afid><affilname>Universita degli Studi di Siena</affilname><name-variant>Università di Siena</name-variant><affiliation-city>Siena</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002838</affiliation-url><afid>60002838</afid><affilname>Universita degli Studi di Siena</affilname><name-variant>Università di Siena</name-variant><affiliation-city>Siena</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7103297359</author-url><authid>7103297359</authid><authname>Bocci V.</authname><surname>Bocci</surname><given-name>Velio</given-name><initials>V.</initials><afid>60002838</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006750011</author-url><authid>7006750011</authid><authname>Borrelli E.</authname><surname>Borrelli</surname><given-name>Emma</given-name><initials>E.</initials><afid>60002838</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:14051222900</author-url><authid>14051222900</authid><authname>Zanardi I.</authname><surname>Zanardi</surname><given-name>Iacopo</given-name><initials>I.</initials><afid>60002838</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603451420</author-url><authid>6603451420</authid><authname>Travagli V.</authname><surname>Travagli</surname><given-name>Valter</given-name><initials>V.</initials><afid>60002838</afid></author><authkeywords>Antioxidants | Oxidants | Oxidative stress</authkeywords><intid>1035976998</intid><source-id>19700175230</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929431596"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929431596?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929431596&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929431596&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929431596</prism:url><dc:identifier>SCOPUS_ID:84929431596</dc:identifier><eid>2-s2.0-84929431596</eid><dc:title>Love, Incorporated</dc:title><dc:creator>Martin A.</dc:creator><prism:publicationName>Ethical Theory and Moral Practice</prism:publicationName><prism:issn>13862820</prism:issn><prism:eIssn>15728447</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10677-015-9597-1</prism:doi><dc:description>© 2015 Springer Science+Business Media Dordrecht In this paper, I outline a Kantian moral psychology and use it to generate an analysis of the emotional attitude, love. At the heart of this moral psychology is a distinction between rational and subrational motives, and the thesis that interpersonal emotional attitudes like love are governed by a norm of respect. I show how an analysis of love that relies on this moral psychology—which I call “the incorporation conception” of love—tightly fits with paradigmatic cases of romantic love, reveals both the continuities and differences between romantic and other forms of love, and also explicates our ambivalence about certain cases. Finally, I argue that this analysis, although it sees love as essentially a bundle of volitions, has the resources to respond to both David Velleman’s and Niko Kolodny’s critiques of volition-based analyses of love. Taken as a whole, the discussion provides an argument for both this analysis of love and the moral psychology it presupposes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005080</affiliation-url><afid>60005080</afid><affilname>Claremont McKenna College</affilname><name-variant>Claremont McKenna College</name-variant><affiliation-city>Claremont</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645389700</author-url><authid>56645389700</authid><authname>Martin A.</authname><surname>Martin</surname><given-name>Adrienne M.</given-name><initials>A.M.</initials><afid>60005080</afid></author><authkeywords>Emotion | Love | Moral philosophy | Moral psychology | Motivation</authkeywords><intid>1535954692</intid><source-id>23509</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930193257"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930193257?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930193257&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930193257&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930193257</prism:url><dc:identifier>SCOPUS_ID:84930193257</dc:identifier><eid>2-s2.0-84930193257</eid><dc:title>Safety and efficacy of combined epidural/general anesthesia during major abdominal surgery in patients with increased intracranial pressure: A cohort study</dc:title><dc:creator>Zabolotskikh I.</dc:creator><prism:publicationName>BMC Anesthesiology</prism:publicationName><prism:eIssn>14712253</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>May 15, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12871-015-0056-2</prism:doi><dc:description>© Zabolotskikh and Trembach.; licensee BioMed Central. Background: The increased intracranial pressure can significantly complicate the perioperative period in major abdominal surgery, increasing the risk of complications, the length of recovery from the surgery, worsening the outcome. Epidural anesthesia has become a routine component of abdominal surgery, but its use in patients with increased intracranial pressure remains controversial. The goal of the study was to evaluate the safety and efficacy of epidural anesthesia, according to monitoring of intracranial pressure in patients with increased intracranial pressure. Methods: The study includes 65 surgical patients who were routinely undergone the major abdominal surgery under combined epidural/general anesthesia. Depending on the initial ICP all patients were divided into 2 groups: 1 (N group) - patients with the normal intracranial pressure (≤12 mm Hg, n = 35) and 2 (E group) - patients with the elevated intracranial pressure (ICP &gt; 12 mm Hg, n = 30). During the surgery we evaluated ICP, blood pressure, cerebral perfusion pressure (CPP). The parameters of recovery from anesthesia and the effectiveness of postoperative analgesia were also assessed. Results: In N group ICP remained stable. In E group ICP decreased during anesthesia, the overall decline was 40 % at the end of the operation (from 15 to 9 mm Hg (P &lt;0.05)). The correction of MAP with vasopressors to maintain normal CPP was required mainly in patients with increased ICP (70 % vs. 45 %, p &lt;0.05). CPP declined by 19 % in N group. In E group the CPP reduction was 23 %, and then it remained stable at 60 mm Hg. No significant differences in time of the recovery of consciousness, effectiveness of postoperative analgesia and complications between patients with initially normal levels of ICP and patients with ICH were noted. Conclusions: The combination of general and epidural anesthesia is safe and effective in patients with increased intracranial pressure undergoing elective abdominal surgery under the condition of maintaining the arterial pressure. Its use is not associated with the increase in intracranial pressure during the anesthesia, but it needs an intraoperative monitoring of ICP in order to prevent CPP reduction.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112712998</affiliation-url><afid>112712998</afid><affilname>Kuban State Medical University</affilname><name-variant>Kuban State Medical University</name-variant><affiliation-city>Krasnodar</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6508104506</author-url><authid>6508104506</authid><authname>Zabolotskikh I.</authname><surname>Zabolotskikh</surname><given-name>Igor</given-name><initials>I.</initials><afid>112712998</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56042781600</author-url><authid>56042781600</authid><authname>Trembach N.</authname><surname>Trembach</surname><given-name>Nikita</given-name><initials>N.</initials><afid>112712998</afid></author><authkeywords>Abdominal surgery | Epidural anesthesia | Intracranial pressure</authkeywords><intid>1036082972</intid><article-number>76</article-number><source-id>21855</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929428311"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929428311?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929428311&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929428311&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929428311</prism:url><dc:identifier>SCOPUS_ID:84929428311</dc:identifier><eid>2-s2.0-84929428311</eid><dc:title>Duality for Frames</dc:title><dc:creator>Fan Z.</dc:creator><prism:publicationName>Journal of Fourier Analysis and Applications</prism:publicationName><prism:issn>10695869</prism:issn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00041-015-9415-0</prism:doi><dc:description>© 2015 Springer Science+Business Media New York The subject of this article is the duality principle, which, well beyond its stand at the heart of Gabor analysis, is a universal principle in frame theory that gives insight into many phenomena. Its fiber matrix formulation for Gabor systems is the driving principle behind seemingly different results. We show how the classical duality identities, operator representations and constructions for dual Gabor frames are in fact aspects of the dual Gramian matrix fiberization and its sole duality principle, giving a unified view to all of them. We show that the same duality principle, via dual Gramian matrix analysis, holds for dual (or bi-) systems in abstract Hilbert spaces. The essence of the duality principle is the unitary equivalence of the frame operator and the Gramian of certain adjoint systems. An immediate consequence is, for example, that, even on this level of generality, dual frames are characterized in terms of biorthogonality relations of adjoint systems. We formulate the duality principle for irregular Gabor systems which have no structure whatsoever to the sampling of the shifts and modulations of the generating window. In case the shifts and modulations are sampled from lattices we show how the abstract matrices can be reduced to the simple structured fiber matrices of shift-invariant systems, thus arriving back in the well understood territory. Moreover, in the arena of multiresolution analysis (MRA)-wavelet frames, the mixed unitary extension principle can be viewed as the duality principle in a sequence space. This perspective leads to a construction scheme for dual wavelet frames which is strikingly simple in the sense that it only needs the completion of an invertible constant matrix. Under minimal conditions on the MRA, our construction guarantees the existence and easy constructability of non-separable multivariate dual MRA-wavelet frames. The wavelets have compact support and we show examples for multivariate interpolatory refinable functions. Finally, we generalize the duality principle to the case of transforms that are no longer defined by discrete systems, but may have discrete adjoint systems.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017161</affiliation-url><afid>60017161</afid><affilname>National University of Singapore</affilname><name-variant>National University of Singapore</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56086005000</author-url><authid>56086005000</authid><authname>Fan Z.</authname><surname>Fan</surname><given-name>Zhitao</given-name><initials>Z.</initials><afid>60017161</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005906667</author-url><authid>7005906667</authid><authname>Heinecke A.</authname><surname>Heinecke</surname><given-name>Andreas</given-name><initials>A.</initials><afid>60017161</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7403324097</author-url><authid>7403324097</authid><authname>Shen Z.</authname><surname>Shen</surname><given-name>Zuowei</given-name><initials>Z.</initials><afid>60017161</afid></author><authkeywords>Adjoint system | Dual frame | Dual Gramian analysis | Duality principle | Filter bank | Gabor frame | Wavelets</authkeywords><intid>35954771</intid><source-id>23893</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929431183"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929431183?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929431183&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929431183&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929431183</prism:url><dc:identifier>SCOPUS_ID:84929431183</dc:identifier><eid>2-s2.0-84929431183</eid><dc:title>Left Ventricular Remodeling and Function in Children with Biventricular Circulation After Fetal Aortic Valvuloplasty</dc:title><dc:creator>Friedman K.</dc:creator><prism:publicationName>Pediatric Cardiology</prism:publicationName><prism:issn>01720643</prism:issn><prism:eIssn>14321971</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00246-015-1193-6</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Fetal aortic valvuloplasty (FAV) has shown promise in averting the progression of fetal aortic stenosis to hypoplastic left-heart syndrome. Altered loading conditions due to valvar disease, intrinsic endomyocardial abnormalities, and procedures that alter endomyocardial mechanics may place patients with biventricular circulation (BiV) after FAV at risk of abnormal LV remodeling and function. Using the most recent echo data on BiV patients after technically successful FAV (n = 34), we evaluated LV remodeling pattern, risk factors for pathologic LV remodeling, and the association between LV remodeling pattern and LV function. Median age at follow-up was 4.7 years (range 1.0–12.5). Cardiac interventions were common. At latest follow-up, no patient had hypoplastic LV. Nineteen patients (55 %) had dilated LV, and five (16 %) patients had severely dilated LV. LV remodeling patterns were as follows: 12 (35 %) normal ventricle, 11 (32 %) mixed hypertrophy, 8 (24 %) eccentric hypertrophy or remodeling, and 3 (9 %) concentric hypertrophy. Univariate factors associated with pathologic LV remodeling were long-standing AR, ≥2 cardiac interventions, EFE resection, and aortic or mitral regurgitation ≥ moderate at most recent follow-up. In multivariate analysis, only long-standing AR fraction remained associated with pathologic remodeling. Pathologic LV remodeling was associated with depressed ejection fraction, lower septal E´, and higher E/E´. Pathologic LV remodeling, primarily eccentric or mixed hypertrophy, is common in BiV patients after FAV and is related to LV loading conditions imposed by valvar disease. Pathologic remodeling is associated with both systolic and diastolic dysfunction in this population.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030521</affiliation-url><afid>60030521</afid><affilname>Children's Hospital Boston</affilname><name-variant>Children's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002746</affiliation-url><afid>60002746</afid><affilname>Harvard Medical School</affilname><name-variant>Harvard Medical School</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36195468000</author-url><authid>36195468000</authid><authname>Friedman K.</authname><surname>Friedman</surname><given-name>Kevin G.</given-name><initials>K.G.</initials><afid>60030521</afid><afid>60002746</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36195468000</author-url><authid>36195468000</authid><authname>Friedman K.</authname><surname>Friedman</surname><given-name>Kevin G.</given-name><initials>K.G.</initials><afid>60030521</afid><afid>60002746</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56148326200</author-url><authid>56148326200</authid><authname>Freud L.</authname><surname>Freud</surname><given-name>Lindsay</given-name><initials>L.</initials><afid>60030521</afid><afid>60002746</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56148326200</author-url><authid>56148326200</authid><authname>Freud L.</authname><surname>Freud</surname><given-name>Lindsay</given-name><initials>L.</initials><afid>60030521</afid><afid>60002746</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:40161403000</author-url><authid>40161403000</authid><authname>Escobar-Diaz M.</authname><surname>Escobar-Diaz</surname><given-name>Maria</given-name><initials>M.</initials><afid>60030521</afid><afid>60002746</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:40161403000</author-url><authid>40161403000</authid><authname>Escobar-Diaz M.</authname><surname>Escobar-Diaz</surname><given-name>Maria</given-name><initials>M.</initials><afid>60030521</afid><afid>60002746</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:28367555500</author-url><authid>28367555500</authid><authname>Banka P.</authname><surname>Banka</surname><given-name>Puja</given-name><initials>P.</initials><afid>60030521</afid><afid>60002746</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:28367555500</author-url><authid>28367555500</authid><authname>Banka P.</authname><surname>Banka</surname><given-name>Puja</given-name><initials>P.</initials><afid>60030521</afid><afid>60002746</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:34876424400</author-url><authid>34876424400</authid><authname>Emani S.</authname><surname>Emani</surname><given-name>Sitaram</given-name><initials>S.</initials><afid>60030521</afid><afid>60002746</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:34876424400</author-url><authid>34876424400</authid><authname>Emani S.</authname><surname>Emani</surname><given-name>Sitaram</given-name><initials>S.</initials><afid>60030521</afid><afid>60002746</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602702603</author-url><authid>6602702603</authid><authname>Tworetzky W.</authname><surname>Tworetzky</surname><given-name>Wayne</given-name><initials>W.</initials><afid>60030521</afid><afid>60002746</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602702603</author-url><authid>6602702603</authid><authname>Tworetzky W.</authname><surname>Tworetzky</surname><given-name>Wayne</given-name><initials>W.</initials><afid>60030521</afid><afid>60002746</afid></author><authkeywords>Aortic stenosis | Diastolic dysfunction | Fetal cardiology | Left ventricular remodeling</authkeywords><intid>1785955524</intid><source-id>20526</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929593807"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929593807?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929593807&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929593807&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929593807</prism:url><dc:identifier>SCOPUS_ID:84929593807</dc:identifier><eid>2-s2.0-84929593807</eid><dc:title>Successful use of Rituximab in a patient with recalcitrant multisystemic eosinophilic granulomatosis with polyangiitis</dc:title><dc:creator>Najem C.</dc:creator><prism:publicationName>BMJ Case Reports</prism:publicationName><prism:eIssn>1757790X</prism:eIssn><prism:volume>2015</prism:volume><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1136/bcr-2014-206421</prism:doi><dc:description>Copyright © 2015 BMJ Publishing Group. All rights reserved. Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare eosinophil-rich disorder characterised by necrotising granulomatous inflammation affecting small to medium sized vessels. Extrapulmonary manifestations can be lifethreatening when heart, central nervous system (CNS), gastrointestinal tract or kidneys are affected. We describe a case of a 56-year-old woman with a long-standing history of asthma, who presented with an acute sudden painless loss of vision after she had been recently diagnosed with EGPA and induced with pulse steroids and cyclophosphamide. The patient had a complicated hospital course with multisystemic involvement of active vasculitis, involving heart, kidneys, muscles, eyes and CNS. The patient's devastating condition responded remarkably to Rituximab. The role of Rituximab in EGPA is not yet proven. Few cases are reported in the literature about the role of Rituximab in EGPA, of which only one described retinal artery occlusion as a presentation of a recently treated patient with EGPA.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000927</affiliation-url><afid>60000927</afid><affilname>Roger Williams Hospital</affilname><name-variant>Roger Williams Medical Center</name-variant><affiliation-city>Providence</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015232</affiliation-url><afid>60015232</afid><affilname>Yale-New Haven Hospital</affilname><name-variant>Yale New Haven Hospital</name-variant><affiliation-city>New Haven</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55504438700</author-url><authid>55504438700</authid><authname>Najem C.</authname><surname>Najem</surname><given-name>Catherine E.</given-name><initials>C.E.</initials><afid>60000927</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56650558300</author-url><authid>56650558300</authid><authname>Yadav R.</authname><surname>Yadav</surname><given-name>Rajwardhan</given-name><initials>R.</initials><afid>60015232</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56650613300</author-url><authid>56650613300</authid><authname>Carlson E.</authname><surname>Carlson</surname><given-name>Elise</given-name><initials>E.</initials><afid>60015232</afid></author><intid>535982517</intid><article-number>206421</article-number><source-id>19700201654</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925448638"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925448638?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925448638&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925448638&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915001739"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925448638</prism:url><dc:identifier>SCOPUS_ID:84925448638</dc:identifier><eid>2-s2.0-84925448638</eid><dc:title>GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial</dc:title><dc:creator>Dobbins R.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>755</prism:volume><prism:pageRange>95-101</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.03.005</prism:doi><pii>S0014299915001739</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. This study investigated safety and efficacy of GSK256073, an in vitro potent, selective GPR109A agonist, for treatment of subjects with type 2 diabetes mellitus (Type 2 DM) poorly controlled with metformin alone. Patients with Type 2 DM (n=94) were enroled into this randomised, double-blind (sponsor unblinded), placebo-controlled, parallel group trial. Participants received placebo for two weeks before being randomised (2:2:2:2:1:1) to receive doses of GSK256073 5 mg twice-daily (BID), 10 mg once-daily (QD), 25 mg BID, 50 mg QD or placebo BID or QD in addition to their current metformin treatment. The primary efficacy endpoint was change from baseline in glycosylated haemoglobin (HbA1c) at week 12. The safety profile of GSK256073 did not significantly differ from that of placebo. Decreases from baseline in HbA1c were observed in all treatment groups but were not statistically significant compared to placebo; at week 12 a maximum decrease of 0.30% from placebo was reached in the GSK256073 50 mg QD group. On day 2, GSK256073 significantly decreased non-esterified fatty acid (NEFA) (0-12 h) concentrations but pharmacological activity was lost (5 mg BID, 10 mg QD, 25 mg BID) or reduced (50 mg QD) at week 6. Drug exposure demonstrated 2-fold accumulation over 6 weeks. The primary efficacy objective of the study was not met. GSK256073 did not improve HbA1c concentrations at week 12. Despite sustained drug exposure, the ability of the HCA2 agonist to suppress plasma NEFA concentrations waned over time and targeted effects on glucose oxidation and insulin sensitivity subsided.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020649</affiliation-url><afid>60020649</afid><affilname>GlaxoSmithKline</affilname><name-variant>GlaxoSmithKline</name-variant><affiliation-city>Brentford</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020649</affiliation-url><afid>60020649</afid><affilname>GlaxoSmithKline</affilname><name-variant>GlaxoSmithKline</name-variant><affiliation-city>Brentford</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020649</affiliation-url><afid>60020649</afid><affilname>GlaxoSmithKline</affilname><name-variant>GlaxoSmithKline</name-variant><affiliation-city>Brentford</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017488</affiliation-url><afid>60017488</afid><affilname>Addenbrooke's Hospital</affilname><name-variant>Addenbrooke's Hospital</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020649</affiliation-url><afid>60020649</afid><affilname>GlaxoSmithKline</affilname><name-variant>GlaxoSmithKline</name-variant><affiliation-city>Brentford</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7007173968</author-url><authid>7007173968</authid><authname>Dobbins R.</authname><surname>Dobbins</surname><given-name>Robert</given-name><initials>R.</initials><afid>60020649</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55908053200</author-url><authid>55908053200</authid><authname>Byerly R.</authname><surname>Byerly</surname><given-name>Robert</given-name><initials>R.</initials><afid>60020649</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56568169700</author-url><authid>56568169700</authid><authname>Gaddy R.</authname><surname>Gaddy</surname><given-name>Riley</given-name><initials>R.</initials><afid>60020649</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56567109500</author-url><authid>56567109500</authid><authname>Gao F.</authname><surname>Gao</surname><given-name>Feng</given-name><initials>F.</initials><afid>60020649</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55192262700</author-url><authid>55192262700</authid><authname>Mahar K.</authname><surname>Mahar</surname><given-name>Kelly</given-name><initials>K.</initials><afid>60020649</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:23568408000</author-url><authid>23568408000</authid><authname>Napolitano A.</authname><surname>Napolitano</surname><given-name>Antonella</given-name><initials>A.</initials><afid>60020649</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:22033480200</author-url><authid>22033480200</authid><authname>Ambery P.</authname><surname>Ambery</surname><given-name>Philip</given-name><initials>P.</initials><afid>60017488</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603258043</author-url><authid>6603258043</authid><authname>Le Monnier De Gouville A.</authname><surname>Le Monnier De Gouville</surname><given-name>Anne Charlotte</given-name><initials>A.C.</initials><afid>60020649</afid></author><authkeywords>GSK 256073 | HbA1c | Non Esterified Fatty Acid(NEFA)-Hydroxy-carboxylicacidreceptor2(HCA2) | Type 2diabetes</authkeywords><intid>1535293640</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929456933"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929456933?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929456933&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929456933&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378778814008962"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929456933</prism:url><dc:identifier>SCOPUS_ID:84929456933</dc:identifier><eid>2-s2.0-84929456933</eid><dc:title>Towards a systematic approach for energy refurbishment of historical buildings. the case study of Albergo dei Poveri in Genoa, Italy</dc:title><dc:creator>Franco G.</dc:creator><prism:publicationName>Energy and Buildings</prism:publicationName><prism:issn>03787788</prism:issn><prism:volume>95</prism:volume><prism:pageRange>153-159</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.enbuild.2014.10.051</prism:doi><pii>S0378778814008962</pii><dc:description>© 2014 Elsevier B.V. All rights reserved. The article deals with the main problems arising during the sustainable renovation process and energy refurbishment of historical architecture. In particular, it focuses on the feasibility study for a huge historical listed building, aiming at its progressive and complete re-utilization as university campus, respectful of the many cultural values of which it is the depository. The complex of the 'Albergo dei Poveri' was built in Genoa between the late seventeenth century and the middle of the nineteenth century, as a monumental structure for charitable purposes. Given its size and location in the heart of the city, it still represents an important urban structure and a great opportunity for urban renewal, even though it is actually almost completely abandoned. Main aim of the research is the definition, from a methodological and technical point of view, of feasibility studies in order to submit the historical monumental heritage to a process of 'energy efficiency' and 'energy production', even recurring to the most suitable technologies supplied by renewable energies. In this paper, a preliminiary approach and general criteria for the building refurbishment, in relation to the architectural and historical commitments, are presented.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025153</affiliation-url><afid>60025153</afid><affilname>Universita degli Studi di Genova</affilname><name-variant>University of Genova</name-variant><affiliation-city>Genoa</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015197</affiliation-url><afid>60015197</afid><affilname>Universita degli Studi di Pavia</affilname><name-variant>Università di Pavia</name-variant><affiliation-city>Pavia</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115250133</affiliation-url><afid>115250133</afid><affilname>HVAC Systems Design</affilname><name-variant>HVAC Systems Design</name-variant><affiliation-city>Genoa</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56647666600</author-url><authid>56647666600</authid><authname>Franco G.</authname><surname>Franco</surname><given-name>Giovanna</given-name><initials>G.</initials><afid>60025153</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55327954300</author-url><authid>55327954300</authid><authname>Magrini A.</authname><surname>Magrini</surname><given-name>Anna</given-name><initials>A.</initials><afid>60015197</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56647960900</author-url><authid>56647960900</authid><authname>Cartesegna M.</authname><surname>Cartesegna</surname><given-name>Marco</given-name><initials>M.</initials><afid>115250133</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56647801000</author-url><authid>56647801000</authid><authname>Guerrini M.</authname><surname>Guerrini</surname><given-name>Marco</given-name><initials>M.</initials><afid>60025153</afid></author><authkeywords>Energy audit | Energy performance | Energy refurbishment | Monumental historical architecture</authkeywords><intid>2035959498</intid><source-id>29359</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929398649"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929398649?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929398649&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929398649&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929398649</prism:url><dc:identifier>SCOPUS_ID:84929398649</dc:identifier><eid>2-s2.0-84929398649</eid><dc:title>Effect of laser acupuncture on obesity: Study protocol for a randomized controlled trial</dc:title><dc:creator>Tseng C.</dc:creator><prism:publicationName>Trials</prism:publicationName><prism:eIssn>17456215</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>May 15, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13063-015-0748-4</prism:doi><dc:description>© 2015 Tseng et al.; licensee BioMed Central. Background: Obesity-related diseases have a profound economic impact on health care systems. Laser acupuncture has been shown to have beneficial effects on obesity. However, to our knowledge, those trials were either non-randomized, non-blinded or included low-calorie diet control. We have, therefore, designed a patient-assessor-blinded, randomized, sham-controlled crossover trial to investigate the significance of laser acupuncture on obesity. Methods/Design: 104 subjects above 20 years of age with a body mass index (BMI) of over 25 kg/m&lt;sup&gt;2&lt;/sup&gt; will be divided into 2 groups: experimental and control. Each subject will receive the treatment relevant to their group 3 times a week for 8 weeks. After 8 weeks of treatment the subject will enter a 2-week washout period, after which the subjects will switch groups. Measurements will include BMI, body fat percentage, waist-to-hip ratio (WHR), waist circumference, hip circumference, skinfold thickness, thigh circumference, body fat, blood pressure, heart rate, hunger and the 36-item Short-Form Health Survey (SF-36). Discussion: The results of this study will provide the basis for future large-scale multicenter trials investigating the effects of laser acupuncture on obesity. Trial registration: ClinicalTrials.gov Identifier: NCT02167308; registration date: 14 June 2014.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031913</affiliation-url><afid>60031913</afid><affilname>Chang Gung Memorial Hospital</affilname><name-variant>Chang Gung Memorial Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020351</affiliation-url><afid>60020351</afid><affilname>Chang Gung University</affilname><name-variant>Chang Gung University</name-variant><affiliation-city>Taoyuan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090105</affiliation-url><afid>60090105</afid><affilname>Chang Gung University of Science and Technology</affilname><name-variant>Chang-Gung Institute of Technology</name-variant><affiliation-city>Taoyuan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090105</affiliation-url><afid>60090105</afid><affilname>Chang Gung University of Science and Technology</affilname><name-variant>Chang-Gung Institute of Technology</name-variant><affiliation-city>Taoyuan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645545300</author-url><authid>56645545300</authid><authname>Tseng C.</authname><surname>Tseng</surname><given-name>Chi Chuan</given-name><initials>C.C.</initials><afid>60031913</afid><afid>60020351</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645545300</author-url><authid>56645545300</authid><authname>Tseng C.</authname><surname>Tseng</surname><given-name>Chi Chuan</given-name><initials>C.C.</initials><afid>60031913</afid><afid>60020351</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56645993200</author-url><authid>56645993200</authid><authname>Tseng A.</authname><surname>Tseng</surname><given-name>Alan</given-name><initials>A.</initials><afid>60016849</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35073552600</author-url><authid>35073552600</authid><authname>Chang C.</authname><surname>Chang</surname><given-name>Chia Hao</given-name><initials>C.H.</initials><afid>60090105</afid><afid>60090105</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35073552600</author-url><authid>35073552600</authid><authname>Chang C.</authname><surname>Chang</surname><given-name>Chia Hao</given-name><initials>C.H.</initials><afid>60090105</afid><afid>60090105</afid></author><authkeywords>Body mass index | Laser acupuncture | Obesity</authkeywords><intid>1035951786</intid><source-id>4700151726</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929359039"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929359039?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929359039&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929359039&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929359039</prism:url><dc:identifier>SCOPUS_ID:84929359039</dc:identifier><eid>2-s2.0-84929359039</eid><dc:title>Morphological characterisation of unstained and intact tissue micro-architecture by X-ray computed micro- and nano-tomography</dc:title><dc:creator>Walton L.</dc:creator><prism:publicationName>Scientific Reports</prism:publicationName><prism:eIssn>20452322</prism:eIssn><prism:volume>5</prism:volume><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1038/srep10074</prism:doi><pii>srep10074</pii><dc:description>© 2015 Macmillan Publishers Limited. Characterisation and quantification of tissue structures is limited by sectioning-induced artefacts and by the difficulties of visualising and segmenting 3D volumes. Here we demonstrate that, even in the absence of X-ray contrast agents, X-ray computed microtomography (microCT) and nanotomography (nanoCT) can circumvent these problems by rapidly resolving compositionally discrete 3D tissue regions (such as the collagen-rich adventitia and elastin-rich lamellae in intact rat arteries) which in turn can be segmented due to their different X-ray opacities and morphologies. We then establish, using X-ray tomograms of both unpressurised and pressurised arteries that intra-luminal pressure not only increases lumen cross-sectional area and straightens medial elastic lamellae but also induces profound remodelling of the adventitial layer. Finally we apply microCT to another human organ (skin) to visualise the cell-rich epidermis and extracellular matrix-rich dermis and to show that conventional histological and immunohistochemical staining protocols are compatible with prior X-ray exposure. As a consequence we suggest that microCT could be combined with optical microscopy to characterise the 3D structure and composition of archival paraffin embedded biological materials and of mechanically stressed dynamic tissues such as the heart, lungs and tendons.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003771</affiliation-url><afid>60003771</afid><affilname>University of Manchester</affilname><name-variant>University of Manchester</name-variant><affiliation-city>Manchester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003771</affiliation-url><afid>60003771</afid><affilname>University of Manchester</affilname><name-variant>University of Manchester</name-variant><affiliation-city>Manchester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003771</affiliation-url><afid>60003771</afid><affilname>University of Manchester</affilname><name-variant>University of Manchester</name-variant><affiliation-city>Manchester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022506</affiliation-url><afid>60022506</afid><affilname>Edge Hill University College</affilname><name-variant>Edge Hill University</name-variant><affiliation-city>Ormskirk</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56290608000</author-url><authid>56290608000</authid><authname>Walton L.</authname><surname>Walton</surname><given-name>Lucy A.</given-name><initials>L.A.</initials><afid>60003771</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:14064447600</author-url><authid>14064447600</authid><authname>Bradley R.</authname><surname>Bradley</surname><given-name>Robert S.</given-name><initials>R.S.</initials><afid>60003771</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102893317</author-url><authid>7102893317</authid><authname>Withers P.</authname><surname>Withers</surname><given-name>Philip J.</given-name><initials>P.J.</initials><afid>60003771</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56644413700</author-url><authid>56644413700</authid><authname>Newton V.</authname><surname>Newton</surname><given-name>Victoria L.</given-name><initials>V.L.</initials><afid>60003771</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:12242442800</author-url><authid>12242442800</authid><authname>Watson R.</authname><surname>Watson</surname><given-name>Rachel E B</given-name><initials>R.E.B.</initials><afid>60003771</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7201681421</author-url><authid>7201681421</authid><authname>Austin C.</authname><surname>Austin</surname><given-name>Clare</given-name><initials>C.</initials><afid>60003771</afid><afid>60022506</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7201681421</author-url><authid>7201681421</authid><authname>Austin C.</authname><surname>Austin</surname><given-name>Clare</given-name><initials>C.</initials><afid>60003771</afid><afid>60022506</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6701449297</author-url><authid>6701449297</authid><authname>Sherratt M.</authname><surname>Sherratt</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>60003771</afid></author><intid>535945161</intid><article-number>10074</article-number><source-id>21100200805</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929304884"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929304884?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929304884&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929304884&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929304884</prism:url><dc:identifier>SCOPUS_ID:84929304884</dc:identifier><eid>2-s2.0-84929304884</eid><dc:title>Obesity, metabolic syndrome and risk of atrial fibrillation: A swedish, prospective cohort study</dc:title><dc:creator>Nyström P.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0127111</prism:doi><dc:description>© 2015 Nyström et al. Aim: We aimed to investigate whether different measures of obesity could similarly predict atrial fibrillation, and whether the atrial fibrillation risk associated with obesity is dependent on presence of metabolic syndrome. Material and Methods: We performed our study in a population-based longitudinal cardiovascular study, comprising 1 924 men and 2 097 women, aged 60 years, from Stockholm. Body mass index, waist circumference, sagittal abdominal diameter and components of metabolic syndrome (systolic- and diastolic blood pressure, fasting glucose, triglycerides, high-density lipoproteincholesterol) were recorded at baseline. Participants were classified by their body mass index (normal weight, overweight or obese), waist circumference (normal, semi-elevated or elevated), and according to presence of metabolic syndrome. Atrial fibrillation risk was estimated by Cox proportional hazards regression models, adjusted for common atrial fibrillation risk factors, expressed as HR and 95% CI. Results: During a mean follow-up of 13.6 years, 285 incident atrial fibrillation cases were recorded. One standard deviation increment of each obesity measure was associated with increased atrial fibrillation risk as: bodymass index 1.25 (1.12 - 1.40), waist circumference 1.35 (1.19 - 1.54) and sagittal abdominal diameter 1.28 (1.14 - 1.44). Compared to normal weight subjects without metabolic syndrome, increased atrial fibrillation risk was noted for overweight subjects with metabolic syndrome, 1.67 (1.16 - 2.41), obese subjects without metabolic syndrome, 1.75 (1.11 - 2.74) and obese subjects withmetabolic syndrome, 1.92 (1.34 - 2.74). Compared to subjects with normal waist circumference without metabolic syndrome, subjects with elevated waist circumference and metabolic syndrome suffered increased atrial fibrillation risk, 2.03 (1.44 - 2.87). Conclusions: Body mass index, waist circumference and sagittal abdominal diameter could similarly predict atrial fibrillation. Obesity was associated with an increased atrial fibrillation risk regardless of metabolic syndrome, whereas overweight and elevated waist circumference was associated with increased atrial fibrillation risk only if metabolic syndrome was present</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012311</affiliation-url><afid>60012311</afid><affilname>Karolinska Institutet</affilname><name-variant>Karolinska Institutet</name-variant><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012311</affiliation-url><afid>60012311</afid><affilname>Karolinska Institutet</affilname><name-variant>Karolinska Institutet</name-variant><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003858</affiliation-url><afid>60003858</afid><affilname>Uppsala Universitet</affilname><name-variant>Uppsala University</name-variant><affiliation-city>Uppsala</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019295</affiliation-url><afid>60019295</afid><affilname>Karolinska University Hospital</affilname><name-variant>Karolinska University Hospital</name-variant><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026150</affiliation-url><afid>60026150</afid><affilname>Danderyd Hospital</affilname><name-variant>Danderyd Hospital</name-variant><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56644318700</author-url><authid>56644318700</authid><authname>Nyström P.</authname><surname>Nyström</surname><given-name>Petter K.</given-name><initials>P.K.</initials><afid>60012311</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24448186700</author-url><authid>24448186700</authid><authname>Carlsson A.</authname><surname>Carlsson</surname><given-name>Axel C.</given-name><initials>A.C.</initials><afid>60012311</afid><afid>60003858</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24448186700</author-url><authid>24448186700</authid><authname>Carlsson A.</authname><surname>Carlsson</surname><given-name>Axel C.</given-name><initials>A.C.</initials><afid>60012311</afid><afid>60003858</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55388819100</author-url><authid>55388819100</authid><authname>Leander K.</authname><surname>Leander</surname><given-name>Karin</given-name><initials>K.</initials><afid>60012311</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7103145439</author-url><authid>7103145439</authid><authname>De Faire U.</authname><surname>De Faire</surname><given-name>Ulf</given-name><initials>U.</initials><afid>60012311</afid><afid>60019295</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7103145439</author-url><authid>7103145439</authid><authname>De Faire U.</authname><surname>De Faire</surname><given-name>Ulf</given-name><initials>U.</initials><afid>60012311</afid><afid>60019295</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:13605140300</author-url><authid>13605140300</authid><authname>Hellenius M.</authname><surname>Hellenius</surname><given-name>Mai Lis</given-name><initials>M.L.</initials><afid>60019295</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7003480904</author-url><authid>7003480904</authid><authname>Gigante B.</authname><surname>Gigante</surname><given-name>Bruna</given-name><initials>B.</initials><afid>60012311</afid><afid>60026150</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7003480904</author-url><authid>7003480904</authid><authname>Gigante B.</authname><surname>Gigante</surname><given-name>Bruna</given-name><initials>B.</initials><afid>60012311</afid><afid>60026150</afid></author><intid>1785945232</intid><article-number>0127111</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929438669"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929438669?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929438669&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929438669&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929438669</prism:url><dc:identifier>SCOPUS_ID:84929438669</dc:identifier><eid>2-s2.0-84929438669</eid><dc:title>Myocardial deformation imaging unmasks subtle left ventricular systolic dysfunction in asymptomatic and treatment-naïve HIV patients</dc:title><dc:creator>Karavidas A.</dc:creator><prism:publicationName>Clinical Research in Cardiology</prism:publicationName><prism:issn>18610684</prism:issn><prism:eIssn>18610692</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00392-015-0866-8</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Background: Patients infected by the human immunodeficiency virus (HIV) and receiving highly active antiretroviral therapy have a higher incidence of cardiovascular disease than healthy subjects, but little is known about cardiac function in asymptomatic and treatment-naïve patients. We sought to study cardiac function in asymptomatic HIV-infected, treatment-naïve patients. Methods: We studied 41 HIV-infected and treatment-naïve patients and 20 age- and sex-matched healthy controls. Patients with cardiac symptoms, history of cardiac disease or NT-proBNP &gt;100 pg/mL were excluded. We addressed cardiac function using standard echocardiography along with tissue Doppler (TDI) measurements, including strain/strain rate assessment. Results: Standard echocardiographic parameters did not differ between groups, except for transmitral E wave velocity (64.8 ± 14 cm/s in HIV vs 76.1 ± 10 cm/s in controls, p = 0.002). In contrast, TDI mitral and tricuspid annulus s velocity and all strain/strain rate measurements were significantly lower in HIV patients: s lateral, 10.2 ± 2.4/11.3 ± 0.7, p = 0.011; s septal, 8.1 ± 1.6/8.7 ± 0.8, p = 0.045; s tricuspid, 13.4 ± 2.3/14.9 ± 1.3, p = 0.002; strain/strain rate, septal (strain/strain rate, 15.1 ± 5.7/−0.9 ± 0.3, 25.3 ± 1.7/−1.9 ± 0.2, p &lt; 0.001), anterior (16.7 ± 3/−1.0 ± 0.1, 26.7 ± 1.7/−1.9 ± 0.2, p &lt; 0.001), lateral (16.0 ± 6/−1.0 ± 0.1, 27.5 ± 1.8/−2.2 ± 0.3, p &lt; 0.001) and posterior (15.2 ± 5.8/−1.0 ± 0.2, 26.2 ± 1.8/−2.2 ± 0.3, p &lt; 0.001) left ventricular wall. Conclusions: HIV infection itself is accompanied by subclinical systolic dysfunction, not apparent to standard echocardiography that can be unmasked though using sensitive echocardiographic techniques.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031193</affiliation-url><afid>60031193</afid><affilname>G. Gennimatas General Hospital</affilname><name-variant>G. Gennimatas Hospital</name-variant><affiliation-city>Athens</affiliation-city><affiliation-country>Greece</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031193</affiliation-url><afid>60031193</afid><affilname>G. Gennimatas General Hospital</affilname><name-variant>G. Gennimatas Hospital</name-variant><affiliation-city>Athens</affiliation-city><affiliation-country>Greece</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015528</affiliation-url><afid>60015528</afid><affilname>Attikon University Hospital</affilname><name-variant>Attikon University Hospital</name-variant><affiliation-city>Athens</affiliation-city><affiliation-country>Greece</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602792451</author-url><authid>6602792451</authid><authname>Karavidas A.</authname><surname>Karavidas</surname><given-name>Apostolos</given-name><initials>A.</initials><afid>60031193</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35314173800</author-url><authid>35314173800</authid><authname>Xylomenos G.</authname><surname>Xylomenos</surname><given-name>George</given-name><initials>G.</initials><afid>60031193</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16022498300</author-url><authid>16022498300</authid><authname>Matzaraki V.</authname><surname>Matzaraki</surname><given-name>Vassiliki</given-name><initials>V.</initials><afid>60031193</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:26647732400</author-url><authid>26647732400</authid><authname>Papoutsidakis N.</authname><surname>Papoutsidakis</surname><given-name>Nikolaos</given-name><initials>N.</initials><afid>60031193</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23019019100</author-url><authid>23019019100</authid><authname>Leventopoulos G.</authname><surname>Leventopoulos</surname><given-name>Georgios</given-name><initials>G.</initials><afid>60031193</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55296706200</author-url><authid>55296706200</authid><authname>Farmakis D.</authname><surname>Farmakis</surname><given-name>Dimitrios</given-name><initials>D.</initials><afid>60015528</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6701530653</author-url><authid>6701530653</authid><authname>Lazaros G.</authname><surname>Lazaros</surname><given-name>George</given-name><initials>G.</initials><afid>60031193</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7801330892</author-url><authid>7801330892</authid><authname>Perpinia A.</authname><surname>Perpinia</surname><given-name>Anastasia</given-name><initials>A.</initials><afid>60031193</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:22133699500</author-url><authid>22133699500</authid><authname>Arapi S.</authname><surname>Arapi</surname><given-name>Sophia</given-name><initials>S.</initials><afid>60031193</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56646381800</author-url><authid>56646381800</authid><authname>Paisios N.</authname><surname>Paisios</surname><given-name>Nikolaos</given-name><initials>N.</initials><afid>60031193</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7004855782</author-url><authid>7004855782</authid><authname>Parissis J.</authname><surname>Parissis</surname><given-name>John</given-name><initials>J.</initials><afid>60015528</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:55395104200</author-url><authid>55395104200</authid><authname>Pyrgakis V.</authname><surname>Pyrgakis</surname><given-name>Vlasios</given-name><initials>V.</initials><afid>60031193</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:6701735475</author-url><authid>6701735475</authid><authname>Gargalianos P.</authname><surname>Gargalianos</surname><given-name>Panagiotis</given-name><initials>P.</initials><afid>60031193</afid></author><authkeywords>HIV | Myocardial deformation | Strain | Strain rate | Systolic dysfunction</authkeywords><intid>1785956107</intid><source-id>3100147501</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929428685"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929428685?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929428685&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929428685&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929428685</prism:url><dc:identifier>SCOPUS_ID:84929428685</dc:identifier><eid>2-s2.0-84929428685</eid><dc:title>Cytoplasmic translocation, aggregation, and cleavage of TDP-43 by enteroviral proteases modulate viral pathogenesis</dc:title><dc:creator>Fung G.</dc:creator><prism:publicationName>Cell Death and Differentiation</prism:publicationName><prism:issn>13509047</prism:issn><prism:eIssn>14765403</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1038/cdd.2015.58</prism:doi><pii>cdd201558</pii><dc:description>© 2015 Macmillan Publishers Limited We have previously demonstrated that infection by coxsackievirus B3 (CVB3), a positive-stranded RNA enterovirus, results in the accumulation of insoluble ubiquitin–protein aggregates, which resembles the common feature of neurodegenerative diseases. The importance of protein aggregation in viral pathogenesis has been recognized; however, the underlying regulatory mechanisms remain ill-defined. Transactive response DNA-binding protein-43 (TDP-43) is an RNA-binding protein that has an essential role in regulating RNA metabolism at multiple levels. Cleavage and cytoplasmic aggregation of TDP-43 serves as a major molecular marker for amyotrophic lateral sclerosis and frontotemporal lobar degeneration and contributes significantly to disease progression. In this study, we reported that TDP-43 is translocated from the nucleus to the cytoplasm during CVB3 infection through the activity of viral protease 2A, followed by the cleavage mediated by viral protease 3C. Cytoplasmic translocation of TDP-43 is accompanied by reduced solubility and increased formation of protein aggregates. The cleavage takes place at amino-acid 327 between glutamine and alanine, resulting in the generation of an N- and C-terminal cleavage fragment of ~35 and ~8 kDa, respectively. The C-terminal product of TDP-43 is unstable and quickly degraded through the proteasome degradation pathway, whereas the N-terminal truncation of TDP-43 acts as a dominant-negative mutant that inhibits the function of native TDP-43 in alternative RNA splicing. Lastly, we demonstrated that knockdown of TDP-43 results in an increase in viral titers, suggesting a protective role for TDP-43 in CVB3 infection. Taken together, our findings suggest a novel model by which cytoplasmic redistribution and cleavage of TDP-43 as a consequence of CVB3 infection disrupts the solubility and transcriptional activity of TDP-43. Our results also reveal a mechanism evolved by enteroviruses to support efficient viral infection.Cell Death and Differentiation advance online publication, 15 May 2015; doi:10.1038/cdd.2015.58.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010365</affiliation-url><afid>60010365</afid><affilname>The University of British Columbia</affilname><name-variant>University of British Columbia</name-variant><affiliation-city>Vancouver</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55164189500</author-url><authid>55164189500</authid><authname>Fung G.</authname><surname>Fung</surname><given-name>G.</given-name><initials>G.</initials><afid>60010365</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56645272000</author-url><authid>56645272000</authid><authname>Shi J.</authname><surname>Shi</surname><given-name>J.</given-name><initials>J.</initials></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56645478500</author-url><authid>56645478500</authid><authname>Deng H.</authname><surname>Deng</surname><given-name>H.</given-name><initials>H.</initials></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56645480900</author-url><authid>56645480900</authid><authname>Hou J.</authname><surname>Hou</surname><given-name>J.</given-name><initials>J.</initials></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56645455500</author-url><authid>56645455500</authid><authname>Wang C.</authname><surname>Wang</surname><given-name>C.</given-name><initials>C.</initials></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56645970700</author-url><authid>56645970700</authid><authname>Hong A.</authname><surname>Hong</surname><given-name>A.</given-name><initials>A.</initials></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56645307900</author-url><authid>56645307900</authid><authname>Zhang J.</authname><surname>Zhang</surname><given-name>J.</given-name><initials>J.</initials></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56645633300</author-url><authid>56645633300</authid><authname>Jia W.</authname><surname>Jia</surname><given-name>W.</given-name><initials>W.</initials></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56645426800</author-url><authid>56645426800</authid><authname>Luo H.</authname><surname>Luo</surname><given-name>H.</given-name><initials>H.</initials></author><intid>1035950536</intid><source-id>18457</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929447894"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929447894?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929447894&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929447894&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929447894</prism:url><dc:identifier>SCOPUS_ID:84929447894</dc:identifier><eid>2-s2.0-84929447894</eid><dc:title>Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease</dc:title><dc:creator>Sinha M.</dc:creator><prism:publicationName>Pediatric Nephrology</prism:publicationName><prism:issn>0931041X</prism:issn><prism:eIssn>1432198X</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00467-015-3125-3</prism:doi><dc:description>© 2015 IPNA Background: The aim of this study was to evaluate the association of serum intact fibroblast growth factor 23 (FGF23) concentrations with indexed left ventricular mass in children with non-dialysis stages 3–5 of chronic kidney disease (CKD). Methods: The study cohort comprised 83 children (51 boys; mean age 12.1 ± 3.2 years) with a mean estimated glomerular filtration rate (eGFR) of 32.3 ± 14.6 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; who underwent clinic and ambulatory blood pressure measurement (ABPM), echocardiography and evaluation of biochemical markers of CKD-associated mineral bone disease. Results: The mean left ventricular mass index (LVMI) was 35.9 ± 8.5 g/m&lt;sup&gt;2.7&lt;/sup&gt; (± standard deviation), with 30 (36.1 %) children showing left ventricular hypertrophy (LVH), all eccentric, as defined using age-specific criteria. For all subjects, the mean FGF23 concentration was 142.2 ± 204.4 ng/l and the normalised distribution following log transformation was 1.94 ± 0.39. There was significant univariate correlation of LVMI with GFR, body mass index (BMI) z-score and calcium intake, but not with 24-h systolic ABPM z-score, log intact parathyroid hormone or log FGF23. On multivariate analysis following adjustment for confounders, only elemental calcium content (g/kg/day) estimated from prescribed calcium-based phosphate binder dose (β = 154.9, p &lt; 0.001) and BMI z-score (β = 2.397, p = 0.003) maintained a significant positive relationship with LVMI (model r&lt;sup&gt;2&lt;/sup&gt; = 0.225). Conclusions: We observed no significant relationship of FGF23 with LVMI. Larger studies in children are needed to clarify the roles of calcium-containing phosphate binders and FGF23 with LV mass and their roles in the evolution of the development of adverse cardiovascular outcomes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005518</affiliation-url><afid>60005518</afid><affilname>Guy's and St Thomas' NHS Foundation Trust</affilname><name-variant>Guy's and St. Thomas' NHS Foundation Trust</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005518</affiliation-url><afid>60005518</afid><affilname>Guy's and St Thomas' NHS Foundation Trust</affilname><name-variant>Guy's and St. Thomas' NHS Foundation Trust</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009797</affiliation-url><afid>60009797</afid><affilname>Guy's Hospital</affilname><name-variant>Guy's Hospital</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005518</affiliation-url><afid>60005518</afid><affilname>Guy's and St Thomas' NHS Foundation Trust</affilname><name-variant>Guy's and St. Thomas' NHS Foundation Trust</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55509589000</author-url><authid>55509589000</authid><authname>Sinha M.</authname><surname>Sinha</surname><given-name>Manish D.</given-name><initials>M.D.</initials><afid>60005518</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7402367238</author-url><authid>7402367238</authid><authname>Turner C.</authname><surname>Turner</surname><given-name>Charles</given-name><initials>C.</initials><afid>60005518</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7203045822</author-url><authid>7203045822</authid><authname>Booth C.</authname><surname>Booth</surname><given-name>Caroline J.</given-name><initials>C.J.</initials><afid>60005518</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7103038181</author-url><authid>7103038181</authid><authname>Waller S.</authname><surname>Waller</surname><given-name>Simon</given-name><initials>S.</initials><afid>60005518</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35189439500</author-url><authid>35189439500</authid><authname>Rasmussen P.</authname><surname>Rasmussen</surname><given-name>Pernille</given-name><initials>P.</initials><afid>60005518</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7102057832</author-url><authid>7102057832</authid><authname>Goldsmith D.</authname><surname>Goldsmith</surname><given-name>David J A</given-name><initials>D.J.A.</initials><afid>60009797</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7404325466</author-url><authid>7404325466</authid><authname>Simpson J.</authname><surname>Simpson</surname><given-name>John M.</given-name><initials>J.M.</initials><afid>60005518</afid></author><authkeywords>Cardiac | Chronic kidney disease | CKD-MBD | FGF-23 | Hypertension</authkeywords><intid>1035950734</intid><source-id>20471</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929440053"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929440053?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929440053&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929440053&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929440053</prism:url><dc:identifier>SCOPUS_ID:84929440053</dc:identifier><eid>2-s2.0-84929440053</eid><dc:title>C-Raf deficiency leads to hearing loss and increased noise susceptibility</dc:title><dc:creator>de Iriarte Rodríguez R.</dc:creator><prism:publicationName>Cellular and Molecular Life Sciences</prism:publicationName><prism:issn>1420682X</prism:issn><prism:eIssn>14209071</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00018-015-1919-x</prism:doi><dc:description>© 2015 The Author(s) The family of RAF kinases transduces extracellular information to the nucleus, and their activation is crucial for cellular regulation on many levels, ranging from embryonic development to carcinogenesis. B-RAF and C-RAF modulate neurogenesis and neuritogenesis during chicken inner ear development. C-RAF deficiency in humans is associated with deafness in the rare genetic insulin-like growth factor 1 (IGF-1), Noonan and Leopard syndromes. In this study, we show that RAF kinases are expressed in the developing inner ear and in adult mouse cochlea. A homozygous C-Raf deletion in mice caused profound deafness with no evident cellular aberrations except for a remarkable reduction of the K&lt;sup&gt;+&lt;/sup&gt; channel Kir4.1 expression, a trait that suffices as a cause of deafness. To explore the role of C-Raf in cellular protection and repair, heterozygous C-Raf&lt;sup&gt;+/−&lt;/sup&gt; mice were exposed to noise. A reduced C-RAF level negatively affected hearing preservation in response to noise through mechanisms involving the activation of JNK and an exacerbated apoptotic response. Taken together, these results strongly support a role for C-RAF in hearing protection.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115246500</affiliation-url><afid>115246500</afid><affilname>Instituto de Investigaciones Biomédicas “Alberto Sols”</affilname><name-variant>Instituto de Investigaciones Biomédicas “Alberto Sols”</name-variant><affiliation-city/><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001602</affiliation-url><afid>60001602</afid><affilname>Instituto de Salud Carlos III</affilname><name-variant>Instituto de Salud Carlos III</name-variant><affiliation-city>Madrid</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026796</affiliation-url><afid>60026796</afid><affilname>Universidad Autonoma de Madrid</affilname><name-variant>Universidad Autónoma de Madrid</name-variant><affiliation-city>Madrid</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012689</affiliation-url><afid>60012689</afid><affilname>Julius-Maximilians-Universitat Wurzburg</affilname><name-variant>University of Würzburg</name-variant><affiliation-city>Wurzburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028162</affiliation-url><afid>60028162</afid><affilname>Hospital Universitario La Paz</affilname><name-variant>Hospital Universitario La Paz</name-variant><affiliation-city>Madrid</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012689</affiliation-url><afid>60012689</afid><affilname>Julius-Maximilians-Universitat Wurzburg</affilname><name-variant>University of Würzburg</name-variant><affiliation-city>Wurzburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016415</affiliation-url><afid>60016415</afid><affilname>Max-Planck-Institut fur Herz- und Lungenforschung</affilname><affiliation-city>Bad Nauheim</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56646568500</author-url><authid>56646568500</authid><authname>de Iriarte Rodríguez R.</authname><surname>de Iriarte Rodríguez</surname><given-name>Rocío</given-name><initials>R.</initials><afid>115246500</afid><afid>60001602</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56646568500</author-url><authid>56646568500</authid><authname>de Iriarte Rodríguez R.</authname><surname>de Iriarte Rodríguez</surname><given-name>Rocío</given-name><initials>R.</initials><afid>115246500</afid><afid>60001602</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602583044</author-url><authid>6602583044</authid><authname>Magariños M.</authname><surname>Magariños</surname><given-name>Marta</given-name><initials>M.</initials><afid>115246500</afid><afid>60001602</afid><afid>60026796</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602583044</author-url><authid>6602583044</authid><authname>Magariños M.</authname><surname>Magariños</surname><given-name>Marta</given-name><initials>M.</initials><afid>115246500</afid><afid>60001602</afid><afid>60026796</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602583044</author-url><authid>6602583044</authid><authname>Magariños M.</authname><surname>Magariños</surname><given-name>Marta</given-name><initials>M.</initials><afid>115246500</afid><afid>60001602</afid><afid>60026796</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:15074349800</author-url><authid>15074349800</authid><authname>Pfeiffer V.</authname><surname>Pfeiffer</surname><given-name>Verena</given-name><initials>V.</initials><afid>60012689</afid><afid>60012689</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:15074349800</author-url><authid>15074349800</authid><authname>Pfeiffer V.</authname><surname>Pfeiffer</surname><given-name>Verena</given-name><initials>V.</initials><afid>60012689</afid><afid>60012689</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35453695000</author-url><authid>35453695000</authid><authname>Rapp U.</authname><surname>Rapp</surname><given-name>Ulf R.</given-name><initials>U.R.</initials><afid>60012689</afid><afid>60016415</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35453695000</author-url><authid>35453695000</authid><authname>Rapp U.</authname><surname>Rapp</surname><given-name>Ulf R.</given-name><initials>U.R.</initials><afid>60012689</afid><afid>60016415</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004650477</author-url><authid>7004650477</authid><authname>Varela-Nieto I.</authname><surname>Varela-Nieto</surname><given-name>Isabel</given-name><initials>I.</initials><afid>115246500</afid><afid>60001602</afid><afid>60028162</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004650477</author-url><authid>7004650477</authid><authname>Varela-Nieto I.</authname><surname>Varela-Nieto</surname><given-name>Isabel</given-name><initials>I.</initials><afid>115246500</afid><afid>60001602</afid><afid>60028162</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004650477</author-url><authid>7004650477</authid><authname>Varela-Nieto I.</authname><surname>Varela-Nieto</surname><given-name>Isabel</given-name><initials>I.</initials><afid>115246500</afid><afid>60001602</afid><afid>60028162</afid></author><authkeywords>ERK | FoxG1 | Inflammation | NIHL | Otic | Programmed cell death</authkeywords><intid>35954176</intid><source-id>13903</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929440199"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929440199?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929440199&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929440199&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929440199</prism:url><dc:identifier>SCOPUS_ID:84929440199</dc:identifier><eid>2-s2.0-84929440199</eid><dc:title>Sleep apnea and severe bradyarrhythmia - an alternative treatment option: A case report</dc:title><dc:creator>Daoulah A.</dc:creator><prism:publicationName>Journal of Medical Case Reports</prism:publicationName><prism:eIssn>17521947</prism:eIssn><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>May 15, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13256-015-0596-6</prism:doi><dc:description>© 2015 Daoulah et al.; licensee BioMed Central. Introduction: Sinus arrest, atrio-ventricular block, supraventricular, and ventricular arrhythmias have been reported in patients with sleep apnea syndrome. The arrhythmias usually occur during sleep and contribute to the cardiovascular morbidity and mortality, and the treatment of sleep apnea usually results in the resolution of the brady- arrhythmias. Weight loss, continuous positive airway pressure (CPAP), oral appliances, and upper airway surgery are the recommended treatments, however, compliance and efficacy are issues. Case presentation: A 58-year-old Arab man presented with recurrent presyncope. He was subsequently diagnosed with sleep apnea associated with frequent and significant sinus pauses. He presented a treatment challenge because he refused continuous positive airway pressure and pacemaker, however, he was successfully treated with theophylline. Conclusion: Frequent and significant sinus pause associated with sleep apnea was successfully treated with theophylline in our patient when the standard treatment of care was refused.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016332</affiliation-url><afid>60016332</afid><affilname>King Faisal Specialist Hospital and Research Centre</affilname><name-variant>King Faisal Specialist Hospital and Research Centre</name-variant><affiliation-city>Riyadh</affiliation-city><affiliation-country>Saudi Arabia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115246194</affiliation-url><afid>115246194</afid><affilname>Internal Medicine Department</affilname><name-variant>Internal Medicine Department</name-variant><affiliation-city>Huntsville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016332</affiliation-url><afid>60016332</afid><affilname>King Faisal Specialist Hospital and Research Centre</affilname><name-variant>King Faisal Specialist Hospital and Research Centre</name-variant><affiliation-city>Riyadh</affiliation-city><affiliation-country>Saudi Arabia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016332</affiliation-url><afid>60016332</afid><affilname>King Faisal Specialist Hospital and Research Centre</affilname><name-variant>King Faisal Specialist Hospital and Research Centre</name-variant><affiliation-city>Riyadh</affiliation-city><affiliation-country>Saudi Arabia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070809</affiliation-url><afid>60070809</afid><affilname>Sheikh Khalifa Medical City</affilname><name-variant>Sheikh Khalifa Medical City</name-variant><affiliation-city>Abu Dhabi</affiliation-city><affiliation-country>United Arab Emirates</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015849</affiliation-url><afid>60015849</afid><affilname>Tufts University School of Medicine</affilname><name-variant>Tufts University School of Medicine</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031828</affiliation-url><afid>60031828</afid><affilname>McMaster University</affilname><name-variant>McMaster University</name-variant><affiliation-city>Hamilton</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015849</affiliation-url><afid>60015849</afid><affilname>Tufts University School of Medicine</affilname><name-variant>Tufts University School of Medicine</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6504256437</author-url><authid>6504256437</authid><authname>Daoulah A.</authname><surname>Daoulah</surname><given-name>Amin</given-name><initials>A.</initials><afid>60016332</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54179612600</author-url><authid>54179612600</authid><authname>Ocheltree S.</authname><surname>Ocheltree</surname><given-name>Sara</given-name><initials>S.</initials><afid>115246194</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6503897571</author-url><authid>6503897571</authid><authname>Al-Faifi S.</authname><surname>Al-Faifi</surname><given-name>Salem M.</given-name><initials>S.M.</initials><afid>60016332</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56645892300</author-url><authid>56645892300</authid><authname>Ahmed W.</authname><surname>Ahmed</surname><given-name>Waleed</given-name><initials>W.</initials><afid>60016332</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7801308828</author-url><authid>7801308828</authid><authname>Alsheikh-Ali A.</authname><surname>Alsheikh-Ali</surname><given-name>Alawi A.</given-name><initials>A.A.</initials><afid>60070809</afid><afid>60015849</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7801308828</author-url><authid>7801308828</authid><authname>Alsheikh-Ali A.</authname><surname>Alsheikh-Ali</surname><given-name>Alawi A.</given-name><initials>A.A.</initials><afid>60070809</afid><afid>60015849</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8849077800</author-url><authid>8849077800</authid><authname>Asrar F.</authname><surname>Asrar</surname><given-name>Farhan</given-name><initials>F.</initials><afid>60031828</afid><afid>60016849</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8849077800</author-url><authid>8849077800</authid><authname>Asrar F.</authname><surname>Asrar</surname><given-name>Farhan</given-name><initials>F.</initials><afid>60031828</afid><afid>60016849</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:16555844600</author-url><authid>16555844600</authid><authname>Lotfi A.</authname><surname>Lotfi</surname><given-name>Amir</given-name><initials>A.</initials><afid>60015849</afid></author><authkeywords>Bradycardia | Sinus arrest | Sleep apnea | Theophylline</authkeywords><intid>1035951025</intid><source-id>11700154616</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929346754"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929346754?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929346754&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929346754&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929346754</prism:url><dc:identifier>SCOPUS_ID:84929346754</dc:identifier><eid>2-s2.0-84929346754</eid><dc:title>The intraperitoneal transcriptome of the opportunistic pathogen Enterococcus faecalis in mice</dc:title><dc:creator>Muller C.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0126143</prism:doi><dc:description>© 2015 Muller et al. Enterococcus faecalis is a Gram-positive lactic acid intestinal opportunistic bacterium with virulence potential. For a better understanding of the adapation of this bacterium to the host conditions, we performed a transcriptome analysis of bacteria isolated from an infection site (mouse peritonitis) by RNA-sequencing. We identified a total of 211 genes with significantly higher transcript levels and 157 repressed genes. Our in vivo gene expression database reflects well the infection process since genes encoding important virulence factors like cytolysin, gelatinase or aggregation substance as well as stress response proteins, are significantly induced. Genes encoding metabolic activities are the second most abundant in vivo induced genes demonstrating that the bacteria are metabolically active and adapt to the special nutrient conditions of the host. α- and β-glucosides seem to be important substrates for E. faecalis inside the host. Compared to laboratory conditions, the flux through the upper part of glycolysis seems to be reduced and more carbon may enter the pentose phosphate pathway. This may reflect the need of the bacteria under infection conditions to produce more reducing power for biosynthesis. Another important substrate is certainly glycerol since both pathways of glycerol catabolism are strongly induced. Strongly in vivo induced genes should be important for the infection process. This assumption has been verified in a virulence test using well characterized mutants affected in glycerol metabolism. This showed indeed that mutants unable to metabolize this sugar alcohol are affected in organ colonisation in a mouse model.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032215</affiliation-url><afid>60032215</afid><affilname>Universite de Caen Basse Normandie</affilname><name-variant>Université de Caen</name-variant><affiliation-city>Caen</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031984</affiliation-url><afid>60031984</afid><affilname>Universita Cattolica del Sacro Cuore, Rome</affilname><name-variant>Catholic University</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025988</affiliation-url><afid>60025988</afid><affilname>Universitat Wien</affilname><name-variant>Universität Wien</name-variant><affiliation-city>Vienna</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015595</affiliation-url><afid>60015595</afid><affilname>Universitat Bielefeld</affilname><name-variant>Bielefeld University</name-variant><affiliation-city>Bielefeld</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017134</affiliation-url><afid>60017134</afid><affilname>Justus Liebig University Giessen</affilname><affiliation-city>Giessen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7404110328</author-url><authid>7404110328</authid><authname>Muller C.</authname><surname>Muller</surname><given-name>Cécile</given-name><initials>C.</initials><afid>60032215</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55700735900</author-url><authid>55700735900</authid><authname>Cacaci M.</authname><surname>Cacaci</surname><given-name>Margherita</given-name><initials>M.</initials><afid>60032215</afid><afid>60031984</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55700735900</author-url><authid>55700735900</authid><authname>Cacaci M.</authname><surname>Cacaci</surname><given-name>Margherita</given-name><initials>M.</initials><afid>60032215</afid><afid>60031984</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6506550680</author-url><authid>6506550680</authid><authname>Sauvageot N.</authname><surname>Sauvageot</surname><given-name>Nicolas</given-name><initials>N.</initials><afid>60032215</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7102603341</author-url><authid>7102603341</authid><authname>Sanguinetti M.</authname><surname>Sanguinetti</surname><given-name>Maurizio</given-name><initials>M.</initials><afid>60031984</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8927051100</author-url><authid>8927051100</authid><authname>Rattei T.</authname><surname>Rattei</surname><given-name>Thomas</given-name><initials>T.</initials><afid>60025988</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603286317</author-url><authid>6603286317</authid><authname>Eder T.</authname><surname>Eder</surname><given-name>Thomas</given-name><initials>T.</initials><afid>60025988</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6603682223</author-url><authid>6603682223</authid><authname>Giard J.</authname><surname>Giard</surname><given-name>Jean Christophe</given-name><initials>J.C.</initials><afid>60032215</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7101959761</author-url><authid>7101959761</authid><authname>Kalinowski J.</authname><surname>Kalinowski</surname><given-name>Jörn</given-name><initials>J.</initials><afid>60015595</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7005249330</author-url><authid>7005249330</authid><authname>Hain T.</authname><surname>Hain</surname><given-name>Torsten</given-name><initials>T.</initials><afid>60017134</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7004850374</author-url><authid>7004850374</authid><authname>Hartke A.</authname><surname>Hartke</surname><given-name>Axel</given-name><initials>A.</initials><afid>60032215</afid></author><intid>1035941326</intid><article-number>0126143</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929377682"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929377682?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929377682&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929377682&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929377682</prism:url><dc:identifier>SCOPUS_ID:84929377682</dc:identifier><eid>2-s2.0-84929377682</eid><dc:title>Evaluating information content of SNPs for sample-tagging in re-sequencing projects</dc:title><dc:creator>Hu H.</dc:creator><prism:publicationName>Scientific Reports</prism:publicationName><prism:eIssn>20452322</prism:eIssn><prism:volume>5</prism:volume><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1038/srep10247</prism:doi><pii>srep10247</pii><dc:description>© 2015 Macmillan Publishers Limited. Sample-tagging is designed for identification of accidental sample mix-up, which is a major issue in re-sequencing studies. In this work, we develop a model to measure the information content of SNPs, so that we can optimize a panel of SNPs that approach the maximal information for discrimination. The analysis shows that as low as 60 optimized SNPs can differentiate the individuals in a population as large as the present world, and only 30 optimized SNPs are in practice sufficient in labeling up to 100 thousand individuals. In the simulated populations of 100 thousand individuals, the average Hamming distances, generated by the optimized set of 30 SNPs are larger than 18, and the duality frequency, is lower than 1 in 10 thousand. This strategy of sample discrimination is proved robust in large sample size and different datasets. The optimized sets of SNPs are designed for Whole Exome Sequencing, and a program is provided for SNP selection, allowing for customized SNP numbers and interested genes. The sample-tagging plan based on this framework will improve re-sequencing projects in terms of reliability and cost-effectiveness.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030619</affiliation-url><afid>60030619</afid><affilname>Max Planck Institute for Molecular Genetics</affilname><name-variant>Max Planck Institute for Molecular Genetics</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114601000</affiliation-url><afid>114601000</afid><affilname>BlackBerry Deutschland GmbH</affilname><name-variant>BlackBerry Deutschland GmbH</name-variant><affiliation-city>Bochum</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006577</affiliation-url><afid>60006577</afid><affilname>National Institutes of Health, Bethesda</affilname><name-variant>National Institute of Health</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55740773400</author-url><authid>55740773400</authid><authname>Hu H.</authname><surname>Hu</surname><given-name>Hao</given-name><initials>H.</initials><afid>60030619</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56643472600</author-url><authid>56643472600</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xiang</given-name><initials>X.</initials><afid>114601000</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35191794200</author-url><authid>35191794200</authid><authname>Jin W.</authname><surname>Jin</surname><given-name>Wenfei</given-name><initials>W.</initials><afid>60006577</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:16939739000</author-url><authid>16939739000</authid><authname>Ropers H.</authname><surname>Ropers</surname><given-name>H. Hilger</given-name><initials>H.H.</initials><afid>60030619</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006044822</author-url><authid>7006044822</authid><authname>Wienker T.</authname><surname>Wienker</surname><given-name>Thomas F.</given-name><initials>T.F.</initials><afid>60030619</afid></author><intid>35943585</intid><article-number>10247</article-number><source-id>21100200805</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929377737"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929377737?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929377737&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929377737&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929377737</prism:url><dc:identifier>SCOPUS_ID:84929377737</dc:identifier><eid>2-s2.0-84929377737</eid><dc:title>Development of a learning-oriented computer assisted instruction designed to improve skills in the clinical assessment of the nutritional status: A pilot evaluation</dc:title><dc:creator>De Diego L.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0126345</prism:doi><dc:description>© 2015 García de Diego et al. Computer assisted instruction (CAI) is an effective tool for evaluating and training students and professionals. In this article we will present a learning-oriented CAI, which has been developed for students and health professionals to acquire and retain new knowledge through the practice. A two-phase pilot evaluation was conducted, involving 8 nutrition experts and 30 postgraduate students, respectively. In each training session, the software developed guides users in the integral evaluation of a patient's nutritional status and helps them to implement actions. The program includes into the format clinical tools, which can be used to recognize possible patient's needs, to improve the clinical reasoning and to develop professional skills. Among them are assessment questionnaires and evaluation criteria, cardiovascular risk charts, clinical guidelines and photographs of various diseases. This CAI is a complete software package easy to use and versatile, aimed at clinical specialists, medical staff, scientists, educators and clinical students, which can be used as a learning tool. This application constitutes an advanced method for students and health professionals to accomplish nutritional assessments combining theoretical and empirical issues, which can be implemented in their academic curriculum.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033320</affiliation-url><afid>60033320</afid><affilname>Universidad de Navarra</affilname><name-variant>Universidad de Navarra</name-variant><affiliation-city>Pamplona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001602</affiliation-url><afid>60001602</afid><affilname>Instituto de Salud Carlos III</affilname><name-variant>Instituto de Salud Carlos III</name-variant><affiliation-city>Madrid</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55932609500</author-url><authid>55932609500</authid><authname>De Diego L.</authname><surname>De Diego</surname><given-name>Laura García</given-name><initials>L.G.</initials><afid>60033320</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24376176600</author-url><authid>24376176600</authid><authname>Cuervo M.</authname><surname>Cuervo</surname><given-name>Marta</given-name><initials>M.</initials><afid>60033320</afid><afid>60001602</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24376176600</author-url><authid>24376176600</authid><authname>Cuervo M.</authname><surname>Cuervo</surname><given-name>Marta</given-name><initials>M.</initials><afid>60033320</afid><afid>60001602</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7404311833</author-url><authid>7404311833</authid><authname>Martínez J.</authname><surname>Martínez</surname><given-name>J. Alfredo</given-name><initials>J.A.</initials><afid>60033320</afid><afid>60001602</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7404311833</author-url><authid>7404311833</authid><authname>Martínez J.</authname><surname>Martínez</surname><given-name>J. Alfredo</given-name><initials>J.A.</initials><afid>60033320</afid><afid>60001602</afid></author><intid>35945442</intid><article-number>0126345</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924063079"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924063079?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924063079&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924063079&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0165032715000208"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924063079</prism:url><dc:identifier>SCOPUS_ID:84924063079</dc:identifier><eid>2-s2.0-84924063079</eid><dc:title>An examination of myth: A favorable cardiovascular risk-benefit analysis of high-dose thyroid for affective disorders</dc:title><dc:creator>Kelly T.</dc:creator><prism:publicationName>Journal of Affective Disorders</prism:publicationName><prism:issn>01650327</prism:issn><prism:eIssn>15732517</prism:eIssn><prism:volume>177</prism:volume><prism:pageRange>49-58</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jad.2015.01.016</prism:doi><pii>S0165032715000208</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Introduction High dose thyroid (HDT) is included in major treatment guidelines for the treatment of bipolar disorders. Yet it is seldom used partly based on perceived cardiovascular risks. The cardiovascular risks of HDT are examined. Methods A literature search was conducted for the cardiovascular risks of HDT and for comparisons sake psychiatric medications. Case reports of atrial fibrillation (afib) associated with HDT are reported. Results While hyperthyroidism is a significant cardiovascular risk factor causing a 20% premature death rate, HDT treatment does not appear to be of significant cardiovascular risk. HDT differs from hyperthyroidism in significant ways. The sequela of hyperthyroidism are increasingly tied to autoimmune complications which are absent with HDT. Equating hyperthyroidism with HDT is incorrect. The five case reports of HDT treatment associated with afib were potentially caused by other factors. If HDT increases the risks of afib, monitoring for afib would minimizes the risk. Even in overt hyperthyroidism the risk of other arrhythmias are minimal. When compared to many psychiatric medications HDT is as safe or safer. Limitations There are no direct studies of cardiovascular risks of HDT for affective patients. High tolerance of a medication does not necessarily imply lack of risk. The five case reports were spontaneous, other cases may not have been reported. Conclusion The cardiovascular risks of HDT appear to be low. HDT is at least as safe as or safer than many psychiatric medications. It is effective and well tolerated.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015424</affiliation-url><afid>60015424</afid><affilname>University of Washington</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23570508600</author-url><authid>23570508600</authid><authname>Kelly T.</authname><surname>Kelly</surname><given-name>Tammas</given-name><initials>T.</initials><afid>60015424</afid></author><authkeywords>Cardiovascular | High dose thyroid | Risk | T3 | T4</authkeywords><intid>1035075096</intid><source-id>16245</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929306768"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929306768?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929306768&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929306768&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929306768</prism:url><dc:identifier>SCOPUS_ID:84929306768</dc:identifier><eid>2-s2.0-84929306768</eid><dc:title>Normal range albuminuria and metabolic syndrome in South Korea: The 2011-2012 Korean National Health and Nutrition Examination Survey</dc:title><dc:creator>Park S.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0125615</prism:doi><dc:description>© 2015 Park et al. Background: It is well-known that there is a close relationship between metabolic syndrome (MetS) and microalbuminuria. However, some recent studies have found that even normal range albuminuria was associated with MetS and cardiometabolic risk factors. The purpose of this study is to analyze the relationship between MetS and normal range albuminuria and to calculate the cutoff value for albuminuria that correlates with MetS in the representative fraction of Korean population. Methods: Data were obtained from the 2011-2012 Korea National Health and Nutrition Examination Survey and included 9,650 subjects aged ≥19 years. We measured metabolic parameters: fasting blood glucose, waist circumference, blood pressure, and lipids, and albumin-to-creatinine ratio (ACR). The optimal ACR cutoff points for MetS were examined by the receiver operating characteristic curve. Multivariate logistic regression was used to obtain the prevalence of MetS and its components according to the ACR levels. Results: The first cutoff value of ACR were 4.8 mg/g for subjects with ≥3 components of MetS. There was a graded association between ACR and prevalence of MetS and its components. If ACR was &lt;4 mg/g, there was no significant increase in the prevalence of MetS or its components. From the ACR level of 4-5 mg/g, the prevalence of MetS significantly increased after adjusting for age, sex, body mass index, smoking, alcohol intake, exercise, and medications for diabetes mellitus and hypertension (odds ratio; 95% confidence intervals = 1.416; 1.041-1.926). Conclusions: Albuminuria within the normal range (around 5 mg/g) was associated with prevalence of MetS in the Korean population.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030953</affiliation-url><afid>60030953</afid><affilname>Eulji University</affilname><name-variant>Eulji University</name-variant><affiliation-city>Daejeon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003087</affiliation-url><afid>60003087</afid><affilname>The Catholic University of Korea</affilname><name-variant>The Catholic University of Korea</name-variant><affiliation-city>Youngdeungpo</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005273</affiliation-url><afid>60005273</afid><affilname>Korea University</affilname><name-variant>Korea University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643293600</author-url><authid>56643293600</authid><authname>Park S.</authname><surname>Park</surname><given-name>Si Young</given-name><initials>S.Y.</initials><afid>60030953</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56643408200</author-url><authid>56643408200</authid><authname>Park Y.</authname><surname>Park</surname><given-name>Yong Kyu</given-name><initials>Y.K.</initials><afid>60003087</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56643601400</author-url><authid>56643601400</authid><authname>Cho K.</authname><surname>Cho</surname><given-name>Kyung Hwan</given-name><initials>K.H.</initials><afid>60005273</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56643492400</author-url><authid>56643492400</authid><authname>Choi H.</authname><surname>Choi</surname><given-name>Hee Jeong</given-name><initials>H.J.</initials><afid>60030953</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56347546600</author-url><authid>56347546600</authid><authname>Han J.</authname><surname>Han</surname><given-name>Jee Hye</given-name><initials>J.H.</initials><afid>60030953</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36828132500</author-url><authid>36828132500</authid><authname>Han K.</authname><surname>Han</surname><given-name>Kyung Do</given-name><initials>K.D.</initials><afid>60003087</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56643649300</author-url><authid>56643649300</authid><authname>Han B.</authname><surname>Han</surname><given-name>Byung Duck</given-name><initials>B.D.</initials><afid>60005273</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56412359700</author-url><authid>56412359700</authid><authname>Yoon Y.</authname><surname>Yoon</surname><given-name>Yeo Joon</given-name><initials>Y.J.</initials><afid>60005273</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55746328100</author-url><authid>55746328100</authid><authname>Kim Y.</authname><surname>Kim</surname><given-name>Yang Hyun</given-name><initials>Y.H.</initials><afid>60005273</afid></author><intid>535945790</intid><article-number>0125615</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923934453"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923934453?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923934453&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923934453&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0165032715000105"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923934453</prism:url><dc:identifier>SCOPUS_ID:84923934453</dc:identifier><eid>2-s2.0-84923934453</eid><dc:title>Effects of adjunctive exercise on physiological and psychological parameters in depression: A randomized pilot trial</dc:title><dc:creator>Kerling A.</dc:creator><prism:publicationName>Journal of Affective Disorders</prism:publicationName><prism:issn>01650327</prism:issn><prism:eIssn>15732517</prism:eIssn><prism:volume>177</prism:volume><prism:pageRange>1-6</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jad.2015.01.006</prism:doi><pii>S0165032715000105</pii><dc:description>© 2015 Elsevier B.V. Objective Major depressive disorder (MDD) is associated with decreased physical activity and increased rates of the metabolic syndrome (MetS), a risk factor for the development of type 2 diabetes and cardiovascular disorders. Exercise training has been shown to improve cardiorespiratory fitness and metabolic syndrome factors. Therefore, our study aimed at examining whether patients receiving an exercise program as an adjunct to inpatient treatment will benefit in terms of physiological and psychological factors. Method Fourty-two inpatients with moderate to severe depression were included. Twenty-two patients were randomized to additional 3x weekly exercise training (EXERCISE) and compared to treatment as usual (TAU). Exercise capacity was assessed as peak oxygen uptake (VO2peak), ventilatory anaerobic threshold (VAT) and workload expressed as Watts (W). Metabolic syndrome was defined according to NCEP ATPIII panel criteria. Results After 6 weeks of treatment, cardiorespiratory fitness (VO2peak, VAT, Watt), waist circumference and HDL cholesterol were significantly improved in EXERCISE participants. Treatment response expressed as ≥50% MADRS reduction was more frequent in the EXERCISE group. Conclusions Adjunctive exercise training in depressed inpatients improves physical fitness, MetS factors, and psychological outcome. Given the association of depression with cardiometablic disorders, exercise training is recommended as an adjunct to standard antidepressant treatment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024052</affiliation-url><afid>60024052</afid><affilname>Medizinische Hochschule Hannover (MHH)</affilname><name-variant>Hannover Medical School</name-variant><affiliation-city>Hannover</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024052</affiliation-url><afid>60024052</afid><affilname>Medizinische Hochschule Hannover (MHH)</affilname><name-variant>Hannover Medical School</name-variant><affiliation-city>Hannover</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024052</affiliation-url><afid>60024052</afid><affilname>Medizinische Hochschule Hannover (MHH)</affilname><name-variant>Hannover Medical School</name-variant><affiliation-city>Hannover</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012408</affiliation-url><afid>60012408</afid><affilname>Universitat zu Lubeck</affilname><name-variant>University of Lübeck</name-variant><affiliation-city>Lubeck</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36704030400</author-url><authid>36704030400</authid><authname>Kerling A.</authname><surname>Kerling</surname><given-name>Arno</given-name><initials>A.</initials><afid>60024052</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602547383</author-url><authid>6602547383</authid><authname>Tegtbur U.</authname><surname>Tegtbur</surname><given-name>Uwe</given-name><initials>U.</initials><afid>60024052</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6504175075</author-url><authid>6504175075</authid><authname>Gützlaff E.</authname><surname>Gützlaff</surname><given-name>Elke</given-name><initials>E.</initials><afid>60024052</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:44361266500</author-url><authid>44361266500</authid><authname>Kück M.</authname><surname>Kück</surname><given-name>Momme</given-name><initials>M.</initials><afid>60024052</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56533964300</author-url><authid>56533964300</authid><authname>Borchert L.</authname><surname>Borchert</surname><given-name>Luise</given-name><initials>L.</initials><afid>60024052</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56534115900</author-url><authid>56534115900</authid><authname>Ates Z.</authname><surname>Ates</surname><given-name>Zeynep</given-name><initials>Z.</initials><afid>60024052</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56533575100</author-url><authid>56533575100</authid><authname>Von Bohlen A.</authname><surname>Von Bohlen</surname><given-name>Anne</given-name><initials>A.</initials><afid>60024052</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56533570100</author-url><authid>56533570100</authid><authname>Frieling H.</authname><surname>Frieling</surname><given-name>Helge</given-name><initials>H.</initials><afid>60024052</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:37031056000</author-url><authid>37031056000</authid><authname>Hüper K.</authname><surname>Hüper</surname><given-name>Katja</given-name><initials>K.</initials><afid>60024052</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:16241692800</author-url><authid>16241692800</authid><authname>Hartung D.</authname><surname>Hartung</surname><given-name>Dagmar</given-name><initials>D.</initials><afid>60024052</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7006267004</author-url><authid>7006267004</authid><authname>Schweiger U.</authname><surname>Schweiger</surname><given-name>Ulrich</given-name><initials>U.</initials><afid>60012408</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:35555162600</author-url><authid>35555162600</authid><authname>Kahl K.</authname><surname>Kahl</surname><given-name>Kai G.</given-name><initials>K.G.</initials><afid>60024052</afid></author><authkeywords>Depression | Metabolic syndrome | Physical exercise</authkeywords><intid>535080422</intid><source-id>16245</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929377536"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929377536?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929377536&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929377536&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929377536</prism:url><dc:identifier>SCOPUS_ID:84929377536</dc:identifier><eid>2-s2.0-84929377536</eid><dc:title>Sex differences in the impact of the Mediterranean diet on LDL particle size distribution and oxidation</dc:title><dc:creator>Bédard A.</dc:creator><prism:publicationName>Nutrients</prism:publicationName><prism:eIssn>20726643</prism:eIssn><prism:volume>7</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>3705-3723</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.3390/nu7053705</prism:doi><dc:description>© 2015 by the authors; licensee MDPI, Basel, Switzerland. Sex differences have been previously highlighted in the cardioprotective effects of the Mediterranean diet (MedDiet). The objective of this study was to investigate whether sex differences also exist with regard to LDL particle size distribution and oxidation. Participants were 37 men and 32 premenopausal women (24–53 years) with slightly elevated LDL-C concentrations (3.4–4.9 mmol/L) or total cholesterol/HDL-C ≥5.0. Variables were measured before and after a four-week isoenergetic MedDiet. Sex differences were found in response to the MedDiet for the proportion of medium LDL (255–260 Å) (p for sex-by-time interaction = 0.01) and small, dense LDL (sdLDL; &lt;255 Å) (trend; p for sex-by-time interaction = 0.06), men experiencing an increase in the proportion of medium LDL with a concomitant reduction in the proportion of sdLDL, while an opposite trend was observed in women. A sex difference was also noted for estimated cholesterol concentrations among sdLDL (p for sex-by-time interaction = 0.03), with only men experiencing a reduction in response to the MedDiet. The MedDiet marginally reduced oxidized LDL (oxLDL) concentrations (p = 0.07), with no sex difference. Results suggest that short-term consumption of the MedDiet leads to a favorable redistribution of LDL subclasses from smaller to larger LDL only in men. These results highlight the importance of considering sex issues in cardiovascular benefits of the MedDiet.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032619</affiliation-url><afid>60032619</afid><affilname>Universite Laval</affilname><name-variant>Université Laval</name-variant><affiliation-city>Quebec</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032619</affiliation-url><afid>60032619</afid><affilname>Universite Laval</affilname><name-variant>Université Laval</name-variant><affiliation-city>Quebec</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032619</affiliation-url><afid>60032619</afid><affilname>Universite Laval</affilname><name-variant>Université Laval</name-variant><affiliation-city>Quebec</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36715974900</author-url><authid>36715974900</authid><authname>Bédard A.</authname><surname>Bédard</surname><given-name>Alexandra</given-name><initials>A.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36715974900</author-url><authid>36715974900</authid><authname>Bédard A.</authname><surname>Bédard</surname><given-name>Alexandra</given-name><initials>A.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603116639</author-url><authid>6603116639</authid><authname>Corneau L.</authname><surname>Corneau</surname><given-name>Louise</given-name><initials>L.</initials><afid>60032619</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55409540700</author-url><authid>55409540700</authid><authname>Lamarche B.</authname><surname>Lamarche</surname><given-name>Benoît</given-name><initials>B.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55409540700</author-url><authid>55409540700</authid><authname>Lamarche B.</authname><surname>Lamarche</surname><given-name>Benoît</given-name><initials>B.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603919262</author-url><authid>6603919262</authid><authname>Dodin S.</authname><surname>Dodin</surname><given-name>Sylvie</given-name><initials>S.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603919262</author-url><authid>6603919262</authid><authname>Dodin S.</authname><surname>Dodin</surname><given-name>Sylvie</given-name><initials>S.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004556060</author-url><authid>7004556060</authid><authname>Lemieux S.</authname><surname>Lemieux</surname><given-name>Simone</given-name><initials>S.</initials><afid>60032619</afid><afid>60032619</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004556060</author-url><authid>7004556060</authid><authname>Lemieux S.</authname><surname>Lemieux</surname><given-name>Simone</given-name><initials>S.</initials><afid>60032619</afid><afid>60032619</afid></author><authkeywords>LDL size | Mediterranean diet | Men | Oxidized LDL | Women</authkeywords><intid>1785946571</intid><source-id>19700188323</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929377478"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929377478?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929377478&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929377478&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929377478</prism:url><dc:identifier>SCOPUS_ID:84929377478</dc:identifier><eid>2-s2.0-84929377478</eid><dc:title>Sugar sweetened beverage consumption among adults with gout or type 2 diabetes</dc:title><dc:creator>Murphy R.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0125543</prism:doi><dc:description>© 2015 Murphy et al. Background: Current guidelines for the management of type 2 diabetes and gout recommend that people with these conditions limit their sugar sweetened beverage (SSB) intake. We examined self-reported SSB intake among New Zealand adults with gout or type 2 diabetes, including those on hemodialysis. Method: 1023 adults with gout and 580 adults (including 206 receiving hemodialysis) with type 2 diabetes, participated in this study of between 2009 and 2012. Participants completed an intervieweradministered SSB intake question "how many sugar sweetened drinks (including fruit juice), but not including diet drinks, do you normally drink per day?" SSB consumption was recorded as a circled number 0, 1, 2, 3, 4, 5, or &gt;5, cans or large glasses (300mL) per day. Results: Consuming one or more SSB per day was reported by 64% (622/1023) of subjects with gout, 49% (176/374) with type 2 diabetes without dialysis, and 47% (96/206) with diabetes on dialysis. Consuming four or more SSBs per day was reported by 18% (179/1023), 9% (31/374) and 9% (18/206), respectively. Such high consumers of SSB were characterized after multivariable analysis to be more likely to be male (adjusted odds ratio (OR) 1.8; 95% confidence interval 1.1-2.9), younger in age (40 vs 65 years: 1.6; 1.1-2.3), current smoker (5.2; 2.7-10.1), obese (BMI 41 vs 26kg/m&lt;sup&gt;2&lt;/sup&gt;: 1.4; 1-1.9), and report Ma¯ori (1.8; 1.2-2.8) or Pacific (1.6; 1.1-2.5) ancestry, compared to Caucasian. People with gout were more likely to report heavy SSB intake compared to people with diabetes (OR 2.4, 95% CI 1.5-3.9). Heavy SSB consumption reported by people with diabetes was similar if they did or did not require dialysis. Conclusion: A high proportion of patients with gout and type 2 diabetes, including those on haemodialysis, are not responding to health messages to abstain from SSB consumption.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029749</affiliation-url><afid>60029749</afid><affilname>Medical and Health Sciences, University of Auckland</affilname><name-variant>The University of Auckland</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108265554</affiliation-url><afid>108265554</afid><affilname>Maurice Wilkins Centre for Molecular Biodiscovery</affilname><name-variant>Maurice Wilkins Centre for Molecular Biodiscovery</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115242280</affiliation-url><afid>115242280</afid><affilname>Population Health Direc.</affilname><name-variant>Population Health Direc.</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Waitemata District Health Board</affilname><name-variant>Department of Renal Medicine</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017311</affiliation-url><afid>60017311</afid><affilname>University of Otago</affilname><name-variant>University of Otago</name-variant><affiliation-city>Dunedin</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017311</affiliation-url><afid>60017311</afid><affilname>University of Otago</affilname><name-variant>University of Otago</name-variant><affiliation-city>Dunedin</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24725287000</author-url><authid>24725287000</authid><authname>Murphy R.</authname><surname>Murphy</surname><given-name>Rinki</given-name><initials>R.</initials><afid>60029749</afid><afid>108265554</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24725287000</author-url><authid>24725287000</authid><authname>Murphy R.</authname><surname>Murphy</surname><given-name>Rinki</given-name><initials>R.</initials><afid>60029749</afid><afid>108265554</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:23568966000</author-url><authid>23568966000</authid><authname>Thornley S.</authname><surname>Thornley</surname><given-name>Simon</given-name><initials>S.</initials><afid>115242280</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23666722100</author-url><authid>23666722100</authid><authname>De Zoysa J.</authname><surname>De Zoysa</surname><given-name>Janak</given-name><initials>J.</initials><afid>60029749</afid><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23666722100</author-url><authid>23666722100</authid><authname>De Zoysa J.</authname><surname>De Zoysa</surname><given-name>Janak</given-name><initials>J.</initials><afid>60029749</afid><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602140085</author-url><authid>6602140085</authid><authname>Stamp L.</authname><surname>Stamp</surname><given-name>Lisa K.</given-name><initials>L.K.</initials><afid>60017311</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23011158700</author-url><authid>23011158700</authid><authname>Dalbeth N.</authname><surname>Dalbeth</surname><given-name>Nicola</given-name><initials>N.</initials><afid>60029749</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56374982000</author-url><authid>56374982000</authid><authname>Merriman T.</authname><surname>Merriman</surname><given-name>Tony R.</given-name><initials>T.R.</initials><afid>60017311</afid></author><intid>1035939611</intid><article-number>e0125543</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929323838"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929323838?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929323838&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929323838&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929323838</prism:url><dc:identifier>SCOPUS_ID:84929323838</dc:identifier><eid>2-s2.0-84929323838</eid><dc:title>Investigating the possible effect of electrode support structure on motion artifact in wearable bioelectric signal monitoring</dc:title><dc:creator>Cömert A.</dc:creator><prism:publicationName>BioMedical Engineering Online</prism:publicationName><prism:eIssn>1475925X</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>May 15, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12938-015-0044-2</prism:doi><dc:description>© 2015 Cömert and Hyttinen. Background: With advances in technology and increasing demand, wearable biosignal monitoring is developing and new applications are emerging. One of the main challenges facing the widespread use of wearable monitoring systems is the motion artifact. The sources of the motion artifact lie in the skin-electrode interface. Reducing the motion and deformation at this interface should have positive effects on signal quality. In this study, we aim to investigate whether the structure supporting the electrode can be designed to reduce the motion artifact with the hypothesis that this can be achieved by stabilizing the skin deformations around the electrode. Methods: We compare four textile electrodes with different support structure designs: a soft padding larger than the electrode area, a soft padding larger than the electrode area with a novel skin deformation restricting design, a soft padding the same size as the electrode area, and a rigid support the same size as the electrode. With five subjects and two electrode locations placed over different kinds of tissue at various mounting forces, we simultaneously measured the motion artifact, a motion affected ECG, and the real-time skin-electrode impedance during the application of controlled motion to the electrodes. Results: The design of the electrode support structure has an effect on the generated motion artifact; good design with a skin stabilizing structure makes the electrodes physically more motion artifact resilient, directly affecting signal quality. Increasing the applied mounting force shows a positive effect up to 1,000gr applied force. The properties of tissue under the electrode are an important factor in the generation of the motion artifact and the functioning of the electrodes. The relationship of motion artifact amplitude to the electrode movement magnitude is seen to be linear for smaller movements. For larger movements, the increase of motion generated a disproportionally larger artifact. The motion artifact and the induced impedance change were caused by the electrode motion and contained the same frequency components as the applied electrode motion pattern. Conclusion: We found that stabilizing the skin around the electrode using an electrode structure that manages to successfully distribute the force and movement to an area beyond the borders of the electrical contact area reduces the motion artifact when compared to structures that are the same size as the electrode area.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009565</affiliation-url><afid>60009565</afid><affilname>Tampereen Teknillinen Yliopisto</affilname><name-variant>Tampere University of Technology</name-variant><affiliation-city>Tampere</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26321376700</author-url><authid>26321376700</authid><authname>Cömert A.</authname><surname>Cömert</surname><given-name>Alper</given-name><initials>A.</initials><afid>60009565</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35515938800</author-url><authid>35515938800</authid><authname>Hyttinen J.</authname><surname>Hyttinen</surname><given-name>Jari</given-name><initials>J.</initials><afid>60009565</afid></author><authkeywords>ECG | Electrode design | Electrode structure | EMG | Motion artifact | Skin-electrode impedance | Surface electrodes | Textile electrodes | Un-gelled electrodes | Wearable monitoring</authkeywords><intid>535946068</intid><article-number>44</article-number><source-id>28586</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929322016"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929322016?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929322016&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929322016&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929322016</prism:url><dc:identifier>SCOPUS_ID:84929322016</dc:identifier><eid>2-s2.0-84929322016</eid><dc:title>Smoking is associated with more abdominal fat in morbidly obese patients</dc:title><dc:creator>Chatkin R.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0126146</prism:doi><dc:description>© 2015 Chatkin et al. Introduction: While the association between cigarette smoking and abdominal fat has been well studied in normal and overweight patients, data regarding the influence of tobacco use in patients with morbid obesity remain scarce. The aim of this study is to evaluate body fat distribution in morbidly obese smokers. Methods: We employed a cross-sectional study and grouped severely obese patients (body mass index [BMI] &gt;40 kg/m2 or &gt;35 kg/m&lt;sup&gt;2&lt;/sup&gt; with comorbidities) according to their smoking habits (smokers or non-smokers). We next compared the anthropometrical measurements and body composition data (measured by electric bioimpedance) of both groups.We analyzed the effect of smoking on body composition variables using univariate and multiple linear regression (MLR); differences are presented as regression coefficients (b) and their respective 95% confidence intervals. Results: We included 536 morbidly obese individuals, 453 (84.5%) non-smokers and 83 (15.5%) smokers. Male smokers had a higher BMI (b=3.28 kg/m2, p=0.036), larger waist circumference (b=6.07 cm, p=0.041) and higher percentage of body fat (b=2.33%, p=0.050) than non-smokers. These differences remained significant even after controlling for confounding factors. For females, the only significant finding in MLR was a greater muscle mass among smokers (b=1.34kg, p=0.028). No associations were found between tobacco load measured in pack-years and anthropometric measures or body composition. Discussion: Positive associations between smoking and BMI, and waist circumference and percentage of body fat, were found among male morbidly obese patients, but not among females. To the best of our knowledge, this study is the first investigation of these aspects in morbidly obese subjects. We speculate that our findings may indicate that the coexistence of morbid obesity and smoking helps to explain the more serious medical conditions, particularly cardiovascular diseases and neoplasms, seen in these patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015760</affiliation-url><afid>60015760</afid><affilname>Pontificia Universidade Catolica do Rio Grande do Sul</affilname><name-variant>Pontifícia Universidade Católica do Rio Grande do Sul</name-variant><affiliation-city>Porto Alegre</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015760</affiliation-url><afid>60015760</afid><affilname>Pontificia Universidade Catolica do Rio Grande do Sul</affilname><name-variant>Pontifícia Universidade Católica do Rio Grande do Sul</name-variant><affiliation-city>Porto Alegre</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015760</affiliation-url><afid>60015760</afid><affilname>Pontificia Universidade Catolica do Rio Grande do Sul</affilname><name-variant>Pontifícia Universidade Católica do Rio Grande do Sul</name-variant><affiliation-city>Porto Alegre</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23097046300</author-url><authid>23097046300</authid><authname>Chatkin R.</authname><surname>Chatkin</surname><given-name>Raquel</given-name><initials>R.</initials><afid>60015760</afid><afid>60015760</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23097046300</author-url><authid>23097046300</authid><authname>Chatkin R.</authname><surname>Chatkin</surname><given-name>Raquel</given-name><initials>R.</initials><afid>60015760</afid><afid>60015760</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701741015</author-url><authid>6701741015</authid><authname>Chatkin J.</authname><surname>Chatkin</surname><given-name>José Miguel</given-name><initials>J.M.</initials><afid>60015760</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:15027638200</author-url><authid>15027638200</authid><authname>Spanemberg L.</authname><surname>Spanemberg</surname><given-name>Lucas</given-name><initials>L.</initials><afid>60015760</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:19834135500</author-url><authid>19834135500</authid><authname>Casagrande D.</authname><surname>Casagrande</surname><given-name>Daniela</given-name><initials>D.</initials><afid>60015760</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7404049765</author-url><authid>7404049765</authid><authname>Wagner M.</authname><surname>Wagner</surname><given-name>Mario</given-name><initials>M.</initials><afid>60015760</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6506636293</author-url><authid>6506636293</authid><authname>Mottin C.</authname><surname>Mottin</surname><given-name>Cláudio</given-name><initials>C.</initials><afid>60015760</afid><afid>60015760</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6506636293</author-url><authid>6506636293</authid><authname>Mottin C.</authname><surname>Mottin</surname><given-name>Cláudio</given-name><initials>C.</initials><afid>60015760</afid><afid>60015760</afid></author><intid>535946420</intid><article-number>e0126146</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929340201"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929340201?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929340201&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929340201&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929340201</prism:url><dc:identifier>SCOPUS_ID:84929340201</dc:identifier><eid>2-s2.0-84929340201</eid><dc:title>Health effects of long-term rapamycin treatment: The impact on mouse health of enteric rapamycin treatment from four months of age throughout life</dc:title><dc:creator>Fischer K.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0126644</prism:doi><dc:description>Rapamycin, an mTOR inhibitor, has been shown to extend lifespan in a range of model organisms. It has been reported to extend lifespan in multiple strains of mice, administered chronically or acutely early or late in life. The ability of rapamycin to extend health (healthspan) as opposed to life is less well documented. To assess the effects chronic rapamycin treatment on healthspan, enteric rapamycin was given to male and female C57BL/6J mice starting at 4 months of age and continued throughout life. Repeated, longitudinal assessments of health in individual animals were made starting at 16 months of age (=12 months of treatment) until death. A number of health parameters were improved (female grip strength, female body mass and reduced sleep fragmentation in both sexes), others showed no significant difference, while at least one (male rotarod performance) was negatively affected. Rapamycin treatment affected many measures of health in a highly sex-specific manner. While sex-specific phenotypic effects of rapamycin treatment have been widely reported, in this study we document sex differences in the direction of phenotypic change. Rapamycin-fed males and females were both significantly different from controls; however the differences were in the opposite direction in measures of body mass, percent fat and resting metabolic rate, a pattern not previously reported.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018573</affiliation-url><afid>60018573</afid><affilname>University of Texas Health Science Center at San Antonio</affilname><name-variant>Univ. of Texas Health Science Center</name-variant><affiliation-city>San Antonio</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018573</affiliation-url><afid>60018573</afid><affilname>University of Texas Health Science Center at San Antonio</affilname><name-variant>Univ. of Texas Health Science Center</name-variant><affiliation-city>San Antonio</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018573</affiliation-url><afid>60018573</afid><affilname>University of Texas Health Science Center at San Antonio</affilname><name-variant>Univ. of Texas Health Science Center</name-variant><affiliation-city>San Antonio</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013959</affiliation-url><afid>60013959</afid><affilname>University of Florida</affilname><name-variant>University of Florida</name-variant><affiliation-city>Gainesville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018573</affiliation-url><afid>60018573</afid><affilname>University of Texas Health Science Center at San Antonio</affilname><name-variant>Univ. of Texas Health Science Center</name-variant><affiliation-city>San Antonio</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027086</affiliation-url><afid>60027086</afid><affilname>University of Alabama at Birmingham</affilname><name-variant>University of Alabama at Birmingham</name-variant><affiliation-city>Birmingham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030931</affiliation-url><afid>60030931</afid><affilname>University of Oklahoma</affilname><name-variant>University of Oklahoma</name-variant><affiliation-city>Norman</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56479901100</author-url><authid>56479901100</authid><authname>Fischer K.</authname><surname>Fischer</surname><given-name>Kathleen E.</given-name><initials>K.E.</initials><afid>60018573</afid><afid>60018573</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56479901100</author-url><authid>56479901100</authid><authname>Fischer K.</authname><surname>Fischer</surname><given-name>Kathleen E.</given-name><initials>K.E.</initials><afid>60018573</afid><afid>60018573</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24824646100</author-url><authid>24824646100</authid><authname>Gelfond J.</authname><surname>Gelfond</surname><given-name>Jonathan A L</given-name><initials>J.A.L.</initials><afid>60018573</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56081286300</author-url><authid>56081286300</authid><authname>Soto V.</authname><surname>Soto</surname><given-name>Vanessa Y.</given-name><initials>V.Y.</initials><afid>60018573</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55324338300</author-url><authid>55324338300</authid><authname>Han C.</authname><surname>Han</surname><given-name>Chul</given-name><initials>C.</initials><afid>60013959</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:18438531000</author-url><authid>18438531000</authid><authname>Someya S.</authname><surname>Someya</surname><given-name>Shinichi</given-name><initials>S.</initials><afid>60013959</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56643865900</author-url><authid>56643865900</authid><authname>Richardson A.</authname><surname>Richardson</surname><given-name>Arlan</given-name><initials>A.</initials><afid>60018573</afid><afid>60018573</afid><afid>60030931</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56643865900</author-url><authid>56643865900</authid><authname>Richardson A.</authname><surname>Richardson</surname><given-name>Arlan</given-name><initials>A.</initials><afid>60018573</afid><afid>60018573</afid><afid>60030931</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56643865900</author-url><authid>56643865900</authid><authname>Richardson A.</authname><surname>Richardson</surname><given-name>Arlan</given-name><initials>A.</initials><afid>60018573</afid><afid>60018573</afid><afid>60030931</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006581196</author-url><authid>7006581196</authid><authname>Austad S.</authname><surname>Austad</surname><given-name>Steven N.</given-name><initials>S.N.</initials><afid>60018573</afid><afid>60018573</afid><afid>60027086</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006581196</author-url><authid>7006581196</authid><authname>Austad S.</authname><surname>Austad</surname><given-name>Steven N.</given-name><initials>S.N.</initials><afid>60018573</afid><afid>60018573</afid><afid>60027086</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006581196</author-url><authid>7006581196</authid><authname>Austad S.</authname><surname>Austad</surname><given-name>Steven N.</given-name><initials>S.N.</initials><afid>60018573</afid><afid>60018573</afid><afid>60027086</afid></author><intid>2035941037</intid><article-number>0126644</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925374854"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925374854?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925374854&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925374854&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915001727"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925374854</prism:url><dc:identifier>SCOPUS_ID:84925374854</dc:identifier><eid>2-s2.0-84925374854</eid><dc:title>Ghrelin ameliorates catabolic conditions and respiratory dysfunction in a chronic obstructive pulmonary disease model of chronic cigarette smoke-exposed rats</dc:title><dc:creator>Kamiide Y.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>755</prism:volume><prism:pageRange>88-94</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.02.049</prism:doi><pii>S0014299915001727</pii><dc:description>© 2015 Elsevier B.V. Cigarette smoking, which is a well-known major risk factor for chronic obstructive pulmonary disease (COPD), causes both pulmonary and extrapulmonary abnormalities. Ghrelin is a gastric peptide that regulates energy homeostasis. In the present study, we investigated the effects of ghrelin on the catabolic changes, respiratory function and emphysema in an animal model of COPD induced by chronic exposure to cigarette smoke. Rats were exposed to cigarette smoke, and they were administered human ghrelin (0.1 or 1 mg/kg, subcutaneous, twice daily) for 12 weeks. Compared with air-exposed rats, body weight gain, food intake, food efficiency, tidal volume, peak expiratory flow rate, and forced expiratory volume at 100 ms were significantly lower, while functional residual capacity, lung capacity, and neutrophils in bronchoalveolar lavage fluid were significantly higher in cigarette smoke-exposed rats. These indicated that the systemic abnormalities associated with COPD developed after the exposure to cigarette smoke. Ghrelin significantly and dose-dependently increased the body weight gain and food efficiency in cigarette smoke-exposed rats. In ghrelin-treated rats, skeletal muscle strength, which tended to be lowered by cigarette smoke exposure, was improved. Ghrelin ameliorated respiratory function and emphysema in a dose-dependent manner, but did not inhibit the increase in neutrophils in the bronchoalveolar lavage fluid. The respiratory functional parameters and lung capacity were significantly correlated with body weight gain. These results suggest that ghrelin inhibited the development of the catabolic changes, respiratory dysfunction, and emphysema that were induced by cigarette smoke exposure in rats, at least in part, through the amelioration of nutritional status.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115086476</affiliation-url><afid>115086476</afid><affilname>Ltd.</affilname><name-variant>Ltd.</name-variant><affiliation-city>Kobe</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102128</affiliation-url><afid>60102128</afid><affilname>Jichi Medical University</affilname><name-variant>Jichi Medical University</name-variant><affiliation-city>Kawachi District</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56548989800</author-url><authid>56548989800</authid><authname>Kamiide Y.</authname><surname>Kamiide</surname><given-name>Yoshiyuki</given-name><initials>Y.</initials><afid>115086476</afid><afid>60102128</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56548989800</author-url><authid>56548989800</authid><authname>Kamiide Y.</authname><surname>Kamiide</surname><given-name>Yoshiyuki</given-name><initials>Y.</initials><afid>115086476</afid><afid>60102128</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56548438000</author-url><authid>56548438000</authid><authname>Inomata N.</authname><surname>Inomata</surname><given-name>Norio</given-name><initials>N.</initials><afid>115086476</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7103184246</author-url><authid>7103184246</authid><authname>Furuya M.</authname><surname>Furuya</surname><given-name>Mayumi</given-name><initials>M.</initials><afid>115086476</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7103270844</author-url><authid>7103270844</authid><authname>Yada T.</authname><surname>Yada</surname><given-name>Toshihiko</given-name><initials>T.</initials><afid>60102128</afid></author><authkeywords>Cachexia | Chronic obstructive pulmonary disease | Cigarette smoke | Ghrelin | Rat</authkeywords><intid>2035284561</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929340153"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929340153?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929340153&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929340153&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929340153</prism:url><dc:identifier>SCOPUS_ID:84929340153</dc:identifier><eid>2-s2.0-84929340153</eid><dc:title>MicroRNAs 9 and 370 association with biochemical markers in T2D and CAD complication of T2D</dc:title><dc:creator>Motawae T.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0126957</prism:doi><dc:description>© 2015 Motawae et al. Background: MicroRNAs (miRNAs) are small non coding RNAs with essential roles, of which any alteration leads to several conditions. Their roles in diabetes (DM) and its vascular complications have not been completely assessed. Aim: to study the association of two miRNAs; 9 and 370, with biochemical parameters of type 2 diabetic (T2D), dyslipidemia and coronary artery disease (CAD). Subjects and Methods: Blood samples were taken from 200 subjects of both genders, in the Outpatient clinic of Al Qasr El-Einy teaching hospitals, in which levels of both miRNAs (using real time PCR) and routine parameters were measured. Subjects were divided over four groups, 50 in each group as follows; patients with T2D, patients with CAD, patients with T2D and CAD, and healthy control subjects. Main Outcome: miRNA 9 levels were expected to be over expressed in diabetic patients, while miRNA 370 levels were expected to be over expressed in those suffering from CAD and their association with CAD complication of T2D. Results: miRNA 9 levels were significantly higher in T2D patients and T2D patients with CAD, (1.18 ±0.07, and 1.31±0.08 respectively), while miRNA 370 levels were significantly higher in T2D patients, CAD patients, and T2D patients with CAD (0.59±0.05, 1.00±0.05, and 1.20±0.06 respectively), compared to control group at p = 0.000. In addition both miRNAs were still significantly associated with each other even after conducting multiple regression analysis. Conclusion: This study associates the possible role of miRNAs in the diagnosis/prognosis of CAD complication of T2D.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004782</affiliation-url><afid>60004782</afid><affilname>Cairo University Faculty of Pharmacy</affilname><name-variant>Cairo University</name-variant><affiliation-city>Cairo</affiliation-city><affiliation-country>Egypt</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108418039</affiliation-url><afid>108418039</afid><affilname>Future University</affilname><name-variant>Future University</name-variant><affiliation-city>Cairo</affiliation-city><affiliation-country>Egypt</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56644870400</author-url><authid>56644870400</authid><authname>Motawae T.</authname><surname>Motawae</surname><given-name>Tarek M.</given-name><initials>T.M.</initials><afid>60004782</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:25951438300</author-url><authid>25951438300</authid><authname>Ismail M.</authname><surname>Ismail</surname><given-name>Manal F.</given-name><initials>M.F.</initials><afid>60004782</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55770096800</author-url><authid>55770096800</authid><authname>Shabayek M.</authname><surname>Shabayek</surname><given-name>Marwa I.</given-name><initials>M.I.</initials><afid>108418039</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56644491100</author-url><authid>56644491100</authid><authname>Seleem M.</authname><surname>Seleem</surname><given-name>Mae M.</given-name><initials>M.M.</initials><afid>108418039</afid></author><intid>535946687</intid><article-number>0126957</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928243379"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928243379?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928243379&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928243379&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0024320514007991"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928243379</prism:url><dc:identifier>SCOPUS_ID:84928243379</dc:identifier><eid>2-s2.0-84928243379</eid><dc:title>Proposing interactions between maternal phospholipids and the one carbon cycle: A novel mechanism influencing the risk for cardiovascular diseases in the offspring in later life</dc:title><dc:creator>Khot V.</dc:creator><prism:publicationName>Life Sciences</prism:publicationName><prism:issn>00243205</prism:issn><prism:eIssn>18790631</prism:eIssn><prism:volume>129</prism:volume><prism:pageRange>16-21</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.lfs.2014.09.026</prism:doi><pii>S0024320514007991</pii><dc:description>© 2014 Elsevier Inc. Studies have adequately demonstrated the importance of maternal nutrition, particularly, micronutrients (folic acid, vitamin B&lt;inf&gt;12&lt;/inf&gt;) and long chain polyunsaturated fatty acids (LCPUFAs) in determining pregnancy outcome. Reports indicate that children born preterm or to mothers with preeclampsia are at increased risk of developing cardiovascular diseases (CVD) in later life although mechanisms are unclear. Our earlier studies have established that micronutrients (folic acid, vitamin B&lt;inf&gt;12&lt;/inf&gt;) and LCPUFAs are interlinked in the one carbon cycle and influence methylation reactions. Here, we propose a novel hypothesis that altered phospholipid metabolism and dysregulation in the one carbon cycle will result in altered epigenetic programming of placental genes leading to an adverse pregnancy outcome with increased risk of adult diseases in the offspring. Folic acid and vitamin B&lt;inf&gt;12&lt;/inf&gt; are involved in S-adenosylmethionine (SAM) synthesis, the major methyl donor for most methyl acceptors. Inadequacy of LCPUFA containing phospholipids, one of the major methyl group acceptors in the one carbon metabolic pathway, may cause diversion of methyl groups toward deoxyribonucleic acid (DNA) eventually resulting in aberrant DNA methylation patterns. These modified DNA methylation patterns lead to alterations in the expression of vital genes e.g. angiogenic factor genes thereby contributing to the dysregulation of angiogenesis/vasculogenesis further affecting placental development. This consequently would adversely "program" the fetus for increased risk of CVD in later life.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006074</affiliation-url><afid>60006074</afid><affilname>Bharati Vidyapeeth University</affilname><name-variant>Bharati Vidyapeeth Deemed University</name-variant><affiliation-city>Pune</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55554471300</author-url><authid>55554471300</authid><authname>Khot V.</authname><surname>Khot</surname><given-name>Vinita</given-name><initials>V.</initials><afid>60006074</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36929955800</author-url><authid>36929955800</authid><authname>Chavan-Gautam P.</authname><surname>Chavan-Gautam</surname><given-name>Preeti</given-name><initials>P.</initials><afid>60006074</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:22950886400</author-url><authid>22950886400</authid><authname>Joshi S.</authname><surname>Joshi</surname><given-name>Sadhana</given-name><initials>S.</initials><afid>60006074</afid></author><authkeywords>Epigenetic programming | Micronutrients | One carbon cycle | Phospholipids</authkeywords><intid>35753737</intid><source-id>20473</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924859287"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924859287?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924859287&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924859287&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915001533"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924859287</prism:url><dc:identifier>SCOPUS_ID:84924859287</dc:identifier><eid>2-s2.0-84924859287</eid><dc:title>Identification and characterisation of a prototype for a new class of competitive PPARγ antagonists</dc:title><dc:creator>Knape T.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>755</prism:volume><prism:pageRange>16-26</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.02.034</prism:doi><pii>S0014299915001533</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Understanding of the physiological role of peroxisome proliferator-activated receptor gamma (PPARγ) offers new opportunities for the treatment of cancers, immune disorders and inflammatory diseases. In contrast to PPARγ agonists, few PPARγ antagonists have been studied, though they do exert immunomodulatory effects. Currently, no therapeutically useful PPARγ antagonist is commercially available. The aim of this study was to identify and kinetically characterise a new competitive PPARγ antagonist for therapeutic use. A PPARγ-dependent transactivation assay was used to kinetically characterise (E)-2-(5-((4-methoxy-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-((4-(trifluoromethyl)benzyl)oxy)-benzylidene)-hexanoic acid (MTTB) in kidney, T and monocytic cell lines. Cytotoxic effects were analysed and intracellular accumulation of MTTB was assessed by tandem mass spectrometry (LC-MS/MS). Potential interactions of MTTB with the PPARγ protein were suggested by molecular docking analysis. In contrast to non-competitive, irreversible inhibition caused by 2-chloro-5-nitrobenzanilide (GW9662), MTTB exhibited competitive antagonism against rosiglitazone in HEK293T and Jurkat T cells, with IC50 values in HEK293T cells of 4.3 μM and 1.6 μM, using the PPARγ ligand binding domain (PPARγ-LBD) and the full PPARγ protein, respectively. In all cell lines used, however, MTTB showed much higher intracellular accumulation than GW9662. MTTB alone exhibited weak partial agonistic effects and low cytotoxicity. Molecular docking of MTTB with the PPARγ-LBD supported direct interaction with the nuclear receptor. MTTB is a promising prototype for a new class of competitive PPARγ antagonists. It has weak partial agonistic and clear competitive antagonistic characteristics associated with rapid cellular uptake. Compared to commercially available PPARγ modulators, this offers the possibility of dose regulation of PPARγ and immune responses.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114778995</affiliation-url><afid>114778995</afid><affilname>Fraunhofer Institute for Molecular Biology and Applied Ecology IME</affilname><name-variant>Fraunhofer Institute for Molecular Biology and Applied Ecology IME</name-variant><affiliation-city>Frankfurt am Main</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007762</affiliation-url><afid>60007762</afid><affilname>Johann Wolfgang Goethe Universitat Frankfurt am Main</affilname><affiliation-city>Frankfurt am Main</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007762</affiliation-url><afid>60007762</afid><affilname>Johann Wolfgang Goethe Universitat Frankfurt am Main</affilname><affiliation-city>Frankfurt am Main</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007762</affiliation-url><afid>60007762</afid><affilname>Johann Wolfgang Goethe Universitat Frankfurt am Main</affilname><affiliation-city>Frankfurt am Main</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56437614800</author-url><authid>56437614800</authid><authname>Knape T.</authname><surname>Knape</surname><given-name>Tilo</given-name><initials>T.</initials><afid>114778995</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55232203000</author-url><authid>55232203000</authid><authname>Flesch D.</authname><surname>Flesch</surname><given-name>Daniel</given-name><initials>D.</initials><afid>60007762</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:54389231400</author-url><authid>54389231400</authid><authname>Kuchler L.</authname><surname>Kuchler</surname><given-name>Laura</given-name><initials>L.</initials><afid>60007762</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56553790000</author-url><authid>56553790000</authid><authname>Sha L.</authname><surname>Sha</surname><given-name>Lisa K.</given-name><initials>L.K.</initials><afid>60007762</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56437686000</author-url><authid>56437686000</authid><authname>Giegerich A.</authname><surname>Giegerich</surname><given-name>Annika K.</given-name><initials>A.K.</initials><afid>60007762</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36702947100</author-url><authid>36702947100</authid><authname>Labocha S.</authname><surname>Labocha</surname><given-name>Sandra</given-name><initials>S.</initials><afid>60007762</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:15047865500</author-url><authid>15047865500</authid><authname>Ferreirós N.</authname><surname>Ferreirós</surname><given-name>Nerea</given-name><initials>N.</initials><afid>60007762</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8089686200</author-url><authid>8089686200</authid><authname>Schmid T.</authname><surname>Schmid</surname><given-name>Tobias</given-name><initials>T.</initials><afid>60007762</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6603873025</author-url><authid>6603873025</authid><authname>Wurglics M.</authname><surname>Wurglics</surname><given-name>Mario</given-name><initials>M.</initials><afid>60007762</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7007149621</author-url><authid>7007149621</authid><authname>Schubert-Zsilavecz M.</authname><surname>Schubert-Zsilavecz</surname><given-name>Manfred</given-name><initials>M.</initials><afid>60007762</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:42561641300</author-url><authid>42561641300</authid><authname>Proschak E.</authname><surname>Proschak</surname><given-name>Eugen</given-name><initials>E.</initials><afid>60007762</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7102115323</author-url><authid>7102115323</authid><authname>Brüne B.</authname><surname>Brüne</surname><given-name>Bernhard</given-name><initials>B.</initials><afid>60007762</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7005483393</author-url><authid>7005483393</authid><authname>Parnham M.</authname><surname>Parnham</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>114778995</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:6701433340</author-url><authid>6701433340</authid><authname>Von Knethen A.</authname><surname>Von Knethen</surname><given-name>Andreas</given-name><initials>A.</initials><afid>60007762</afid></author><authkeywords>Competitive PPARγ antagonist | MTTB | PPARγ | PPARγ agonist | PPARγ antagonist | SPPARγMs</authkeywords><intid>1785218328</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929379696"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929379696?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929379696&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929379696&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929379696</prism:url><dc:identifier>SCOPUS_ID:84929379696</dc:identifier><eid>2-s2.0-84929379696</eid><dc:title>Adducin is involved in endothelial barrier stabilization</dc:title><dc:creator>Kugelmann D.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0126213</prism:doi><dc:description>© 2015 Kugelmann et al. Adducins tightly regulate actin dynamics which is critical for endothelial barrier function. Adducins were reported to regulate epithelial junctional remodeling by controlling the assembly of actin filaments at areas of cell-cell contact. Here, we investigated the role of α-adducin for endothelial barrier regulation by using microvascular human dermal and myocardial murine endothelial cells. Parallel transendothelial electrical resistance (TER) measurements and immunofluorescence analysis revealed that siRNA-mediated adducin depletion impaired endothelial barrier formation and led to severe fragmentation of VEcadherin immunostaining at cell-cell borders. To further test whether the peripheral localization of α-adducin is functionally linked with the integrity of endothelial adherens junctions, junctional remodeling was induced by a Ca&lt;sup&gt;2+&lt;/sup&gt;-switch assay. Ca&lt;sup&gt;2+&lt;/sup&gt;-depletion disturbed both linear vascular endothelial (VE)-cadherin and adducin location along cell junctions, whereas their localization was restored following Ca&lt;sup&gt;2+&lt;/sup&gt;-repletion. Similar results were obtained for α-adducin phosphorylated at a site typical for PKA (pSer481). To verify that endothelial barrier properties and junction reorganization can be effectively modulated by altering Ca&lt;sup&gt;2+&lt;/sup&gt;-concentration, TER measurements were performed. Thus, Ca&lt;sup&gt;2+&lt;/sup&gt;-depletion drastically reduced TER, whereas Ca&lt;sup&gt;2+&lt;/sup&gt;-repletion led to recovery of endothelial barrier properties resulting in increased TER. Interestingly, the Ca&lt;sup&gt;2+&lt;/sup&gt;-dependent increase in TER was also significantly reduced after efficient α-adducin downregulation. Finally, we report that inflammatory mediator-induced endothelial barrier breakdown is associated with loss of α-adducin from the cell membrane. Taken together, our results indicate that α-adducin is involved in remodeling of endothelial adhesion junctions and thereby contributes to endothelial barrier regulation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028717</affiliation-url><afid>60028717</afid><affilname>Ludwig-Maximilians-Universitat Munchen</affilname><name-variant>University of Munich</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56359117600</author-url><authid>56359117600</authid><authname>Kugelmann D.</authname><surname>Kugelmann</surname><given-name>Daniela</given-name><initials>D.</initials><afid>60028717</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506993265</author-url><authid>6506993265</authid><authname>Waschke J.</authname><surname>Waschke</surname><given-name>Jens</given-name><initials>J.</initials><afid>60028717</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56387171900</author-url><authid>56387171900</authid><authname>Radeva M.</authname><surname>Radeva</surname><given-name>Mariya Y.</given-name><initials>M.Y.</initials><afid>60028717</afid></author><intid>1035940079</intid><article-number>e0126213</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929353041"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929353041?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929353041&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929353041&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929353041</prism:url><dc:identifier>SCOPUS_ID:84929353041</dc:identifier><eid>2-s2.0-84929353041</eid><dc:title>Serum amyloid a receptor blockade and incorporation into high-density lipoprotein modulates its pro-inflammatory and pro-thrombotic activities on vascular endothelial cells</dc:title><dc:creator>Chami B.</dc:creator><prism:publicationName>International Journal of Molecular Sciences</prism:publicationName><prism:issn>16616596</prism:issn><prism:eIssn>14220067</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>11101-11124</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.3390/ijms160511101</prism:doi><dc:description>© 2015 by the authors; licensee MDPI, Basel, Switzerland. The acute phase protein serum amyloid A (SAA), a marker of inflammation, induces expression of pro-inflammatory and pro-thrombotic mediators including ICAM-1, VCAM-1, IL-6, IL-8, MCP-1 and tissue factor (TF) in both monocytes/macrophages and endothelial cells, and induces endothelial dysfunction—a precursor to atherosclerosis. In this study, we determined the effect of pharmacological inhibition of known SAA receptors on pro-inflammatory and pro-thrombotic activities of SAA in human carotid artery endothelial cells (HCtAEC). HCtAEC were pre-treated with inhibitors of formyl peptide receptor-like-1 (FPRL-1), WRW4; receptor for advanced glycation-endproducts (RAGE), (endogenous secretory RAGE; esRAGE) and toll-like receptors-2/4 (TLR2/4) (OxPapC), before stimulation by added SAA. Inhibitor activity was also compared to high-density lipoprotein (HDL), a known inhibitor of SAA-induced effects on endothelial cells. SAA significantly increased gene expression of TF, NFκB and TNF and protein levels of TF and VEGF in HCtAEC. These effects were inhibited to variable extents by WRW4, esRAGE and OxPapC either alone or in combination, suggesting involvement of endothelial cell SAA receptors in pro-atherogenic gene expression. In contrast, HDL consistently showed the greatest inhibitory action, and often abrogated SAA-mediated responses. Increasing HDL levels relative to circulating free SAA may prevent SAA-mediated endothelial dysfunction and ameliorate atherogenesis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025709</affiliation-url><afid>60025709</afid><affilname>University of Sydney</affilname><name-variant>University of Sydney</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025709</affiliation-url><afid>60025709</afid><affilname>University of Sydney</affilname><name-variant>University of Sydney</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025709</affiliation-url><afid>60025709</afid><affilname>University of Sydney</affilname><name-variant>University of Sydney</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55797408400</author-url><authid>55797408400</authid><authname>Chami B.</authname><surname>Chami</surname><given-name>Belal</given-name><initials>B.</initials><afid>60025709</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56644816900</author-url><authid>56644816900</authid><authname>Barrie N.</authname><surname>Barrie</surname><given-name>Nicola</given-name><initials>N.</initials><afid>60025709</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55836566600</author-url><authid>55836566600</authid><authname>Cai X.</authname><surname>Cai</surname><given-name>Xiaoping</given-name><initials>X.</initials><afid>60025709</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:25951643200</author-url><authid>25951643200</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xiaosuo</given-name><initials>X.</initials><afid>60025709</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56255553500</author-url><authid>56255553500</authid><authname>Paul M.</authname><surname>Paul</surname><given-name>Moumita</given-name><initials>M.</initials><afid>60025709</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56644971000</author-url><authid>56644971000</authid><authname>Morton-Chandra R.</authname><surname>Morton-Chandra</surname><given-name>Rebecca</given-name><initials>R.</initials><afid>60025709</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602589448</author-url><authid>6602589448</authid><authname>Sharland A.</authname><surname>Sharland</surname><given-name>Alexandra</given-name><initials>A.</initials><afid>60025709</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36672637000</author-url><authid>36672637000</authid><authname>Dennis J.</authname><surname>Dennis</surname><given-name>Joanne M.</given-name><initials>J.M.</initials><afid>60025709</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35481156500</author-url><authid>35481156500</authid><authname>Freedman S.</authname><surname>Freedman</surname><given-name>Saul B.</given-name><initials>S.B.</initials><afid>60025709</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003897016</author-url><authid>7003897016</authid><authname>Witting P.</authname><surname>Witting</surname><given-name>Paul K.</given-name><initials>P.K.</initials><afid>60025709</afid></author><authkeywords>Atherosclerosis | High-density lipoprotein | Inflammation | Serum amyloid A</authkeywords><intid>535944816</intid><source-id>25879</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929376693"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929376693?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929376693&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929376693&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929376693</prism:url><dc:identifier>SCOPUS_ID:84929376693</dc:identifier><eid>2-s2.0-84929376693</eid><dc:title>ABO blood type and personality traits in healthy Japanese subjects</dc:title><dc:creator>Tsuchimine S.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0126983</prism:doi><dc:description>© 2015 Tsuchimine et al. There is no scientific consensus that a relationship exists between the ABO blood group and personality traits. However, a recent study hypothesized that the dopamine betahydroxylase (DBH) gene is in linkage with the ABO gene. The sample population consisted of 1,427 healthy Japanese subjects who completed the Temperament and Character Inventory (TCI). Each subject's ABO blood type was determined by genotyping the rs8176719 and rs8176746 ABO gene single-nucleotide polymorphisms (SNPs) using a TaqMan genotyping assay. The relationships between the six ABO genotypes or four ABO phenotypes and personality traits were examined using a multivariate analysis of covariance (MANCOVA), controlling for age and sex. The MANCOVA data showed a significant difference in TCI scores among the ABO genotype groups (F [7, 1393] = 3.354, p = 0.001). A subsequent univariate analysis showed a significant difference in the mean scores for Persistence among the genotype groups (F = 2.680, partial η&lt;sup&gt;2&lt;/sup&gt; = 0.010, p = 0.020). Similarly, dividing the ABO blood type into four phenotypes revealed a significant difference among the phenotype groups (F [7, 1397] = 2.529, p = 0.014). A subsequent univariate analysis showed a significant difference among the phenotype groups in the mean scores for Persistence (F = 2.952, partial η&lt;sup&gt;2&lt;/sup&gt;= 0.006, p = 0.032). We observed a significant association between ABO blood group genotypes and personality traits in a large number of healthy Japanese subjects. However, these results should be regarded as preliminary and should be interpreted with caution because it is possible that the association between ABO blood group genotype and the Persistence trait is relatively weak.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019579</affiliation-url><afid>60019579</afid><affilname>Hirosaki University School of Medicine</affilname><name-variant>Hirosaki University</name-variant><affiliation-city>Hirosaki</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021120</affiliation-url><afid>60021120</afid><affilname>Kumamoto University</affilname><name-variant>Kumamoto University</name-variant><affiliation-city>Kumamoto</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15754674000</author-url><authid>15754674000</authid><authname>Tsuchimine S.</authname><surname>Tsuchimine</surname><given-name>Shoko</given-name><initials>S.</initials><afid>60019579</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56502450400</author-url><authid>56502450400</authid><authname>Saruwatari J.</authname><surname>Saruwatari</surname><given-name>Junji</given-name><initials>J.</initials><afid>60021120</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:12647255600</author-url><authid>12647255600</authid><authname>Kaneda A.</authname><surname>Kaneda</surname><given-name>Ayako</given-name><initials>A.</initials><afid>60019579</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003935439</author-url><authid>7003935439</authid><authname>Yasui-Furukori N.</authname><surname>Yasui-Furukori</surname><given-name>Norio</given-name><initials>N.</initials><afid>60019579</afid></author><intid>1535943216</intid><article-number>e0126983</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84918563997"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84918563997?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84918563997&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84918563997&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S030881461401886X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84918563997</prism:url><dc:identifier>SCOPUS_ID:84918563997</dc:identifier><eid>2-s2.0-84918563997</eid><dc:title>D-Glucose, D-Galactose, and D-Lactose non-enzyme quantitative and qualitative analysis method based on Cu foam electrode</dc:title><dc:creator>Jin J.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>175</prism:volume><prism:pageRange>485-493</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2014.11.148</prism:doi><pii>S030881461401886X</pii><dc:description>© 2014 Elsevier Ltd. All rights reserved. Here, D-Glucose, D-Galactose, and D-Lactose non-enzyme quantitative and qualitative analysis method using Cu foam electrode had been investigated. Porous Cu foam material was prepared by electrodeposition strategy, and used as working electrode. Cyclic voltammetry (CV) explained sweetener electro-oxidation process occurring on Cu foam electrode. Amperometric i-t scanning results demonstrated that Cu foam electrode fast responded to D-Glucose, D-Galactose, and D-Lactose in linear concentration range between 0.18 mM and 3.47 mM with significant sensitivity of 1.79 mA cm-2 mM-1, 0.57 mA cm-2 mM-1, and 0.64 mA cm-2 mM-1, respectively. Limit of detection (LOD) was 9.30 μM, 29.40 μM, and 26 μM respectively (S/N = 3). Sweetener species was decided by stochastic resonance (SR) signal-to-noise ratio (SNR) eigen peak located noise intensities. Interference experiment results demonstrated that Cu foam electrode selectively responded to sweeteners against interference chemicals. The proposed method provides a promising way for sweetener non-enzyme quantitative and qualitative analysis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012581</affiliation-url><afid>60012581</afid><affilname>Zhejiang Gongshang University</affilname><name-variant>Zhejiang Gongshang University</name-variant><affiliation-city>Hangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012581</affiliation-url><afid>60012581</afid><affilname>Zhejiang Gongshang University</affilname><name-variant>Zhejiang Gongshang University</name-variant><affiliation-city>Hangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56201111800</author-url><authid>56201111800</authid><authname>Jin J.</authname><surname>Jin</surname><given-name>Jiaojiao</given-name><initials>J.</initials><afid>60012581</afid><afid>60012581</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56201111800</author-url><authid>56201111800</authid><authname>Jin J.</authname><surname>Jin</surname><given-name>Jiaojiao</given-name><initials>J.</initials><afid>60012581</afid><afid>60012581</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56447755400</author-url><authid>56447755400</authid><authname>Ge Y.</authname><surname>Ge</surname><given-name>Yangyang</given-name><initials>Y.</initials><afid>60012581</afid><afid>60012581</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56447755400</author-url><authid>56447755400</authid><authname>Ge Y.</authname><surname>Ge</surname><given-name>Yangyang</given-name><initials>Y.</initials><afid>60012581</afid><afid>60012581</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56447696900</author-url><authid>56447696900</authid><authname>Zheng G.</authname><surname>Zheng</surname><given-name>Gangying</given-name><initials>G.</initials><afid>60012581</afid><afid>60012581</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56447696900</author-url><authid>56447696900</authid><authname>Zheng G.</authname><surname>Zheng</surname><given-name>Gangying</given-name><initials>G.</initials><afid>60012581</afid><afid>60012581</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56440589600</author-url><authid>56440589600</authid><authname>Cai Y.</authname><surname>Cai</surname><given-name>Yanping</given-name><initials>Y.</initials><afid>60012581</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56204442100</author-url><authid>56204442100</authid><authname>Liu W.</authname><surname>Liu</surname><given-name>Wei</given-name><initials>W.</initials><afid>60012581</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:14630466500</author-url><authid>14630466500</authid><authname>Hui G.</authname><surname>Hui</surname><given-name>Guohua</given-name><initials>G.</initials><afid>60012581</afid><afid>60012581</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:14630466500</author-url><authid>14630466500</authid><authname>Hui G.</authname><surname>Hui</surname><given-name>Guohua</given-name><initials>G.</initials><afid>60012581</afid><afid>60012581</afid></author><authkeywords>Cu foam | D-Galactose | D-Glucose | D-Lactose | Non-enzyme</authkeywords><intid>2034159315</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930209781"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930209781?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930209781&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930209781&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930209781</prism:url><dc:identifier>SCOPUS_ID:84930209781</dc:identifier><eid>2-s2.0-84930209781</eid><dc:title>Transcriptional events co-regulated by hypoxia and cold stresses in Zebrafish larvae</dc:title><dc:creator>Long Y.</dc:creator><prism:publicationName>BMC Genomics</prism:publicationName><prism:eIssn>14712164</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>May 15, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12864-015-1560-y</prism:doi><dc:description>© 2015 Long et al. Background: Hypoxia and temperature stress are two major adverse environmental conditions often encountered by fishes. The interaction between hypoxia and temperature stresses has been well documented and oxygen is considered to be the limiting factor for the thermal tolerance of fish. Although both high and low temperature stresses can impair the cardiovascular function and the cross-resistance between hypoxia and heat stress has been found, it is not clear whether hypoxia acclimation can protect fish from cold injury. Results: Pre-acclimation of 96-hpf zebrafish larvae to mild hypoxia (5% O2) significantly improved their resistance to lethal hypoxia (2.5% O2) and increased the survival rate of zebrafish larvae after lethal cold (10°C) exposure. However, pre-acclimation of 96-hpf larvae to cold (18°C) decreased their tolerance to lethal hypoxia although their ability to endure lethal cold increased. RNA-seq analysis identified 132 up-regulated and 41 down-regulated genes upon mild hypoxia exposure. Gene ontology enrichment analyses revealed that genes up-regulated by hypoxia are primarily involved in oxygen transport, oxidation-reduction process, hemoglobin biosynthetic process, erythrocyte development and cellular iron ion homeostasis. Hypoxia-inhibited genes are enriched in inorganic anion transport, sodium ion transport, very long-chain fatty acid biosynthetic process and cytidine deamination. A comparison with the dataset of cold-regulated gene expression identified 23 genes co-induced by hypoxia and cold and these genes are mainly associated with oxidation-reduction process, oxygen transport, hemopoiesis, hemoglobin biosynthetic process and cellular iron ion homeostasis. The alleviation of lipid peroxidation damage by both cold- and hypoxia-acclimation upon lethal cold stress suggests the association of these genes with cold resistance. Furthermore, the alternative promoter of hmbsb gene specifically activated by hypoxia and cold was identified and confirmed. Conclusions: Acclimation responses to mild hypoxia and cold stress were found in zebrafish larvae and pre-acclimation to hypoxia significantly improved the tolerance of larvae to lethal cold stress. RNA-seq and bioinformatics analyses revealed the biological processes associated with hypoxia acclimation. Transcriptional events co-induced by hypoxia and cold may represent the molecular basis underlying the protection of hypoxia-acclimation against cold injury.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021836</affiliation-url><afid>60021836</afid><affilname>Institute of Hydrobiology, Chinese Academy of Sciences</affilname><name-variant>Chinese Academy of Sciences</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019499</affiliation-url><afid>60019499</afid><affilname>Chinese Academy of Sciences</affilname><name-variant>Chinese Academy of Sciences</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36468463700</author-url><authid>36468463700</authid><authname>Long Y.</authname><surname>Long</surname><given-name>Yong</given-name><initials>Y.</initials><afid>60021836</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55847590000</author-url><authid>55847590000</authid><authname>Yan J.</authname><surname>Yan</surname><given-name>Junjun</given-name><initials>J.</initials><afid>60021836</afid><afid>60019499</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55847590000</author-url><authid>55847590000</authid><authname>Yan J.</authname><surname>Yan</surname><given-name>Junjun</given-name><initials>J.</initials><afid>60021836</afid><afid>60019499</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55349662700</author-url><authid>55349662700</authid><authname>Song G.</authname><surname>Song</surname><given-name>Guili</given-name><initials>G.</initials><afid>60021836</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56640063800</author-url><authid>56640063800</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xiaohui</given-name><initials>X.</initials><afid>60021836</afid><afid>60019499</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56640063800</author-url><authid>56640063800</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xiaohui</given-name><initials>X.</initials><afid>60021836</afid><afid>60019499</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56640074400</author-url><authid>56640074400</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xixi</given-name><initials>X.</initials><afid>60021836</afid><afid>60019499</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56640074400</author-url><authid>56640074400</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xixi</given-name><initials>X.</initials><afid>60021836</afid><afid>60019499</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8062058100</author-url><authid>8062058100</authid><authname>Li Q.</authname><surname>Li</surname><given-name>Qing</given-name><initials>Q.</initials><afid>60021836</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7202504286</author-url><authid>7202504286</authid><authname>Cui Z.</authname><surname>Cui</surname><given-name>Zongbin</given-name><initials>Z.</initials><afid>60021836</afid></author><authkeywords>Cold stress | Gene expression | Hypoxia | RNA-seq | Zebrafish</authkeywords><intid>1786087903</intid><article-number>385</article-number><source-id>21727</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929378562"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929378562?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929378562&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929378562&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929378562</prism:url><dc:identifier>SCOPUS_ID:84929378562</dc:identifier><eid>2-s2.0-84929378562</eid><dc:title>No positive influence of ingesting chia seed oil on human running performance</dc:title><dc:creator>Nieman D.</dc:creator><prism:publicationName>Nutrients</prism:publicationName><prism:eIssn>20726643</prism:eIssn><prism:volume>7</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>3666-3676</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.3390/nu7053666</prism:doi><dc:description>© 2015 by the authors; licensee MDPI, Basel, Switzerland. Runners (n = 24) reported to the laboratory in an overnight fasted state at 8:00 am on two occasions separated by at least two weeks. After providing a blood sample at 8:00 am, subjects ingested 0.5 liters flavored water alone or 0.5 liters water with 7 kcal kg&lt;sup&gt;−1&lt;/sup&gt; chia seed oil (random order), provided another blood sample at 8:30 am, and then started running to exhaustion (~70% VO&lt;inf&gt;2max&lt;/inf&gt;). Additional blood samples were collected immediately post- and 1-h post-exercise. Despite elevations in plasma alpha-linolenic acid (ALA) during the chia seed oil (337%) versus water trial (35%) (70.8 ± 8.6, 20.3 ± 1.8 μg mL&lt;sup&gt;−1&lt;/sup&gt;, respectively, p &lt; 0.001), run time to exhaustion did not differ between trials (1.86 ± 0.10, 1.91 ± 0.13 h, p = 0.577, respectively). No trial differences were found for respiratory exchange ratio (RER) (0.92 ± 0.01), oxygen consumption, ventilation, ratings of perceived exertion (RPE), and plasma glucose and blood lactate. Significant post-run increases were measured for total leukocyte counts, plasma cortisol, and plasma cytokines (Interleukin-6 (IL-6), Interleukin-8 (IL-8), Interleukin-10 (IL-10), and Tumor necrosis factors-α (TNF-α)), with no trial differences. Chia seed oil supplementation compared to water alone in overnight fasted runners before and during prolonged, intensive running caused an elevation in plasma ALA, but did not enhance run time to exhaustion, alter RER, or counter elevations in cortisol and inflammatory outcome measures.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020441</affiliation-url><afid>60020441</afid><affilname>Appalachian State University</affilname><name-variant>Appalachian State University</name-variant><affiliation-city>Boone</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112088490</affiliation-url><afid>112088490</afid><affilname>Dole Nutrition Research Laboratory</affilname><name-variant>Dole Nutrition Research Laboratory</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7102429071</author-url><authid>7102429071</authid><authname>Nieman D.</authname><surname>Nieman</surname><given-name>David C.</given-name><initials>D.C.</initials><afid>60020441</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55904815200</author-url><authid>55904815200</authid><authname>Gillitt N.</authname><surname>Gillitt</surname><given-name>Nicholas D.</given-name><initials>N.D.</initials><afid>112088490</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55734606800</author-url><authid>55734606800</authid><authname>Meaney M.</authname><surname>Meaney</surname><given-name>Mary Pat</given-name><initials>M.P.</initials><afid>60020441</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55549868200</author-url><authid>55549868200</authid><authname>Dew D.</authname><surname>Dew</surname><given-name>Dustin A.</given-name><initials>D.A.</initials><afid>60020441</afid></author><authkeywords>Alpha-linolenic fatty acid | Cytokines | Exercise | Inflammation</authkeywords><intid>1785944550</intid><source-id>19700188323</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929340199"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929340199?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929340199&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929340199&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929340199</prism:url><dc:identifier>SCOPUS_ID:84929340199</dc:identifier><eid>2-s2.0-84929340199</eid><dc:title>Characteristics of randomized controlled trials designed for elderly: A systematic review</dc:title><dc:creator>Broekhuizen K.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0126709</prism:doi><dc:description>© 2015 Broekhuizen et al. Objectives To quantify the proportion of randomized controlled trials (RCTs) specifically designed for elderly, and to assess their characteristics, as compared to RCTs not specifically designed for elderly. Design Review and synthesis of published literature. Measurements We searched PubMed for articles published in the year 2012. We included RCTs. Articles were excluded if not conducted with human subjects or if findings of secondary analyses were reported. A random sample of 10% was drawn and of this selection the following trial characteristics were extracted: sample size, disease category, age of sample, and agerelated inclusion criteria. Clinical trials were defined to be specifically designed for elderly if a lower age cut-off of ≥ 55 years was used, or when participants had an average age of ≥ 70 years. Results The search strategy yielded 26,740 articles, from which a random sample was drawn, resulting in 2375 articles. After exclusion, data was extracted from 1369 publications. Of these 1369 RCTs, 96 (7%) were specifically designed for elderly. In comparison with trials not designed for older adults, trials designed for elderly contained a significantly larger median number of participants (125 vs. 80, p = 0.008) significantly more trials designed for elderly fell into the disease categories eye (6% vs. 2%, p = 0.005), musculoskeletal (13% vs. 7%, p = 0.023) and circulatory system (16% vs. 9%, p = 0.039). No significant difference was observed with regard to the other disease categories. Conclusion There is a low proportion of RCTs specifically designed for elderly. As older patients will increasingly form the majority in medical practice, there is an urgent need for stronger evidence for the formulation of treatment guidelines specifically for older adults.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015618</affiliation-url><afid>60015618</afid><affilname>Leiden University Medical Center - LUMC</affilname><name-variant>University Hospital</name-variant><affiliation-city>Leiden</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113671322</affiliation-url><afid>113671322</afid><affilname>IEMO</affilname><name-variant>IEMO</name-variant><affiliation-city>Leiden</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35742873800</author-url><authid>35742873800</authid><authname>Broekhuizen K.</authname><surname>Broekhuizen</surname><given-name>Karen</given-name><initials>K.</initials><afid>60015618</afid><afid>113671322</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35742873800</author-url><authid>35742873800</authid><authname>Broekhuizen K.</authname><surname>Broekhuizen</surname><given-name>Karen</given-name><initials>K.</initials><afid>60015618</afid><afid>113671322</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56644964800</author-url><authid>56644964800</authid><authname>Pothof A.</authname><surname>Pothof</surname><given-name>Axel</given-name><initials>A.</initials><afid>60015618</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004695294</author-url><authid>7004695294</authid><authname>De Craen A.</authname><surname>De Craen</surname><given-name>Anton J M</given-name><initials>A.J.M.</initials><afid>60015618</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7801636685</author-url><authid>7801636685</authid><authname>Mooijaart S.</authname><surname>Mooijaart</surname><given-name>Simon P.</given-name><initials>S.P.</initials><afid>60015618</afid><afid>113671322</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7801636685</author-url><authid>7801636685</authid><authname>Mooijaart S.</authname><surname>Mooijaart</surname><given-name>Simon P.</given-name><initials>S.P.</initials><afid>60015618</afid><afid>113671322</afid></author><intid>1785946774</intid><article-number>0126709</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929379427"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929379427?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929379427&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929379427&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929379427</prism:url><dc:identifier>SCOPUS_ID:84929379427</dc:identifier><eid>2-s2.0-84929379427</eid><dc:title>The substrate-free and -bound crystal structures of the duplicated taurocyamine kinase from the human parasite Schistosoma mansoni</dc:title><dc:creator>Merceron R.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>20</prism:issueIdentifier><prism:pageRange>12951-12963</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M114.628909</prism:doi><dc:description>© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. The taurocyamine kinase from the blood fluke Schistosoma mansoni (SmTK) belongs to the phosphagen kinase (PK) family and catalyzes the reversible Mg&lt;sup&gt;2+&lt;/sup&gt;-dependent transfer of a phosphoryl group between ATP and taurocyamine. SmTK is derived from gene duplication, as are all known trematode TKs. Our crystallographic study of SmTK reveals the first atomic structure of both a TK and a PK with a bilobal structure. The two unliganded lobes present a canonical open conformation and interact via their respective C- and N-terminal domains at a helix-mediated interface. This spatial arrangement differs from that observed in true dimeric PKs, in which both N-terminal domains make contact. Our structures of SmTKcomplexed with taurocyamine or L-arginine compounds explain the mechanism by which an arginine residue of the phosphagen specificity loop is crucial for substrate specificity. An SmTK crystal was soaked with the dead end transition state analog (TSA) components taurocyamine-NO&lt;inf&gt;3&lt;/inf&gt; &lt;sup&gt;2-&lt;/sup&gt;-MgADP. One SmTK monomer was observed with two bound TSAs and an asymmetric conformation, with the first lobe semiclosed and the second closed. However, isothermal titration calorimetry and enzyme kinetics experiments showed that the two lobes function independently. A small angle x-ray scattering model of SmTK-TSA in solution with two closed active sites was generated.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069761</affiliation-url><afid>60069761</afid><affilname>IBCP Institut de Biologie et de Chimie des Proteines</affilname><name-variant>CNRS UPR 412</name-variant><affiliation-city>Lyon</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023578</affiliation-url><afid>60023578</afid><affilname>Universite Claude Bernard Lyon 1</affilname><name-variant>Université Lyon 1</name-variant><affiliation-city>Villeurbanne</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:50061369400</author-url><authid>50061369400</authid><authname>Merceron R.</authname><surname>Merceron</surname><given-name>Romain</given-name><initials>R.</initials><afid>60069761</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15839253300</author-url><authid>15839253300</authid><authname>Awama A.</authname><surname>Awama</surname><given-name>Ayman M.</given-name><initials>A.M.</initials><afid>60023578</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603505960</author-url><authid>6603505960</authid><authname>Montserret R.</authname><surname>Montserret</surname><given-name>Roland</given-name><initials>R.</initials><afid>60069761</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602104390</author-url><authid>6602104390</authid><authname>Marcillat O.</authname><surname>Marcillat</surname><given-name>Olivier</given-name><initials>O.</initials><afid>60023578</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006261857</author-url><authid>7006261857</authid><authname>Gouet P.</authname><surname>Gouet</surname><given-name>Patrice</given-name><initials>P.</initials><afid>60069761</afid></author><intid>1785945014</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929333860"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929333860?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929333860&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929333860&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929333860</prism:url><dc:identifier>SCOPUS_ID:84929333860</dc:identifier><eid>2-s2.0-84929333860</eid><dc:title>Induction of Heme Oxygenase-1 by Na&lt;sup&gt;+&lt;/sup&gt;-H&lt;sup&gt;+&lt;/sup&gt; exchanger 1 protein plays a crucial role in Imatinib-resistant chronic myeloid leukemia cells</dc:title><dc:creator>Ma D.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>20</prism:issueIdentifier><prism:pageRange>12558-12571</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M114.626960</prism:doi><dc:description>© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Resistance toward imatinib (IM) and other BCR/ABL tyrosine kinase inhibitors remains troublesome in the treatment of advanced stage chronic myeloid leukemia (CML). The aim of this study was to estimate the reversal effects of down-regulation of Na&lt;sup&gt;+&lt;/sup&gt;/H&lt;sup&gt;+&lt;/sup&gt; exchanger 1 (NHE1) on the chemoresistance of BCR-ABL-positive leukemia patients' cells and cell lines. After treatment with the specific NHE1 inhibitor cariporide to decrease intracellular pH (pH&lt;inf&gt;i&lt;/inf&gt;), the heme oxygenase-1 (HO-1) levels of the K562R cell line and cells from IM-insensitive CML patients decreased. HO-1, as a Bcr/Abl-dependent survival molecule in CML cells, is important for the resistance to tyrosine kinase inhibitors in patients with newly diagnosed CML or IMresistant CML. Silencing PKC-β and Nrf-2 or treatment with inhibitors of p38 pathways obviously blocked NHE1-induced HO-1 expression. Furthermore, treatment with HO-1 or p38 inhibitor plus IM increased the apoptosis of the K562R cell line and IM-insensitive CML patients' cells. Inhibiting HO-1 enhanced the activation of caspase-3 and poly(ADP-ribose) polymerase-1. Hence, the results support the anti-apoptotic role of HO-1 induced by NHE1 in the K562R cell line and IM-insensitive CML patients and provide a mechanism by which inducing HO-1 expression via the PKC-β/p38-MAPK pathway may promote tumor resistance to oxidative stress.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112777474</affiliation-url><afid>112777474</afid><affilname>Affiliated Hospital of Guiyang Medical University</affilname><name-variant>The Affiliated Hospital of Guiyang Medical University</name-variant><affiliation-city>Guiyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115242650</affiliation-url><afid>115242650</afid><affilname>Key Laboratory of Hematological Disease Diagnostic and Treatment Centre</affilname><name-variant>Key Laboratory of Hematological Disease Diagnostic and Treatment Centre</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114942687</affiliation-url><afid>114942687</afid><affilname>Affiliated BaiYun Hospital of Guiyang Medical University</affilname><name-variant>Affiliated BaiYun Hospital of Guiyang Medical University</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112777474</affiliation-url><afid>112777474</afid><affilname>Affiliated Hospital of Guiyang Medical University</affilname><name-variant>The Affiliated Hospital of Guiyang Medical University</name-variant><affiliation-city>Guiyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106591384</affiliation-url><afid>106591384</afid><affilname>Guiyang Medical University</affilname><name-variant>Guiyang Medical University</name-variant><affiliation-city>Guiyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55992237900</author-url><authid>55992237900</authid><authname>Ma D.</authname><surname>Ma</surname><given-name>Dan</given-name><initials>D.</initials><afid>112777474</afid><afid>114942687</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55992237900</author-url><authid>55992237900</authid><authname>Ma D.</authname><surname>Ma</surname><given-name>Dan</given-name><initials>D.</initials><afid>112777474</afid><afid>114942687</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56359260000</author-url><authid>56359260000</authid><authname>Fang Q.</authname><surname>Fang</surname><given-name>Qin</given-name><initials>Q.</initials><afid>114942687</afid><afid>112777474</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56359260000</author-url><authid>56359260000</authid><authname>Fang Q.</authname><surname>Fang</surname><given-name>Qin</given-name><initials>Q.</initials><afid>114942687</afid><afid>112777474</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56512592000</author-url><authid>56512592000</authid><authname>Wang P.</authname><surname>Wang</surname><given-name>Ping</given-name><initials>P.</initials><afid>112777474</afid><afid>115242650</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56512592000</author-url><authid>56512592000</authid><authname>Wang P.</authname><surname>Wang</surname><given-name>Ping</given-name><initials>P.</initials><afid>112777474</afid><afid>115242650</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56107424800</author-url><authid>56107424800</authid><authname>Gao R.</authname><surname>Gao</surname><given-name>Rui</given-name><initials>R.</initials><afid>112777474</afid><afid>115242650</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56107424800</author-url><authid>56107424800</authid><authname>Gao R.</authname><surname>Gao</surname><given-name>Rui</given-name><initials>R.</initials><afid>112777474</afid><afid>115242650</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56497295300</author-url><authid>56497295300</authid><authname>Wu W.</authname><surname>Wu</surname><given-name>Weibing</given-name><initials>W.</initials><afid>112777474</afid><afid>115242650</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56497295300</author-url><authid>56497295300</authid><authname>Wu W.</authname><surname>Wu</surname><given-name>Weibing</given-name><initials>W.</initials><afid>112777474</afid><afid>115242650</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56497398000</author-url><authid>56497398000</authid><authname>Lu T.</authname><surname>Lu</surname><given-name>Tangsheng</given-name><initials>T.</initials><afid>106591384</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56497380200</author-url><authid>56497380200</authid><authname>Cao L.</authname><surname>Cao</surname><given-name>Lu</given-name><initials>L.</initials><afid>106591384</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56512704900</author-url><authid>56512704900</authid><authname>Hu X.</authname><surname>Hu</surname><given-name>Xiuying</given-name><initials>X.</initials><afid>112777474</afid><afid>115242650</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56512704900</author-url><authid>56512704900</authid><authname>Hu X.</authname><surname>Hu</surname><given-name>Xiuying</given-name><initials>X.</initials><afid>112777474</afid><afid>115242650</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55918274300</author-url><authid>55918274300</authid><authname>Wang J.</authname><surname>Wang</surname><given-name>Jishi</given-name><initials>J.</initials><afid>112777474</afid><afid>115242650</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55918274300</author-url><authid>55918274300</authid><authname>Wang J.</authname><surname>Wang</surname><given-name>Jishi</given-name><initials>J.</initials><afid>112777474</afid><afid>115242650</afid></author><intid>35945625</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929952795"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929952795?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929952795&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929952795&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929952795</prism:url><dc:identifier>SCOPUS_ID:84929952795</dc:identifier><eid>2-s2.0-84929952795</eid><dc:title>Microbial diversity and their roles in the vinegar fermentation process</dc:title><dc:creator>Li S.</dc:creator><prism:publicationName>Applied Microbiology and Biotechnology</prism:publicationName><prism:issn>01757598</prism:issn><prism:eIssn>14320614</prism:eIssn><prism:volume>99</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>4997-5024</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00253-015-6659-1</prism:doi><dc:description>© 2015, Springer-Verlag Berlin Heidelberg. Vinegar is one of the oldest acetic acid-diluted solution products in the world. It is produced from any fermentable sugary substrate by various fermentation methods. The final vinegar products possess unique functions, which are endowed with many kinds of compounds formed in the fermentation process. The quality of vinegar is determined by many factors, especially by the raw materials and microbial diversity involved in vinegar fermentation. Given that metabolic products from the fermenting strains are directly related to the quality of the final products of vinegar, the microbial diversity and features of the dominant strains involved in different fermentation stages should be analyzed to improve the strains and stabilize fermentation. Moreover, although numerous microbiological studies have been conducted to examine the process of vinegar fermentation, knowledge about microbial diversity and their roles involved in fermentation is still fragmentary and not systematic enough. Therefore, in this review, the dominant microorganism species involved in the stages of alcoholic fermentation and acetic acid fermentation of dissimilar vinegars were summarized. We also summarized various physicochemical properties and crucial compounds in disparate types of vinegar. Furthermore, the merits and drawbacks of vital fermentation methods were generalized. Finally, we described in detail the relationships among microbial diversity, raw materials, fermentation methods, physicochemical properties, compounds, functionality, and final quality of vinegar. The integration of this information can provide us a detailed map about the microbial diversity and function involved in vinegar fermentation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024542</affiliation-url><afid>60024542</afid><affilname>South China University of Technology</affilname><name-variant>South China University of Technology</name-variant><affiliation-city>Guangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56089485100</author-url><authid>56089485100</authid><authname>Li S.</authname><surname>Li</surname><given-name>Sha</given-name><initials>S.</initials><afid>60024542</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56089308500</author-url><authid>56089308500</authid><authname>Li P.</authname><surname>Li</surname><given-name>Pan</given-name><initials>P.</initials><afid>60024542</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56427530300</author-url><authid>56427530300</authid><authname>Feng F.</authname><surname>Feng</surname><given-name>Feng</given-name><initials>F.</initials><afid>60024542</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35211332900</author-url><authid>35211332900</authid><authname>Luo L.</authname><surname>Luo</surname><given-name>Li Xin</given-name><initials>L.X.</initials><afid>60024542</afid></author><authkeywords>Acetic acid | Fermentation | Microbial diversity | Starter culture | Vinegar</authkeywords><intid>536042634</intid><source-id>14957</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925389163"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925389163?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925389163&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925389163&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915001582"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925389163</prism:url><dc:identifier>SCOPUS_ID:84925389163</dc:identifier><eid>2-s2.0-84925389163</eid><dc:title>Berberine inhibits Chlamydia pneumoniae infection-induced vascular smooth muscle cell migration through downregulating MMP3 and MMP9 via PI3K</dc:title><dc:creator>Zhang L.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>755</prism:volume><prism:pageRange>102-109</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.02.039</prism:doi><pii>S0014299915001582</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. The mechanisms by which Chlamydia pneumoniae infection promote vascular smooth muscle cell (VSMC) migration required in the development of atherosclerosis have not yet been fully clarified. Matrix metalloproteinases (MMPs) have important roles in VSMC migration. However, it is still unknown whether MMPs are involved in C. pneumoniae infection-induced VSMC migration. In addition, whether berberine can exert its inhibitory effects on the infection-induced VSMC migration also remains unclear. Accordingly, we investigated the effects of berberine on C. pneumoniae infection-induced VSMC migration and explored the possible mechanisms involved in this process. Herein, we found that C. pneumoniae infection could induce VSMC migration through Matrigel-coated membrane (P&lt;0.05), which can be significantly inhibited by the broad-spectrum MMP inhibitor GM6001 (P&lt;0.05). Our results also showed that C. pneumoniae infection upregulated both mRNA and protein expressions of MMP3 and MMP9 (P&lt;0.05). The specific phosphoinositide 3-kinase (PI3K) inhibitor LY294002 significantly suppressed the increases in MMP3 and MMP9 protein expressions induced by C. pneumoniae infection (P&lt;0.05). Further experiments showed that berberine significantly attenuated C. pneumoniae infection-induced VSMC migration (P&lt;0.05). Moreover, berberine suppressed the protein expressions of MMP3 and MMP9 caused by C. pneumoniae infection in a dose-dependent manner (P&lt;0.05). C. pneumoniae infection-induced increase in the phosphorylation level of Akt at Ser473 was inhibited by the treatment with berberine (P&lt;0.05). Taken together, our data suggest that berberine inhibits C. pneumoniae infection-induced VSMC migration by downregulating the expressions of MMP3 and MMP9 via PI3K.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011715</affiliation-url><afid>60011715</afid><affilname>Tianjin Medical University</affilname><name-variant>Tianjin Medical University General Hospital</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:52165066000</author-url><authid>52165066000</authid><authname>Zhang L.</authname><surname>Zhang</surname><given-name>Lijun</given-name><initials>L.</initials><afid>60011715</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56567055000</author-url><authid>56567055000</authid><authname>Ma L.</authname><surname>Ma</surname><given-name>Lu</given-name><initials>L.</initials><afid>60011715</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56566848000</author-url><authid>56566848000</authid><authname>Wang B.</authname><surname>Wang</surname><given-name>Beibei</given-name><initials>B.</initials><afid>60011715</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55962295600</author-url><authid>55962295600</authid><authname>Wei J.</authname><surname>Wei</surname><given-name>Junyan</given-name><initials>J.</initials><afid>60011715</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56567947900</author-url><authid>56567947900</authid><authname>Liu J.</authname><surname>Liu</surname><given-name>Jingya</given-name><initials>J.</initials><afid>60011715</afid></author><authkeywords>Berberine | Cell migration | Chlamydia pneumoniae | Matrix metalloproteinase | PI3K | Vascular smooth muscle cell</authkeywords><intid>1785298357</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924125518"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924125518?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924125518&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924125518&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378517315001969"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924125518</prism:url><dc:identifier>SCOPUS_ID:84924125518</dc:identifier><eid>2-s2.0-84924125518</eid><dc:title>Can preschool-aged children swallow several minitablets at a time? Results from a clinical pilot study</dc:title><dc:creator>Sznitowska M.</dc:creator><prism:publicationName>International Journal of Pharmaceutics</prism:publicationName><prism:issn>03785173</prism:issn><prism:eIssn>18733476</prism:eIssn><prism:volume>485</prism:volume><prism:issueIdentifier>1-2</prism:issueIdentifier><prism:pageRange>1-6</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijpharm.2015.02.068</prism:doi><pii>S0378517315001969</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Minitablets are a novel, multi-compartment solid drug formulation, particularly intended for children between 1 and 6 years of age. Available literature shows that even infants are capable of swallowing a single minitablet. In this study, we have explored the level of acceptance of minitablets administered in units of 5 or 10. A group of thirty two 2-year-old children (2-years) and twenty eight 3-year-old children (3-years) have been enrolled in the study. Each child was asked to swallow placebo minitablets (2 mm or 3 mm) suspended in a fruity jelly on a spoon. The swallowing of minitablets (with or without chewing) was registered for 75% of 2-year-olds and for 93% of 3-year-olds. Moreover, most of the children (57% of all participants) were fully capable of swallowing all units without chewing (2-years: 50%; 3-years: 64%). However, no statistically significant differences in the swallowing ability were observed in gender and age groups. None of the children choked. Neither the number, nor the diameter of the administered minitablets have significantly influenced the ability to swallow units. The results show that minitablets administered in several units mixed with jelly food are safe and could be accepted by a pediatric population.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012383</affiliation-url><afid>60012383</afid><affilname>Akademia Medyczna w Gdansku</affilname><name-variant>Medical University of Gdańsk</name-variant><affiliation-city>Gdansk</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012383</affiliation-url><afid>60012383</afid><affilname>Akademia Medyczna w Gdansku</affilname><name-variant>Medical University of Gdańsk</name-variant><affiliation-city>Gdansk</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012383</affiliation-url><afid>60012383</afid><affilname>Akademia Medyczna w Gdansku</affilname><name-variant>Medical University of Gdańsk</name-variant><affiliation-city>Gdansk</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003437608</author-url><authid>7003437608</authid><authname>Sznitowska M.</authname><surname>Sznitowska</surname><given-name>M.</given-name><initials>M.</initials><afid>60012383</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55943548600</author-url><authid>55943548600</authid><authname>Kluk A.</authname><surname>Kluk</surname><given-name>A.</given-name><initials>A.</initials><afid>60012383</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36150434500</author-url><authid>36150434500</authid><authname>Brandt A.</authname><surname>Brandt</surname><given-name>A.</given-name><initials>A.</initials><afid>60012383</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:14054794600</author-url><authid>14054794600</authid><authname>Sznurkowska K.</authname><surname>Sznurkowska</surname><given-name>K.</given-name><initials>K.</initials><afid>60012383</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6506268056</author-url><authid>6506268056</authid><authname>Plata-Nazar K.</authname><surname>Plata-Nazar</surname><given-name>K.</given-name><initials>K.</initials><afid>60012383</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56537940000</author-url><authid>56537940000</authid><authname>Mysliwiec M.</authname><surname>Mysliwiec</surname><given-name>M.</given-name><initials>M.</initials><afid>60012383</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005252356</author-url><authid>7005252356</authid><authname>Kaminska B.</authname><surname>Kaminska</surname><given-name>B.</given-name><initials>B.</initials><afid>60012383</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56538646000</author-url><authid>56538646000</authid><authname>Kotlowska H.</authname><surname>Kotlowska</surname><given-name>H.</given-name><initials>H.</initials><afid>60012383</afid></author><authkeywords>Children | Minitablets | Swallowing</authkeywords><intid>1535082998</intid><source-id>22454</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924815170"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924815170?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924815170&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924815170&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915001570"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924815170</prism:url><dc:identifier>SCOPUS_ID:84924815170</dc:identifier><eid>2-s2.0-84924815170</eid><dc:title>Tingenone, a pentacyclic triterpene, induces peripheral antinociception due to NO/cGMP and ATP-sensitive K+ channels pathway activation in mice</dc:title><dc:creator>De Carvalho Veloso C.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>755</prism:volume><prism:pageRange>1-5</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.02.038</prism:doi><pii>S0014299915001570</pii><dc:description>© 2015 Elsevier B.V.. All rights reserved. Substances derived from plants play an important role in the development of new analgesic drugs, among them, triterpenoids. The connection between the participation of L-arginine/NO/cGMP pathway and the activation of ATP-sensitive K+ channels (KATP) has been established on the peripheral antinociception induced by various drugs. The study assessed the involvement of L-arginine/NO/cGMP/KATP pathway in the antinociceptive effect induced by tingenone, from Maytenus imbricata, against the hyperalgesia evoked by prostaglandin E2 (PGE2) in peripheral pathway. The paw pressure test was used, with hyperalgesia induced by intraplantar injection of PGE2 (2 μg). Tingenone (200 μg/paw) administered into the right hind paw induced a local antinociceptive effect, that was antagonized by l-NOArg, nonselective nitric oxide synthase (NOS) inhibitor and by L-NPA, selective neuronal NOS (nNOS) inhibitor. The L-NIO, selective inhibitor of endothelial (eNOS), and the L-NIL, selective inhibitor of inducible (iNOS), did not alter the peripheral antinociceptive effect of the tingenone. The ODQ, selective soluble guanylyl cyclase inhibitor, prevented the antinociceptive effect of tingenone, and zaprinast, inhibitor of the phosphodiesterase that is cyclic guanosine monophosphate (cGMP) specific, intensified the peripheral antinociceptive effect of the smaller dose of tingenone. Glibenclamide, ATP-sensitive K+ channels (KATP) blocker, but not tetraethylammonium chloride, voltage-dependent K+ channel blocker; dequalinium dichloride, blocker of the small conductance Ca2+-activated K+ channel, and paxilline, a potent blocker of high-conductance Ca2+-activated K+ channels, respectively, prevented the peripheral antinociceptive effect of tingenone. The results demonstrate that tingenone induced a peripheral antinociceptive effect by L-arginine/NO/cGMP/KATP pathway activation, with potential for a new analgesic drug.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030074</affiliation-url><afid>60030074</afid><affilname>Universidade Federal de Minas Gerais</affilname><name-variant>Universidade Federal de Minas Gerais</name-variant><affiliation-city>Belo Horizonte</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030074</affiliation-url><afid>60030074</afid><affilname>Universidade Federal de Minas Gerais</affilname><name-variant>Universidade Federal de Minas Gerais</name-variant><affiliation-city>Belo Horizonte</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56550032000</author-url><authid>56550032000</authid><authname>De Carvalho Veloso C.</authname><surname>De Carvalho Veloso</surname><given-name>Clarice</given-name><initials>C.</initials><afid>60030074</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:34977421200</author-url><authid>34977421200</authid><authname>Rodrigues V.</authname><surname>Rodrigues</surname><given-name>Vanessa Gregório</given-name><initials>V.G.</initials><afid>60030074</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56430430600</author-url><authid>56430430600</authid><authname>Ferreira R.</authname><surname>Ferreira</surname><given-name>Renata Cristina Mendes</given-name><initials>R.C.M.</initials><afid>60030074</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005630095</author-url><authid>7005630095</authid><authname>Duarte L.</authname><surname>Duarte</surname><given-name>Lucienir Pains</given-name><initials>L.P.</initials><afid>60030074</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:13606231100</author-url><authid>13606231100</authid><authname>Klein A.</authname><surname>Klein</surname><given-name>Andre</given-name><initials>A.</initials><afid>60030074</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7007025426</author-url><authid>7007025426</authid><authname>Duarte I.</authname><surname>Duarte</surname><given-name>Igor Dimitri</given-name><initials>I.D.</initials><afid>60030074</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:34873293700</author-url><authid>34873293700</authid><authname>Romero T.</authname><surname>Romero</surname><given-name>Thiago Roberto Lima</given-name><initials>T.R.L.</initials><afid>60030074</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:24450084400</author-url><authid>24450084400</authid><authname>De Castro Perez A.</authname><surname>De Castro Perez</surname><given-name>Andrea</given-name><initials>A.</initials><afid>60030074</afid></author><authkeywords>Antinociception | KATP | Nitric oxide | Pain | Tingenone</authkeywords><intid>2035194565</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929313101"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929313101?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929313101&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929313101&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929313101</prism:url><dc:identifier>SCOPUS_ID:84929313101</dc:identifier><eid>2-s2.0-84929313101</eid><dc:title>Dynamic expression of novel MiRNA candidates and MiRNA-34 family members in early-to mid-gestational fetal keratinocytes contributes to scarless wound healing by targeting the TGF-β pathway</dc:title><dc:creator>Zhao F.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0126087</prism:doi><dc:description>© 2015 Zhao et al. Background Early- to mid-gestational fetal mammalian skin wounds heal rapidly and without scarring. Keratinocytes (KCs) have been found to exert important effects on the regulation of fibroblasts. There may be significant differences of gestational fetal KCs at different ages. The advantages in early- to mid-gestational fetal KCs could lead to fetal scarless wound healing. Methods KCs from six human fetal skin samples were divided into two groups: a mid-gestation group (less than 28 weeks of gestational age) and a late-gestation group (more than 28 weeks of gestational age). RNA extracted from KCs was used to prepare a library of small RNAs for next-generation sequencing (NGS). To uncover potential novel microRNA (miRNAs), the mirTools 2.0 web server was used to identify candidate novel human miRNAs from the NGS data. Other bioinformatical analyses were used to further validate the novel miRNAs. The expression levels of the miRNAs were further confirmed by real-time quantitative RTPCR. Results A total of 61.59 million reads were mapped to 1,170 known human miRNAs in miRBase. Among a total of 202 potential novel miRNAs uncovered, 106 candidates have a higher probability of being novel human miRNAs. A total of 110 miRNAs, including 22 novel miRNA candidates, were significantly differently expressed between mid- and late-gestational fetal KCs. Thirty-three differentially expressed miRNAs and miR-34 family members are correlated with the transforming growth factor-β (TGF-β) pathway. Conclusions Taken together, our results provide compelling evidence supporting the existence of 106 novel miRNAs and the dynamic expression of miRNAs that extensively targets the TGF-β pathway at different gestational ages in fetal KCs. MiRNAs showing altered expression at different gestational ages in fetal KCs may contribute to scarless wound healing in early- to mid-gestational fetal KCs, and thus may be new targets for potential scar prevention and reduction therapies.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008872</affiliation-url><afid>60008872</afid><affilname>China Medical University Shenyang</affilname><name-variant>China Medical University</name-variant><affiliation-city>Shenyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100819206</affiliation-url><afid>100819206</afid><affilname>Shengjing Hospital of China Medical University</affilname><name-variant>Shengjing Hospital of China Medical University</name-variant><affiliation-city>Shenyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113823272</affiliation-url><afid>113823272</afid><affilname>The First Hospital of China Medical University</affilname><name-variant>First Hospital of China Medical University</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55715716700</author-url><authid>55715716700</authid><authname>Zhao F.</authname><surname>Zhao</surname><given-name>Feng</given-name><initials>F.</initials><afid>60008872</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35249825600</author-url><authid>35249825600</authid><authname>Wang Z.</authname><surname>Wang</surname><given-name>Zhe</given-name><initials>Z.</initials><afid>100819206</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56643965300</author-url><authid>56643965300</authid><authname>Lang H.</authname><surname>Lang</surname><given-name>Hongxin</given-name><initials>H.</initials><afid>60008872</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:37045906600</author-url><authid>37045906600</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xiaoyu</given-name><initials>X.</initials><afid>60008872</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56440397800</author-url><authid>56440397800</authid><authname>Zhang D.</authname><surname>Zhang</surname><given-name>Dianbao</given-name><initials>D.</initials><afid>60008872</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8321913300</author-url><authid>8321913300</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xiliang</given-name><initials>X.</initials><afid>60008872</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35212776400</author-url><authid>35212776400</authid><authname>Zhang T.</authname><surname>Zhang</surname><given-name>Tao</given-name><initials>T.</initials><afid>60008872</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7405335475</author-url><authid>7405335475</authid><authname>Wang R.</authname><surname>Wang</surname><given-name>Rui</given-name><initials>R.</initials><afid>60008872</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35241150200</author-url><authid>35241150200</authid><authname>Shi P.</authname><surname>Shi</surname><given-name>Ping</given-name><initials>P.</initials><afid>113823272</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56440848700</author-url><authid>56440848700</authid><authname>Pang X.</authname><surname>Pang</surname><given-name>Xining</given-name><initials>X.</initials><afid>60008872</afid></author><intid>35945626</intid><article-number>0126087</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923872523"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923872523?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923872523&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923872523&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1570963915000175"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923872523</prism:url><dc:identifier>SCOPUS_ID:84923872523</dc:identifier><eid>2-s2.0-84923872523</eid><dc:title>Multidimensional electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) for quantitative analysis of the proteome and phosphoproteome in clinical and biomedical research</dc:title><dc:creator>Loroch S.</dc:creator><prism:publicationName>Biochimica et Biophysica Acta - Proteins and Proteomics</prism:publicationName><prism:issn>15709639</prism:issn><prism:eIssn>18781454</prism:eIssn><prism:volume>1854</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>460-468</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbapap.2015.01.006</prism:doi><pii>S1570963915000175</pii><dc:description>© 2015 Published by Elsevier B.V. Quantitative proteomics and phosphoproteomics have become key disciplines in understanding cellular processes. Fundamental research can be done using cell culture providing researchers with virtually infinite sample amounts. In contrast, clinical, pre-clinical and biomedical research is often restricted to minute sample amounts and requires an efficient analysis with only micrograms of protein. To address this issue, we generated a highly sensitive workflow for combined LC-MS-based quantitative proteomics and phosphoproteomics by refining an ERLIC-based 2D phosphoproteomics workflow into an ERLIC-based 3D workflow covering the global proteome as well. The resulting 3D strategy was successfully used for an in-depth quantitative analysis of both, the proteome and the phosphoproteome of murine cytomegalovirus-infected mouse fibroblasts, a model system for host cell manipulation by a virus. In a 2-plex SILAC experiment with 150 μg of a tryptic digest per condition, the 3D strategy enabled the quantification of ∼ 75% more proteins and even ∼ 134% more peptides compared to the 2D strategy. Additionally, we could quantify ∼ 50% more phosphoproteins by non-phosphorylated peptides, concurrently yielding insights into changes on the levels of protein expression and phosphorylation. Beside its sensitivity, our novel three-dimensional ERLIC-strategy has the potential for semi-automated sample processing rendering it a suitable future perspective for clinical, pre-clinical and biomedical research.</dc:description><citedby-count>2</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072342</affiliation-url><afid>60072342</afid><affilname>Institute for Analytical Sciences, Dortmund</affilname><name-variant>Institut für Spektrochemie und angewandte Spektroskopie</name-variant><affiliation-city>Dortmund</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072360</affiliation-url><afid>60072360</afid><affilname>Heinrich-Pette-Institut</affilname><name-variant>Heinrich-Pette-Institute for Experimental Virology and Immunology</name-variant><affiliation-city>Hamburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015875</affiliation-url><afid>60015875</afid><affilname>University of Aberdeen</affilname><name-variant>University of Aberdeen</name-variant><affiliation-city>Aberdeen</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005322</affiliation-url><afid>60005322</afid><affilname>Universitat Bochum</affilname><name-variant>Ruhr-Universität Bochum</name-variant><affiliation-city>Bochum</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55697384600</author-url><authid>55697384600</authid><authname>Loroch S.</authname><surname>Loroch</surname><given-name>Stefan</given-name><initials>S.</initials><afid>60072342</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:51061516000</author-url><authid>51061516000</authid><authname>Schommartz T.</authname><surname>Schommartz</surname><given-name>Tim</given-name><initials>T.</initials><afid>60072360</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006372690</author-url><authid>7006372690</authid><authname>Brune W.</authname><surname>Brune</surname><given-name>Wolfram</given-name><initials>W.</initials><afid>60072360</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603400119</author-url><authid>6603400119</authid><authname>Zahedi R.</authname><surname>Zahedi</surname><given-name>René Peiman</given-name><initials>R.P.</initials><afid>60072342</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004512650</author-url><authid>7004512650</authid><authname>Sickmann A.</authname><surname>Sickmann</surname><given-name>Albert</given-name><initials>A.</initials><afid>60072342</afid><afid>60015875</afid><afid>60005322</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004512650</author-url><authid>7004512650</authid><authname>Sickmann A.</authname><surname>Sickmann</surname><given-name>Albert</given-name><initials>A.</initials><afid>60072342</afid><afid>60015875</afid><afid>60005322</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004512650</author-url><authid>7004512650</authid><authname>Sickmann A.</authname><surname>Sickmann</surname><given-name>Albert</given-name><initials>A.</initials><afid>60072342</afid><afid>60015875</afid><afid>60005322</afid></author><authkeywords>Clinical research | ERLIC | Multidimensional separation | Phosphoproteomics | Proteomics</authkeywords><intid>35077059</intid><source-id>16832</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927511456"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927511456?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927511456&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927511456&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0944711315000732"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927511456</prism:url><dc:identifier>SCOPUS_ID:84927511456</dc:identifier><eid>2-s2.0-84927511456</eid><dc:title>Differential proteomic analysis on the effects of 2-methoxy-1,4-naphthoquinone towards MDA-MB-231 cell line</dc:title><dc:creator>Liew K.</dc:creator><prism:publicationName>Phytomedicine</prism:publicationName><prism:issn>09447113</prism:issn><prism:eIssn>1618095X</prism:eIssn><prism:volume>22</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>517-527</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.phymed.2015.03.007</prism:doi><pii>S0944711315000732</pii><dc:description>© 2015 Elsevier GmbH. All rights reserved. Background We have previously reported the anti-metastatic effects of 2-methoxy-1,4-naphthoquinone (MNQ) against MDA-MB-231 cell line. Purpose To investigate the molecular mechanism underlying the anti-metastatic effects of MNQ towards MDA-MB-231 cell line via the comparative proteomic approach. Study design/methods Differentially expressed proteins in MNQ-treated MDA-MB-231 cells were identified by using two-dimensional gel electrophoresis coupled with tandem mass spectrometry. Proteins and signalling pathways associated with the identified MNQ-altered proteins were studied by using Western blotting. Results Significant modulation of MDA-MB-231 cell proteome was observed upon treatment with MNQ in which the expressions of 19 proteins were found to be downregulated whereas another eight were upregulated (&gt;1.5 fold, p &lt; 0.05). The altered proteins were mainly related to cytoskeletal functions and regulations, mRNA processing, protein modifications and oxidative stress response. Notably, two of the downregulated proteins, protein S100-A4 (S100A4) and laminin-binding protein (RPSA) are known to play key roles in driving metastasis and were verified using Western blotting. Further investigation using Western blotting also revealed that MNQ decreased the activations of pro-metastatic ERK1/2 and NF-κB signalling pathways. Moreover, MNQ was shown to stimulate the expression of the metastatic suppressor, E-cadherin. Conclusion This study reports a proposed mechanism by which MNQ exerts its anti-metastatic effects against MDA-MB-231 cell line. The findings from this study offer new insights on the potential of MNQ to be developed as a novel anti-metastatic agent.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104614</affiliation-url><afid>60104614</afid><affilname>Taylor's University Malaysia</affilname><name-variant>Taylor's University</name-variant><affiliation-city>Subang Jaya</affiliation-city><affiliation-country>Malaysia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60090708</affiliation-url><afid>60090708</afid><affilname>Universiti Tunku Abdul Rahman</affilname><name-variant>Universiti Tunku Abdul Rahman</name-variant><affiliation-city>Petaling Jaya</affiliation-city><affiliation-country>Malaysia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55987109900</author-url><authid>55987109900</authid><authname>Liew K.</authname><surname>Liew</surname><given-name>Kitson</given-name><initials>K.</initials><afid>60104614</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55986862200</author-url><authid>55986862200</authid><authname>Yong P.</authname><surname>Yong</surname><given-name>Phelim Voon Chen</given-name><initials>P.V.C.</initials><afid>60104614</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005824719</author-url><authid>7005824719</authid><authname>Navaratnam V.</authname><surname>Navaratnam</surname><given-name>Visweswaran</given-name><initials>V.</initials><afid>60104614</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:26325517600</author-url><authid>26325517600</authid><authname>Lim Y.</authname><surname>Lim</surname><given-name>Yang Mooi</given-name><initials>Y.M.</initials><afid>60090708</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:11139153800</author-url><authid>11139153800</authid><authname>Ho A.</authname><surname>Ho</surname><given-name>Anthony Siong Hock</given-name><initials>A.S.H.</initials><afid>60104614</afid></author><authkeywords>2-Methoxy-1 4-naphthoquinone | E-cadherin | ERK1/2 | NF-κB | RPSA | S100A4</authkeywords><intid>535634622</intid><source-id>17067</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929458188"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929458188?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929458188&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929458188&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929458188</prism:url><dc:identifier>SCOPUS_ID:84929458188</dc:identifier><eid>2-s2.0-84929458188</eid><dc:title>Non-invasive brain stimulation: An interventional tool for enhancing behavioral training after stroke</dc:title><dc:creator>Wessel M.</dc:creator><prism:publicationName>Frontiers in Human Neuroscience</prism:publicationName><prism:issn>16625161</prism:issn><prism:eIssn>16625161</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>MAY</prism:issueIdentifier><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.3389/fnhum.2015.00265</prism:doi><dc:description>© 2015 Wessel, Zimerman and Hummel. Stroke is the leading cause of disability among adults. Motor deficit is the most common impairment after stroke. Especially, deficits in fine motor skills impair numerous activities of daily life. Re-acquisition of motor skills resulting in improved or more accurate motor performance is paramount to regain function, and is the basis of behavioral motor therapy after stroke. Within the past years, there has been a rapid technological and methodological development in neuroimaging leading to a significant progress in the understanding of the neural substrates that underlie motor skill acquisition and functional recovery in stroke patients. Based on this and the development of novel non-invasive brain stimulation (NIBS) techniques, new adjuvant interventional approaches that augment the response to behavioral training have been proposed. Transcranial direct current, transcranial magnetic, and paired associative (PAS) stimulation are NIBS techniques that can modulate cortical excitability, neuronal plasticity and interact with learning and memory in both healthy individuals and stroke patients. These techniques can enhance the effect of practice and facilitate the retention of tasks that mimic daily life activities. The purpose of the present review is to provide a comprehensive overview of neuroplastic phenomena in the motor system during learning of a motor skill, recovery after brain injury, and of interventional strategies to enhance the beneficial effects of customarily used neurorehabilitation after stroke.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005036</affiliation-url><afid>60005036</afid><affilname>Universitatsklinikum Hamburg-Eppendorf und Medizinische Fakultat</affilname><name-variant>University Medical Center Hamburg-Eppendorf</name-variant><affiliation-city>Hamburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60092142</affiliation-url><afid>60092142</afid><affilname>Instituto de Neurologia Cognitiva, Buenos Aires</affilname><name-variant>Institute of Cognitive Neurology (INECO)</name-variant><affiliation-city>Buenos Aires</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013553</affiliation-url><afid>60013553</afid><affilname>Universidad Favaloro</affilname><name-variant>Favaloro University</name-variant><affiliation-city>Buenos Aires</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36904649500</author-url><authid>36904649500</authid><authname>Wessel M.</authname><surname>Wessel</surname><given-name>Maximilian J.</given-name><initials>M.J.</initials><afid>60005036</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24077898400</author-url><authid>24077898400</authid><authname>Zimerman M.</authname><surname>Zimerman</surname><given-name>Máximo</given-name><initials>M.</initials><afid>60005036</afid><afid>60092142</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24077898400</author-url><authid>24077898400</authid><authname>Zimerman M.</authname><surname>Zimerman</surname><given-name>Máximo</given-name><initials>M.</initials><afid>60005036</afid><afid>60092142</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003673127</author-url><authid>7003673127</authid><authname>Hummel F.</authname><surname>Hummel</surname><given-name>Friedhelm C.</given-name><initials>F.C.</initials><afid>60005036</afid><afid>60013553</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003673127</author-url><authid>7003673127</authid><authname>Hummel F.</authname><surname>Hummel</surname><given-name>Friedhelm C.</given-name><initials>F.C.</initials><afid>60005036</afid><afid>60013553</afid></author><authkeywords>Motor learning | Motor recovery | Neurorehabilitation | Non-invasive brain stimulation | Stroke | tDCS | TMS</authkeywords><intid>35962709</intid><article-number>265</article-number><source-id>19700175164</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929377385"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929377385?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929377385&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929377385&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929377385</prism:url><dc:identifier>SCOPUS_ID:84929377385</dc:identifier><eid>2-s2.0-84929377385</eid><dc:title>Nuclear localization and functional characteristics of voltage-gated potassium channel Kv1.3</dc:title><dc:creator>Jang S.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>20</prism:issueIdentifier><prism:pageRange>12547-12557</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M114.561324</prism:doi><dc:description>© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. It is widely known that ion channels are expressed in the plasma membrane. However, a few studies have suggested that several ion channels including voltage-gated K&lt;sup&gt;+&lt;/sup&gt; (Kv) channels also exist in intracellular organelles where they are involved in the biochemical events associated with cell signaling. In the present study, Western blot analysis using fractionated protein clearly indicates that Kv1.3 channels are expressed in the nuclei of MCF7, A549, and SNU-484 cancer cells and human brain tissues. In addition, Kv1.3 is located in the plasma membrane and the nucleus of Jurkat T cells. Nuclear membrane hyperpolarization after treatment with margatoxin (MgTX), a specific blocker of Kv1.3 channels, provides evidence for functional channels at the nuclear membrane of A549 cells. MgTX-induced hyperpolarization is abolished in the nuclei of Kv1.3 silenced cells, and the effects of MgTX are dependent on the magnitude of the K&lt;sup&gt;+&lt;/sup&gt; gradient across the nuclear membrane. Selective Kv1.3 blockers induce the phosphorylation of cAMP response element-binding protein (CREB) and c-Fos activation. Moreover, Kv1.3 is shown to form a complex with the upstream binding factor 1 in the nucleus. Chromatin immunoprecipitation assay reveals that Sp1 transcription factor is directly bound to the promoter region of the Kv1.3 gene, and the Sp1 regulates Kv1.3 expression in the nucleus of A549 cells. These results demonstrate that Kv1.3 channels are primarily localized in the nucleus of several types of cancer cells and human brain tissues where they are capable of regulating nuclear membrane potential and activation of transcription factors, such as phosphorylated CREB and c-Fos.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013682</affiliation-url><afid>60013682</afid><affilname>Seoul National University</affilname><name-variant>Seoul National University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013682</affiliation-url><afid>60013682</afid><affilname>Seoul National University</affilname><name-variant>Seoul National University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032624</affiliation-url><afid>60032624</afid><affilname>Ulsan University</affilname><name-variant>University of Ulsan</name-variant><affiliation-city>Ulsan</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014156</affiliation-url><afid>60014156</afid><affilname>Soongsil University</affilname><name-variant>Soongsil University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022417</affiliation-url><afid>60022417</afid><affilname>Chungnam National University</affilname><name-variant>Chungnam National University</name-variant><affiliation-city>Daejeon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005745</affiliation-url><afid>60005745</afid><affilname>University of Minnesota System</affilname><name-variant>University of Minnesota</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643702200</author-url><authid>56643702200</authid><authname>Jang S.</authname><surname>Jang</surname><given-name>Soo Hwa</given-name><initials>S.H.</initials><afid>60013682</afid><afid>60032624</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643702200</author-url><authid>56643702200</authid><authname>Jang S.</authname><surname>Jang</surname><given-name>Soo Hwa</given-name><initials>S.H.</initials><afid>60013682</afid><afid>60032624</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56604679700</author-url><authid>56604679700</authid><authname>Byun J.</authname><surname>Byun</surname><given-name>Jun Kyu</given-name><initials>J.K.</initials><afid>60013682</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:54385525900</author-url><authid>54385525900</authid><authname>Jeon W.</authname><surname>Jeon</surname><given-name>Won Il</given-name><initials>W.I.</initials><afid>60013682</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55949377000</author-url><authid>55949377000</authid><authname>Choi S.</authname><surname>Choi</surname><given-name>Seon Young</given-name><initials>S.Y.</initials><afid>60013682</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55007810700</author-url><authid>55007810700</authid><authname>Park J.</authname><surname>Park</surname><given-name>Jin</given-name><initials>J.</initials><afid>60014156</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56001019800</author-url><authid>56001019800</authid><authname>Lee B.</authname><surname>Lee</surname><given-name>Bo Hyung</given-name><initials>B.H.</initials><afid>60013682</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56644075500</author-url><authid>56644075500</authid><authname>Yang J.</authname><surname>Yang</surname><given-name>Ji Eun</given-name><initials>J.E.</initials><afid>60013682</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56518533200</author-url><authid>56518533200</authid><authname>Park J.</authname><surname>Park</surname><given-name>Jin Bong</given-name><initials>J.B.</initials><afid>60022417</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7005308264</author-url><authid>7005308264</authid><authname>O'Grady S.</authname><surname>O'Grady</surname><given-name>Scott M.</given-name><initials>S.M.</initials><afid>60005745</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56643439200</author-url><authid>56643439200</authid><authname>Kim D.</authname><surname>Kim</surname><given-name>Dae Yong</given-name><initials>D.Y.</initials><afid>60013682</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7003389863</author-url><authid>7003389863</authid><authname>Ryu P.</authname><surname>Ryu</surname><given-name>Pan Dong</given-name><initials>P.D.</initials><afid>60013682</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56644018200</author-url><authid>56644018200</authid><authname>Joo S.</authname><surname>Joo</surname><given-name>Sang Woo</given-name><initials>S.W.</initials><afid>60014156</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:8772436100</author-url><authid>8772436100</authid><authname>Lee S.</authname><surname>Lee</surname><given-name>So Yeong</given-name><initials>S.Y.</initials><afid>60013682</afid></author><intid>1035941553</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84917708675"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84917708675?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84917708675&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84917708675&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814614018135"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84917708675</prism:url><dc:identifier>SCOPUS_ID:84917708675</dc:identifier><eid>2-s2.0-84917708675</eid><dc:title>Proteomic identification of allergenic seed proteins, napin and cruciferin, from cold-pressed rapeseed oils</dc:title><dc:creator>Puumalainen T.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>175</prism:volume><prism:pageRange>381-385</prism:pageRange><prism:coverDate>2015-05-15</prism:coverDate><prism:coverDisplayDate>15 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2014.11.084</prism:doi><pii>S0308814614018135</pii><dc:description>© 2014 Elsevier Ltd. In Finland and France atopic children commonly react to seeds of oilseed rape and turnip rape in skin prick tests (SPT) and open food challenges. These seeds are not as such in dietary use and therefore the routes of sensitization are unknown. Possible allergens were extracted from commercial cold-pressed and refined rapeseed oils and identified by gel-based tandem nanoflow liquid chromatography mass spectrometry (LC-MS/MS). Napin (a 2S albumin), earlier identified as a major allergen in the seeds of oilseed rape and turnip rape, and cruciferin (an 11S globulin), a new potential seed allergen, were detected in cold-pressed oils, but not in refined oils. Pooled sera from five children sensitized or allergic to oilseed rape and turnip rape seeds reacted to these proteins from cold-pressed oil preparations and individual sera from five children reacted to these proteins extracted from the seeds when examined with IgE immunoblotting. Hence cold-pressed rapeseed oil might be one possible route of sensitization for these allergens.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003237</affiliation-url><afid>60003237</afid><affilname>University of Helsinki Haartman Institute</affilname><name-variant>University of Helsinki</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010493</affiliation-url><afid>60010493</afid><affilname>Tyoterveyslaitos</affilname><name-variant>Finnish Inst. of Occupational Health</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Central Finland Health Care District</affilname><name-variant>Department of Dermatology</name-variant><affiliation-city>Jyväskylä</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011170</affiliation-url><afid>60011170</afid><affilname>Tampereen Yliopisto</affilname><name-variant>University of Tampere</name-variant><affiliation-city>Tampere</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104546</affiliation-url><afid>60104546</afid><affilname>National Institute for Health and Welfare</affilname><name-variant>National Institute for Health and Welfare</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030280</affiliation-url><afid>60030280</afid><affilname>Helse Bergen Haukeland University Hospital</affilname><name-variant>Haukeland University Hospital</name-variant><affiliation-city>Bergen</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:12778921500</author-url><authid>12778921500</authid><authname>Puumalainen T.</authname><surname>Puumalainen</surname><given-name>T. J.</given-name><initials>T.J.</initials><afid>60003237</afid><afid>60104546</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:12778921500</author-url><authid>12778921500</authid><authname>Puumalainen T.</authname><surname>Puumalainen</surname><given-name>T. J.</given-name><initials>T.J.</initials><afid>60003237</afid><afid>60104546</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004670901</author-url><authid>7004670901</authid><authname>Puustinen A.</authname><surname>Puustinen</surname><given-name>A.</given-name><initials>A.</initials><afid>60010493</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8247219500</author-url><authid>8247219500</authid><authname>Poikonen S.</authname><surname>Poikonen</surname><given-name>S.</given-name><initials>S.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006150493</author-url><authid>7006150493</authid><authname>Turjanmaa K.</authname><surname>Turjanmaa</surname><given-name>K.</given-name><initials>K.</initials><afid>60011170</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006305551</author-url><authid>7006305551</authid><authname>Palosuo T.</authname><surname>Palosuo</surname><given-name>T.</given-name><initials>T.</initials><afid>60104546</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603560303</author-url><authid>6603560303</authid><authname>Vaali K.</authname><surname>Vaali</surname><given-name>K.</given-name><initials>K.</initials><afid>60003237</afid><afid>60030280</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603560303</author-url><authid>6603560303</authid><authname>Vaali K.</authname><surname>Vaali</surname><given-name>K.</given-name><initials>K.</initials><afid>60003237</afid><afid>60030280</afid></author><authkeywords>11S globulin | 2S albumin | Canola | Food allergy | Oilseed rape | Proteomics | Turnip rape | Vegetable oil</authkeywords><intid>2034020236</intid><source-id>24039</source-id></entry></search-results>
